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G-quadruplexes are four-stranded nucleic acid secondary structures formed from sequences 
rich in guanine. These structures display potential as therapeutic targets and as the basis of 
functional materials. Both of these applications rely on exerting control over the formation of 
these polymorphic architectures. Small molecule ligands can exert this control by selective 
stabilisation of the folded structures, but normally only allow a one-way response as their 
delivery to a system cannot be readily reversed. Photoresponsive ligands offer an opportunity 
to circumvent this limitation, since their activity may be switched on or off with spatiotemporal 
precision based on a change in the ligand structure upon irradiation with light. In therapy, this 
level of control could allow the activity of a G-quadruplex targeting drug to be restricted to a 
desired site of action, such as a tumour, in an approach known as photopharmacology. 
Meanwhile, the possibility to control nucleic acid/ligand assemblies reversibly could be 
deployed in the development of new responsive materials. Despite these opportunities, scant 
attention to date has been devoted towards the development of photoresponsive G-
quadruplex targeting molecules. 
This thesis reports the investigation of two photoresponsive scaffolds, stiff-stilbene and 
dithienylethene, as the basis of novel G-quadruplex ligands (Figure 1). The design, synthesis 
and optimisation of candidate ligands derived from these chromophores is described. The 
ligands are evaluated as G-quadruplex binding agents by means of fluorescence-based 
melting assays, UV/visible spectroscopy, circular dichroism spectroscopy, NMR spectroscopy 
and molecular dynamics simulations. The bioactivity of the ligands against a small panel of 
mammalian cells and parasitic organisms is also investigated. The photochemistry of the 
ligands in physiologically-relevant conditions is explored and the respective photoresponses 




Figure 1: G-quadruplex ligand scaffolds explored in this work. 
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1  Introduction 
This chapter is based in part on a review published in the European Journal of Organic 
Chemistry, of which I am co-corresponding author.1 
 
This thesis reports progress towards the development of new supramolecular tools for the 
photo-responsive regulation of G-quadruplex (G4) structures for therapeutic or 
nanotechnological applications. This introductory chapter aims to give an overview of prior 
work in the field to date. To begin, a brief introduction to nucleic acid chemistry is provided, 
highlighting the features of these molecules that are crucial to their functional roles, especially 
their ability to form a wide range of secondary structures. This allows for a more detailed 
exploration of G4 nucleic acids, the focus of this thesis. The general features of G4 self-
assemblies are first considered, and their structural polymorphism is surveyed in greater 
detail. Next, the relevance of these architectures in biological and nanotechnological 
applications is discussed, particularly the opportunities afforded by regulating these 
oligonucleotide-based structures with small molecule ligands. A focus is placed on 
photoresponsive G-quadruplex systems, owing to the specific advantages of light as a 
stimulus for the regulation of biomolecules, and previous efforts towards the development of 
such systems are discussed. This survey identifies both existing progress towards the 
development of photoresponsive G4 ligands and highlights the limitations in the current state-
of-the-art that justify the new research described herein.  
 
1.1  General nucleic acid chemistry 
Nucleic acids are well known for their ability to form a wide range of higher-order structures, a 
property that allows these molecules to fulfil a variety of important functions.2 In biology, the 
DNA double helix provides the means of information storage for the whole of life.3 Meanwhile, 
RNA is the basis of one of nature’s most impressive machines, the ribosome, that so elegantly 
translates structure to function.4 The following sections briefly explore the fundamentals of 
nucleic acid chemistry that are responsible for the diversity of structural and functional roles 
of these nucleic acid systems. 
 
1.1.1  Watson-Crick base pairing: the classical double helix 
The monomeric unit of nucleic acids is the nucleotide, a small molecule composed of a ribose 
sugar and a nitrogenous base (together termed a nucleoside) conjugated to a phosphate 
group.3 In RNA, the ribose bears a hydroxyl group at the 2’ position of the carbohydrate ring; 
in DNA, the sugar is deoxygenated at this position (as drawn in Figure 1.1a). The polymeric 
Chapter 1: Introduction 
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structure arises from the joining of a chain of nucleotides by phosphodiester bonds formed 
from condensation of the phosphate on the 5’ position of one nucleotide with the 3’ hydroxyl 




Figure 1.1: From nucleotides to B-DNA. (a) structure of a DNA oligonucleotide containing 
four constituent nucleotides chosen to represent the structures each of the four nitrogenous 
bases. The sugar carbon numbering is shown in the adenosine residue; (b) the formation 
of Watson-Crick GC and AT base pairs by complementary hydrogen bonding; (c) cartoon 
representation of the structure of B-DNA showing the double helix and associated 
dimensions. Figure (c) reproduced from the PhD thesis of Steven T.G. Street,5 generated 
from co-ordinates of PDB structure 1BNA.6 
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Four nitrogenous bases occur naturally in DNA, namely guanine and adenosine (purine-
derived bases) and the thymine and cytosine (pyrimidine-derived bases). The structures of 
the four bases are shown in Figure 1.1a. It is this variation that enables DNA to act as an 
information store, since information can be encoded in the sequence of bases that form the 
polynucleotide chain. A remarkable feature of these bases is the preferential association of 
adenosine with thymine and guanine with cytosine, which arises due to the complementary 
nature of the hydrogen bonding moieties in the two pairs (Figure 1b). The tendency for these 
base pairs to hybridise in this way is reflected in the classical “B-DNA” structure elicited in 
1953 in which two complementary strands are wound together into a double helix.7 The pitch 
and handedness of the DNA helix is determined by the subtle interplay of the conformation of 
the individual oligonucleotides in combination with the inherent chirality of the carbohydrate.2,8 
In B-DNA, the most common morphology found in biological settings, all nucleotides exhibit 
the anti conformation of the glycosidic bond angle (as presented in Figure 1a).2 In combination 
with other conformational effects, such as C2’-endo puckering of the five-membered 
carbohydrate ring, this results in a right-handed helix with a pitch of 3.3 nm containing 
approximately 10 base pairs per turn (Figure 1c).3 Meanwhile, the presence of syn glycosyl 
arrangements and alternative sugar ring conformations gives rise to further double-helical  
structures such as the right-handed A-form9,10 and left-handed Z-form.11,12 Whist still featuring 





Figure 1.2: Top-down view of different DNA double-helical forms (a) A-DNA, (b) classical 
B-DNA and (c) Z-DNA. Figure by Mauroesguerroto, distributed under a CC BY-SA 4.0 
license. 
Chapter 1: Introduction 
4 
 
1.1.2  Hoogsteen base pairing: triplexes and beyond 
Beyond the Watson-Crick arrangements observed in DNA double helices, further possibilities 
of base pairing exist. In 1956, Jerry Donohue proposed 24 possible pairings of the four DNA 
bases in which the geometrical arrangement allows at least two hydrogen bonds to form 
between homologous or heterologous pairs.13 Though Donohue acknowledged that not all 
these pairings are likely to be relevant in biology, some evidence in support of additional 
modes of interaction was available at the time, such as the observation an A-A base pair in 
the crystal structure of adenine hydrochloride. More striking evidence was obtained in 1963 
by Karst Hoogsteen, who reported that the 1:1 co-crystal structure of 1-methylthymine and 9-
methyladenine revealed the two species hydrogen bonded in a non-Watson-Crick fashion 
involving the adenine N7 atom acting as the hydrogen bond donor, rather than the N1 atom 
as in the case of Watson-Crick base pairing.14,15 The possibility for a given DNA base to form 
both Watson-Crick and Hoogsteen interactions allows the formation triad ensembles (Figure 
1.3a), which enable the formation of triple-stranded DNA structures by hybridisation of a 
complementary third strand with the free Hoogsteen face of the bases accessible in the DNA 





Figure 1.3. From Hoogsteen base pairing to DNA triplexes. (a) representation of Hoogsteen 
base pairing between thymidine and adenosine showing the involvement of N7 as a 
hydrogen bond donor. The Watson-Crick pairing base pairing is also shown. (b) cartoon 
representation of the structure of a DNA triplex consisting of a classical Watson-Crick (B-
DNA) double helix (green) with a shorter oligomer (pink) bound in the major groove by 
association with the free Hoogsteen face of the DNA bases. Figure (b) by Duboolan, 
distributed under a CC BY-SA 4.0 license. 
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Despite the additional base pairing modes exemplified by these triple-stranded structures, the 
underlying canonical structure of B-DNA remains preserved, with the triplex-forming 
oligonucleotide in associating with the duplex almost in the manner of a ligand. However, 
Hoogsteen base pairing also offers further possibilities for the formation of nucleic acid 
secondary structures that do not resemble the classical double helix at all. In particular, the 
Hoogsteen face of guanine is particularly important in facilitating the self-assembly of nucleic 
acid sequences rich in this base to form a variety of supramolecular architectures. This topic 
is explored in more detail in the following section. 
 
1.2  G4 nucleic acids: discovery and structural features 
As early as 1910, it was reported by Bang that guanylic acid solutions spontaneously formed 
gels.17 This observation is generally considered to be the earliest hint of the propensity of 
guanine to form supramolecular assemblies but the methods required to probe the nature of 
these structures in detail were not yet available. In 1962, Gellert and colleagues disclosed a 
study of the optical properties and X-ray diffraction patterns of these materials.18 Through 
analysis of the diffraction patterns, the team were able demonstrate the aggregates were 
helical, ordered four-stranded structures. They therefore postulated the G-tetrad (Figure 1.4a) 
as the unit of assembly, in which four guanine residues are held together by complementary 
hydrogen bonding stabilised by co-ordination to a central metal cation. Self-association of 





Figure 1.4. Model of self-assembly of guanylic acid proposed by Gellert and co-workers. 
(a) a G-tetrad formed from the Hoogsteen base pairing between four guanine residues; (b) 
proposed helical structure of tetrad self-assembly by π-π stacking. Figure (b) used with 
permission, © National Academy of Sciences.19 
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As can be seen from inspection of the proposed G-tetrad structure, both the Watson-Crick and 
Hoogsteen faces of the guanine bases are required to from the G-tetrad arrangement though, 
at the time, it is unlikely that Gellert and colleagues were aware of Hoogsteen’s own 
discoveries. Gellert’s observations clearly pointed to the potential relevance of guanine self-
assembly in regulating the secondary structure of DNA in biology. Indeed, in the 1970s, similar 
diffraction studies on polyguanylic acid were reported, indicating that these species also form 
four-stranded helical structures in an analogous manner to the monomeric species.20,21  
However, it was not until 1988 that evidence for the self-assembly of biologically-relevant 
oligonucleotides was obtained by Henderson, Blackburn and colleagues.22 Through NMR 
studies, the group observed that human telomeric DNA (discussed in more detail in Section 
1.3.3.1) formed intramolecular structures, stabilised by non-canonical G-G base pairing, at low 
temperatures. Shortly afterwards, Sen and Gilbert observed that guanine-rich oligonucleotides 
spontaneously self-associated into four-stranded, tetrameric structures in monovalent salt 
buffer.23 In light of their results, and those of Henderson and colleagues, Sen and Gilbert 
proposed that telomeric sequences may spontaneously form four-stranded structures under 
physiological conditions. These seminal reports led an intensive flurry of activity in the early 
1990s that aimed to observe these structures more directly. Indeed, several X-ray diffraction24 
and NMR-based25–27 studies at this time unequivocally demonstrated that four-stranded G-rich 
DNA, now referred to as the G-quadruplex, can form in vitro, though much work remained to 
further interrogate its biological relevance. 
These structural studies on model G4-forming oligonucleotides revealed that whilst the G-
tetrad is the common unit of assembly, significant variety exists in the way the nucleic acid 
strands can arrange themselves to form this network (Figures 1.5 and 1.6). Whilst the parallel 
tetramolecular quadruplexes postulated by Sen and Gilbert were observed experimentally by 
Wang and Patel (Figure 1.5a),28,29  Rich and co-workers found that longer sequences 
containing intervening “loop” residues between the G-tracts allow the possibly fold-back 
arrangements, with subsequent dimerisation of two identical residues to form a bimolecular 
quadruplex (Figure 1.5b).30 In these structures, alternate guanines are found to adopt the syn 
conformation to facilitate the necessary antiparallel arrangement between the strands, rather 
than the all-anti arrangements found in the parallel G-quadruplexes. Finally, longer sequences 
containing four G-tracts separated by loop-forming residues can fold to form unimolecular 
quadruplexes (Figure 1.5c), first observed for the thrombin-binding aptamer 
(G2T2G2TGTG2T2G2) in potassium-rich solution.31 Shortly afterwards, a landmark study by  
Wang and Patel demonstrated the formation of an intramolecular G4 formed by the natural 
human telomeric sequence (AG3T2AG3T2AG3T2AG3T2A) in sodium-rich conditions.27  






Figure 1.5. Schematic representation of quadruplex structures formed from different 
numbers of nucleic acid strands: (a) termolecular G-quadruplex (b) bimolecular G-
quadruplex (c) unimolecular G-quadruplex. 
 
Subsequent studies on unimolecular G-quadruplexes, particularly human telomeric DNA 
models, reveal a significant number of possible structures this sequence can form depending 
on the folding conditions.32 The difference in folded arrangements give rise to distinctive 
features of each topology, in particular different loop types (diagonal, lateral and 
propeller/chain reversal), groove sizes and relative orientations (parallel/antiparallel) of the 
adjacent strands (Figure 1.6).33 The structure adopted depends on a variety of factors, such 
as the precise sequence in question, the identity of the metal ion, and the presence or absence 
of crowding agents.34,35 For example, the solution structure of telomeric DNA determined by 
Wang and Patel forms an antiparallel arrangement (known as the “basket form”), connected 
by two lateral loops and one diagonal loop (Figures 1.6a and 1.6b).27 However, when the same 
sequence is crystallised in the presence of potassium ions, an all-parallel conformation is 
found where the strands are connected by chain-reversal (propeller) loops (Figures 1.6c and 
1.6d).36 The structures of several related G4 sequences have also been solved, revealing 
further possibilities of folding topology, such as the (3+1) hybrid form, containing a combination 
of chain-reversal and lateral loops (Figure 1.6e and 1.6f).37  
 





Figure 1.6: Schematic illustrations (a,c,e) and experimentally-determined structures (b,d,f) 
of different polymorphs of the human telomeric G-quadruplex sequence: (a)-(b) antiparallel 
G4 formed from two lateral loops and one diagonal loop (PDB ID: 143D);27 (c)-(d) parallel 
G4 formed by chain-reversal loops (PDB ID: 1K8P);36 (e)-(f) hybrid G4 formed from two 
lateral loops and one chain-reversal loop (PDB ID: 2AQY).38 In (a,c,e) the strand 
directionality is indicated with arrows and the guanine residues are colour coded dark blue 
(syn conformation) and light blue (anti conformation). Experimental structures reproduced 
from the PhD thesis of Steven T.G. Street,5 generated from co-ordinates of the respective 
PDB structures. 
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1.3  Control of G4 structure: relevance and applications 
The discovery that G-quadruplex structures form in physiologically-relevant conditions 
generated huge interest across the scientific community in the wider relevance of these 
structures. The potential biological roles of G-quadruplex DNA have been, and continue to be, 
investigated in detail. G-quadruplexes have been observed in human cells through antibody 
staining39 and in vivo NMR techniques,40 and evidence implicating G-quadruplexes in a large 
number of regulatory roles in biological processes has been obtained.41,42 Because of their 
biological relevance and their distinct structural features compared to B-DNA, G-quadruplexes 
have received significant interest as therapeutic targets, since their unique topography can be 
targeted specifically with small molecule ligands.33,43–45 Meanwhile, the potential of G-
quadruplexes to regulate the formation of nucleic acid architectures has garnered interest as 
a means to exploit the formation of these nanostructures as the basis of DNA-derived 
nanodevices.46,47 This section briefly introduces these two research areas. 
 
1.3.1  G4 as a therapeutic target 
The level of interest in G4 partly stems from its potential as a therapeutic target. Indeed, G4‐
forming DNA and RNA sequences are not confined to the human genome but are also 
observed in a host of other organisms including plants,48 bacteria,49 viruses50,51 and 
parasites.52–54 Several bioinformatics algorithms have been developed to mine genomic 
sequences for putative quadruplex-forming motifs comprising G-tracts and loop residues of 
appropriate length.55 Earlier tools, such as Quadparser, developed by Huppert and 
Balasubramanian,56 have more recently been developed into more sophisticated algorithms, 
for example G4Hunter (developed by Mergny and co-workers) which permit more flexibility in 
the definition of putative G4-forming sequences to reflect the diversity in G4 structures in 
encountered to date.57 These computational approaches indicate the prevalence of potential 
G4-forming sequences across the genomes of many species, suggesting many potential 
opportunities to exploit G4 for the development of new therapeutic strategies. Much of the 
excitement around targeting the G-quadruplex in therapy arises from the possibility to 
specifically target these structures over duplex DNA, based on the difference in size and shape 
of the relevant binding sites. For example, the surface area of a G-tetrad is approximately 
twice the size of a base pair of a classical Watson-Crick double helix.58 Exploiting this selective 
mechanism of action is anticipated to reduce or eliminate the side-effects of traditional DNA-
targeting drugs that induce general DNA damage and off-target toxicity.59 Whilst this 
mechanism of action is designed to affect cancer cells most severely due to their abnormally 
high rate of proliferation60 it also exerts deleterious effects on normal tissue due to the 
homogeneous nature of the majority of cellular DNA. Selective targeting of non-canonical DNA 
Chapter 1: Introduction 
10 
 
structures to trigger anti-tumour action is therefore hypothesised to confer a therapeutic 
advantage.33,44 
The following sections discuss the therapeutic relevance of G-quadruplexes and some 
illustrative examples of previously-developed G-quadruplex targeting agents. 
 
1.3.1.1 Telomeric G-quadruplexes 
Telomeres are found at the end of chromosomes and protect genetic material from damage, 
during normal cellular function and in cell replication.61 The telomeric DNA is composed of 
repeating units of the sequence (TTAGGG)n and is found to be highly conserved across 
organisms.62,63 In humans, telomeres are up to 15 kilobases in length and the DNA is 
associated with a range of proteins, which together are termed the shelterin complex.64,65 A 
notable feature of telomeric DNA is that the 3’-end bears a single-stranded overhang of 
between 15 and 200 nucleotides. During cellular replication, DNA polymerase is unable to 
replicate the full length of this overhang, meaning the telomeres progressively shorted with 
each replication cycle.66,67 Eventually, the shortening of the single-stranded overhang 
telomere reaches a point (known as the “Hayflick limit”) which triggers a variety of process that 
lead to cell death.68 Therefore, as well as protecting the genetic material, the telomere also 
regulates the cellular lifetime (Figure 1.7).69 







Figure 1.7: Illustration of the regulation of cellular lifetime by telomere shortening. With each 
cell division the telomere (represented as red) becomes shorter until the Hayflick limit is 
reached. Figure by Azmitowski17, distributed under a CC BY-SA 4.0 license. 
 
A common feature of cancer cells is the upregulation of telomerase, a reverse transcriptase 
that maintains the length of telomeres by adding TTAGGG sequences to the 3’ end of 
telomeric DNA.70 The activity of telomerase is closely associated with cancer cell immortality,  
since the maintenance of telomere length leads to uncontrolled proliferation as the Hayflick 
limit is not reached.71,72 Indeed, the enzyme is found to be up-regulated in 85-95% of cancers  
and comparatively non-expressed in the majority of non-cancerous cells.73 Thus, inhibition of 
this enzyme receives significant attention as an anti-cancer strategy. Several approaches for 
the inhibition of telomerase have been pursued, including nucleotide-based reverse 
transcriptase chain-terminators such as the anti-HIV drug AZT74 (1, Figure 1.8) and small-
molecule inhibitors such as BIBR153275 (2, Figure 1.8). Though the latter compound proves 
effective in inhibiting telomerase (IC50 = 92 nM) in vitro, very long exposure times (of the order 
of 120 days) appear to be required before critical shortening of the telomere is achieved in 
order to promote senescence, questioning the utility of direct telomerase inhibition as a 
therapeutic strategy.  






Figure 1.8: Examples of direct telomerase inhibitors: AZT (1) and BIBR2 (2). 
 
As an alternative strategy of telomere targeting, the potential of exploiting the propensity of 
telomeric sequences to form G-quadruplexes was first ventured in a seminal study by Zahler 
and co-workers, reported in 1991.76 The team demonstrated that the activity of telomerase is 
stalled when the DNA is folded into quadruplex form, prompting the notion that stabilisation of 
the G-quadruplex by small molecule ligands may indirectly inhibit telomerase. This 
observation led to the therapeutic hypothesis that induction of the telomeric G-quadruplex in 
vivo by a small molecule binding ligand may indirectly inhibit telomerase by preventing the 
binding of the enzyme to its DNA target (Figure 1.9). Proof of this concept was achieved by 
Hurley, Neidle and co-workers in 1997, who reported the first G-quadruplex stabilising ligand, 
an anthracene-9,10-dione (3, Figure 1.10), that displayed potent inhibitory activity (IC50 = 23 
μM) of the enzyme.77  
Following Hurley’s report, significant attention has been devoted to the design of further G-
quadruplex binding ligands as potential therapeutic agents, especially in light of further 
possible quadruplex targets identified across the genomes of humans and pathogens 44,78–84  
Landmarks in G4 ligand development are discussed later (Section 1.3.1.4) in the context of 
general G4-ligand design principles. 
 




Figure 1.9: Therapeutic mechanism of telomerase inhibition by G-quadruplex ligands (a) 
telomerase acts on single-stranded DNA; (b) stabilisation of G-quadruplex by ligand 





Figure 1.10: The first G-quadruplex ligand shown to indirectly inhibit the activity of 
telomerase, reported by Hurley, Neidle and co-workers in 1997. 
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Though G4-binding compounds were initially designed based on a therapeutic hypothesis of 
telomerase inhibition, the antiproliferative effects of telomeric G4 binding ligands often appear 
to be more acute than those observed with direct inhibitors of telomerase such as BIBR1532, 
suggesting greater clinical utility based on a more rapid response, but also pointing to 
additional mechanisms of action than indirect telomerase inhibition.44 Indeed, it has 
subsequently been shown that the stabilisation of the telomeric G4 triggers the uncapping of 
key shelterin proteins from the telomere,85,86 leading to short-term DNA damage responses 
which induce telomeric dysfunction and associated cellular senescence and apoptosis on 
much shorter timescales than required for Hayflick-related cell death.87 It has been ventured 
that the observed selectivity for tumoral cells may be due to an absence of defence 
mechanisms against G4-folding in cancerous cells, such as the helicase enzymes capable of 
unwinding the telomeric quadruplex.44,88,89 However, the true mechanism of action of G4 
targeting compounds is difficult to establish with certainty, not least because the same ligand 
may also target G-quadruplexes at locations other than telomeres (such as those in promoters 
sequences) that may be also responsible for more short-term destructive effects. These non-
telomeric G-quadruplexes are briefly discussed in the following section. 
 
1.3.1.2 G-quadruplexes in oncogene promoters 
Beyond the telomere, bioinformatics approaches have revealed an abundance of putative 
quadruplex forming sequences across the human genome.57 Experimentally, sequencing 
studies by Balasubramanian and co-workers identified 716,310 putative G4-forming 
sequences in genomic DNA90 and, more recently, a chromatin immunoprecipitation strategy 
(ChIP-seq) by the same laboratory observed the formation of approximately 10,000 G4 
structures in endogenous human chromatin,91 further strengthening the evidence for G4 in the 
regulation of genetic processes. Complementary experimental studies have validated the 
occurrence of many G-quadruplexes structures in the promotor regions of several genes 
associated with human cancers, such as the c-myc,92 BCL-2,93 HRAS,94 KRAS,95 c-KIT96 
genes, in addition to many others. Critically, G4-forming sequences are over-represented in 
oncogene promoters (genetic regions which are responsible for the activation of gene 
transcription), with 69% of these sequences found to contain a putative G4, versus a global 
occurrence of 43% across all promoter sequences.97 In 2002, Hurley observed that the G-rich 
strand of the c-myc promoter was able to form G-quadruplex structures, and that the stability 
of this structure correlated with transcriptional activity.92 Moreover, it was observed that the 
presence of a G-quadruplex stabilising compound, TMPyP4 (4, Figure 1.11) led to 
transcriptional suppression. 











Figure 1.12:  Proposed mechanism of oncogene suppression by targeting G4 DNA with 
small molecules. Induction of the G4 fold in the gene promoter by the stabilising ligand 
inhibits the binding of RNA polymerase and transcription factors leading to downstream 
silencing of the gene. Figure adapted from the author’s publication with permission © Wiley.1 
 
Based on these findings, it was proposed the stabilisation of the folded structure prevents the 
binding of transcription factors to the promoter leading to downstream silencing of the gene, 
and therefore targeting G-quadruplexes in promoter regions was introduced as a possible 
anticancer strategy (Figure 1.12). This concept ultimately led to the development of the 
compound quarfloxin (5, Figure 1.11) which was, until recently, the only G4 targeting 
compound to reach clinical trials.45 Though this molecule is shown to bind strongly to c-myc 
(and other G-quadruplexes) in vitro, its biological mechanism of action was found to be more 
complex than that represented in Figure 1.12, instead displacing nucleolin from an RNA 
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quadruplex inside the cell nucleolus, which in turn acts as the c-myc G4 ligand inside the 
nucleoplasm leading to downstream apoptosis of cancer cells. 
 
1.3.1.3 G-quadruplexes as antiparasitic targets 
Though the vast majority of efforts on G4-targeting molecules focus on targeting G4 in the 
human genome as a potential anticancer strategy, attention is increasingly being focused on 
G4 sequences found in the genomes of pathogenic organisms such as bacteria49 and 
viruses50,51 as a means of developing much-needed efficacious treatments against these 
sources of infection. Recently, a bioinformatics search revealed the occurrence of G4 
sequences in the genomes of the protozoan parasites Trypanosoma brucei and Leishmania 
major.52 Both organisms contain frequent occurrences of the conserved telomeric sequence 
in addition to several further unique putative G-quadruplex forming sequences. For example, 
the EBR1 sequence d[G3CAG5TGATG4AG2AGCCAG3] occurs 33 times in the T. brucei 
genome and was subsequently demonstrated to form a stable quadruplex under physiological 
conditions in biophysical studies.52 The sequence predominately occurs in genomic regions 
coding for several proteins including a cysteine peptidase and a purine transporter. G4s 
therefore present a potential opportunity as a target for novel antiparasitic therapies, for which 
there is an urgent need for further development.98 For example, the T. brucei parasite, 
responsible for the Human African Trypanosomiasis (HAT) disease, endangers 69 million 
people across Sub-Saharan Africa,99,100 and existing therapies (such as pentavalent  
antimonial compounds) suffer from severe limitations including severe side effects101 and 




Figure 1.13: Example of a naphthalene diimide G4-targeting ligand that induces selective 
toxicity in T. brucei and L. major parasites over non-tumoral mammalian cells. 
 
The handful of G-quadruplex binding compounds explored for antiparasitic activity to date are 
primarily naphthalene diimide derivatives.52,103  For example, the G-quadruplex targeting 
compound 6 (Figure 1.13) displays low nanomolar (EC50 = 9 nM) toxicity to T. brucei parasites 
Chapter 1: Introduction 
17 
 
whist remaining approximately 40-fold less toxic to non-tumoral mammalian cells. The same 
compound is also toxic to L. major (EC50 = 34 nM). Though the activities observed in these 
early studies are promising, the identification of further DNA-binding chemotypes capable of 
exerting selective antiparasitic activity is of critical relevance to exploring this therapeutic 
hypothesis. Furthermore, the detailed mechanism of action of these compounds remains to 
be fully elucidated. 
 
1.3.1.4 G4 ligand design and screening 
The vast majority of G4 ligands employ rigid aromatic heterocyclic frameworks that are 
designed to π-stack onto the large surface of the G-tetrads in preference to intercalating the 
base pairs of DNA duplexes.79,104 Cationic character (for aqueous solubility and to facilitate 
electrostatic interactions with negatively charged nucleic acids) is often introduced by 
conjugation of these cores to basic amino residues (which are protonated to the ammonium 
form at physiological pH), to quaternised ammonium or pyridinium moieties, or to transition 
metal cations.1,44 Ligands may also target the G4 through other binding modes, such as to the 
loops105 or grooves106 as well as the planar tetrads. 
Standard biophysical techniques are used to probe the strength of small-molecule ligand 
binding to G-quadruplexes, such as spectroscopic or calorimetric titration experiments.107 DNA 
melting assays are frequently employed to examine the ability of molecules to stabilise the 
folded G4 structure to thermal denaturation which also provide an indication of ligand 
binding.108 The binding modes of ligands to the G4 structures may be elucidated using NMR 
spectroscopic techniques109 and X-ray crystallography110 whilst circular dichroism 
spectroscopy is a powerful tool to characterise the effect of the ligand on the G-quadruplex 
topology, since the different topological arrangements give rise to distinctive spectral 
signatures.111 Several of these techniques were employed during the research reported in this 
thesis, and they are introduced in more detail in the relevant results chapters. Meanwhile, 
validation of a ligand’s mode of action requires specific in vitro assays, such as the TRAP 
(telomeric repeat amplification protocol) assay, which allows the ability of a given molecule to 
inhibit the telomerase to be quantified,112 or gene transcription assays in the case of ligands 
designed to target promoter quadruplexes.92 
Some well-studied G-quadruplex ligands are displayed in Figure 1.14 to illustrate ligand 
design principles. Following the discovery that anthracene-9,10-dione ligand 3 (Figure 1.10) 
inhibits telomerase activity by stabilising G-quadruplex DNA, significant efforts were 
undertaken to optimise the quadruplex binding properties of this scaffold in pursuit of a 
therapeutic agent.113,114 However, it was later identified that the relatively low 
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quadruplex/duplex selectivity of these derivatives was unlikely to be sufficient for further 
biological application. Following iterative design by Neidle and co-workers, modifying the  
aromatic core115,116 and groove-binding side-chains,117 it was found that the addition of a third 
side-chain substituent to an acridine scaffold conferred much higher G-quadruplex selectivity 
than observed with the bis-substituted analogues. The emerging lead compound from these 
studies, BRACO-19 (7, Figure 1.14) confers a 27 °C thermal stabilisation to folded quadruplex 
DNA (measured by a fluorescence-based melting assay)104 and the compound was 
subsequently shown to inhibit tumour growth with low micromolar efficacy, with evidence that 
 
 
Figure 1.14: Examples of previously-developed G4 ligands. 
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the toxicity results from telomerase inhibition.118 X-ray crystallography studies indeed 
demonstrated the stacking of the aromatic core with the planar G-tetrads of human telomeric 
DNA, whilst the basic side chains targeting the G4 grooves.110 
Earlier efforts from Hurley’s group focused on the perylene diimide motif, leading to the 
development of PIPER (8, Figure 1.8).119 PIPER shows particular selectivity for quadruplex 
DNA when in an aggregated state at pH 8.5.120 However, little selectivity between DNA 
structures is observed at pH 7 and the very large, flat nature of the central core would be 
unlikely to confer favourable pharmacokinetic properties in vivo.121 This perhaps led Neidle 
and co-workers to focus their studies on the more compact naphthalene diimide (NDI) scaffold. 
These compounds have been extensively developed by both Neidle’s group122 and others123–
126 in recent years, leading to some very promising lead compounds such as MM41 (9, Figure 
1.8). Molecular modelling studies suggest that the tetrasubstitution pattern of these ligands is 
a key factor in achieving high G-quadruplex binding selectivity due to simultaneous recognition 
of four quadruplex grooves.127 However, studies in our group have recently shown that divalent 
NDIs also display good selectivity for human telomeric DNA in potassium buffer, suggesting a 
large number of groove-binding motifs is not necessarily essential for quadruplex/duplex 
selectivity.124 MM41 is currently advancing towards potential therapeutic application and has 
recently shown anti-tumour activity against pancreatic cancer in mice.128 
Nitrogen-containing heteroaromatic groups appear to be rather privileged scaffolds in G-
quadruplex ligand development. TMPyP4 (4, Figure 1.11), containing four N-methylpyridinium 
moieties induces high thermal stabilisation (17 °C)104 in G4 structures but, likely by virtue of 
its high cationic charge, it is non-selective between G-quadruplex and duplex structures.129 
However, a significant development in G-quadruplex ligand design was the observation that 
bis-quinolinium functionalised phenanthroline derivatives are highly effective scaffolds for 
targeting the four-stranded structure.130 Indeed, PhenDC3 (10, Figure 1.14) is one of the most 
potent and selective G-quadruplex ligands reported to date. In this case, the crescent-shaped 
molecular confirmation promoted by intramolecular hydrogen bonding renders the surface 
area of the molecule almost perfect for overlap with square-planar G-tetrads. This is reflected 
in the excellent stabilisation of G-quadruplex structures (up to 30 °C at 1 μM ligand 
concentration) whilst the stability of duplex DNA is unaffected. Moreover, the ligand-induced 
G4 stabilisation is retained even in the presence of high concentrations of duplex competitor, 
indicative of the discrimination between the two structures. Another benchmark G-quadruplex 
ligand is pyridostatin (11, Figure 1.14) which also contains the quinoline moiety though, in this 
case, as the free base form.131 The G4 affinity in this case is therefore afforded by the basic 
amine residues in the side chains when protonated at physiological pH, but also by the 
molecular shape of the aromatic scaffold which, like PhenDC3, is crescent-like owing to 
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intramolecular hydrogen bonding between the pyridine nitrogen lone pair and amide NH 
group. 
The natural product telomestatin (12, Figure 1.14) was first isolated from Streptomyces 
annulatus in 2001.132 This compound induces high thermal stabilisation of quadruplex DNA of 
24 °C.104 Interestingly, these properties arise in spite of the lack of side-chain groove-binding 
motifs that are characteristic of many other G-quadruplex ligands. Instead, the activity of 
telomestatin activity results from the extensive overlap of its delocalised π-electron system 
with the G-tetrad, as demonstrated by the solution structure of the molecule in complex with 
telomeric DNA determined by NMR spectroscopy.133 These characteristics are considered to 
result in the exceptionally high (70-fold) selectivity for quadruplex DNA, with the cyclic shape 
being unsuitable for interaction with DNA duplex. Telomestatin showed promise in early 
biological studies, demonstrating ability to induce cell death in leukaemia cells by telomerase 
inhibition and telomere shortening.134 However the difficulty in obtaining telomestatin by 
natural and synthetic methods,135 as well as its poor aqueous solubility,79 have rendered it 




Figure 1.15: A redox-activated G4 ligand. 
 
Metal complexes have also been employed as G4 ligands, since the square planar 
coordination compounds are well-suited to forming stacking interactions with G-tetrads.136 This 
property allows the engineering of stimuli-responsive ligands based on the redox properties of 
the metal centre, as demonstrated recently by Vilar and co-workers through the design of 
platinum complex 13 (Figure 1.15).137 This octahedral Pt(IV) complex is a poor G4 binder, but 
is readily reduced to the G4-binding square planar Pt(II) complex 14 in the presence of 
bioreductants, such as glutathione or ascorbic acid, suggesting that the compound may serve 
as a prodrug to target the hypoxic environment of tumour cells. 
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1.3.2  G4 as the basis of functional materials 
Though G-quadruplexes have clear potential as therapeutic targets by virtue of the ubiquity of 
nucleic acids amongst all living organisms, this does not restrict the exploitation of G-
quadruplexes solely to biological applications. In particular, the defined polymorphism of these 
structures points to a variety of applications in the development of nanodevices, since 
interconversion between G4 topologies, or between G4 and unfolded structures, may be 
deployed to perform mechanical work at the molecular level.47,138 Alternatively, the switching 
of G4 between distinct conformations may alter its interactions with other components of a 
system, allowing an input (which triggers a change in G4 conformation) to be coupled to an 
output activated by the conformational change, such as the release of a molecular cargo in a 
delivery system139 or the light-up of a fluorescent reporter.140 Towards these applications, 
strategies that allow the responsive control of the G4 assembly are key to realising potential 
applications. This section briefly considers the major ways G4 structure can be reversibly 





Figure 1.16: The G4-derived nanomachine developed by Alberti and Mergny. Figure 
adapted from the author’s publication with permission © Wiley.1 
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1.3.2.1 Nucleic acid triggers 
In 2003, Alberti and Mergny reported the first example of a G4‐based nanomachine, which 
relies on a DNA-hybridisation strategy (Figure 1.16).141 Addition of the complementary 
Watson-Crick strand to a folded G-quadruplex (i.e. a C-rich strand) triggers the unfolding of 
the quadruplex to allow hybridisation with the second strand, thus promoting the conversion 
of the four-stranded folded structure to an extended duplex. Indeed, the effective diameter of 
the oligonucleotide changes from 1.5 nm in the folded state to 7 nm in the single stranded 
form. The effect can then be reversed by addition of a further G-rich fuel, which outcompetes 
the G4-forming sequence for hybridisation with the C-strand, regenerating the folded G4 and 
a duplex DNA waste product. The reversible device could be switched over eleven cycles 
without observable fatigue by addition of appropriate complementary DNA strands. Such 
properties could possibly be exploited to position molecular cargo or exert force at the 
molecular level. Indeed, an application of this approach was later demonstrated by Simmel 
and co-workers, who developed a similar system based on the thrombin binding G4 
aptamer.139 The folded G4 form has high affinity for thrombin (a human blood-clotting enzyme), 
whist triggering of the unfolded form (through addition of a complementary oligonucleotide in 
the matter shown in Figure 1.16) caused the cargo to be released. However, in these 
strategies, the need for repeated additions of two different DNA fuels and the generation of 
the waste oligonucleotide products are potential drawbacks of the approach in terms of 
practical applications. 
 
1.3.1.2 Metal ion triggers 
Considerable success in exploiting G4 for functional applications has been achieved by 
exploiting the sensitivity of the structure to metal ions. In particular, dynamic control of 
quadruplex formation and dissociation can by readily achieved by controlling the concentration 
of free potassium ions, which trigger the folding of the four-stranded structure through 
stabilisation of the G-tetrads. Subsequent addition of a chelating agent, such as 18-crown-6, 
sequesters the metal ion causing unfolding of the G4 structure. Several applications of this 
metal-mediated conformational switch have been demonstrated.46 For example, Willner and 
co-workers have reported DNA-based hydrogels where the stiffness of the material can be 
reversibly controlled by the potassium/18-crown-6 mediated crosslinking of the constituent 
strands into G-quadruplexes (Figure 1.17a).142 






Figure 1.17: functional applications of controlling G4 assembly with metal ions and 
chelators (a) switching of hydrogel stiffness by alternate dosing of K+ and crown ether; (b) a 
Pb2+ sensor based on the activation of fluorescence on Pb2+-induced G4 formation. 
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In a different approach, Wang and co-workers exploited the Pb2+ formation of a G-quadruplex 
structure to act as a sensor for the metal ion itself (Figure 1.17b).140 In this strategy, the metal-
mediated stabilisation of the G4 structure provides a binding site for a fluorophore which 
becomes emissive upon binding, thereby indicating the presence of the metal ion. In a similar 
way to the potassium-responsive hydrogels developed by Willner, the device may be recycled 




Figure 1.18: Reversible ligand-mediated control of G4 structure. (a) chemical structures of 
triaminoanthracene 15 and porphyrazine 16; (b) toggling of G4 between parallel and 
antiparallel G4 topologies of telo24-Na+ by sequential addition of the ligands. Figure (b) 
adapted from the author’s publication with permission © Wiley.1 
 
1.3.2.3 Ligand triggers 
The vast majority of G4 ligand development has been undertaken with a therapeutic goal in 
mind, as discussed previously in Section 1.3.1. During these studies, ligands are often 
screened for binding to pre-formed G4 structures formed under ion-rich conditions, under 
which a major folded nucleic acid conformation predominates. However, especially in the case 
of the highly polymorphic telomeric DNA, certain ligands are actually able to induce changes 
in the G4 folding topology from the native conformation to a different folded structure, providing 
an additional opportunity for the control of G4 architectures.1  As well as inducing the formation 
of G4 from an unfolded structure in the absence of stabilising metal cations,143 some small 
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G4-targeting molecules exert folding changes in the presence of metal ions, thereby displaying 
potential to control G4-based topology in physiologically-relevant conditions where, unlike the 
applications discussed in the previous section, the concentration of metal ions cannot be 
readily controlled. 
One of the first examples of a ligand‐driven G4 nanodevice was reported by Balasubramanian 
and co‐workers in 2007.144 A triamino‐anthracene 15 (Figure 1.18a) derivative was designed 
to bind G4 by simultaneous π‐π stacking interactions with the surface G‐tetrads and threading 
of the side‐chain through the central channel of the G4. The spacing of the amine groups was 
chosen to mimic the distance between K+ ions in the native G4, allowing the amine moieties 
to act as the channel cations when protonated at physiological pH. Interestingly, this ligand 
induces a conformational switch of the telo24 G4 from an antiparallel structure in sodium buffer 
to a parallel form. Furthermore, since the porphyrazine ligand 16 (Figure 1.18a) preferentially 
stabilises the antiparallel form of telo24, the G4 conformation could be toggled between 
antiparallel and parallel forms by sequential addition of the two ligands (Figure 1.18b). 
However, the conformational switch was only reversed once in this manner; possibly further 
cycles were inhibited by an overaccumulation of the ligand fuel, and no specific application 
has yet been developed at the time of writing. 
More recently the Zhou group employed a host/guest approach towards the ligand triggered 
control of G4 structure towards regulation of the enzymatic activity of thrombin.145 This system 
is based on the affinity of the terminal piperidinium moieties of azobenzene derivative 19 for a 
cucurbit[7]uril (CB7, 17) host (Figure 1.19a). Whilst free ligand 19 induces the formation of a 
G4 structure in a G-rich telomeric strand, sequestration by CB7 17 causes dissociation of the 
ligand from the G4 and concomitant unfolding of the DNA secondary structure occurs. By 
fuelling the system alternately with CB7 17 and a competitive guest, (adamantylammonium 
18) 13 switches of G4 unfolding and refolding were achieved. To regulate enzymatic activity, 
an aptamer containing a G4-forming linker (based on telomeric TTAGGG repeats) that binds 
to and inhibits thrombin activity was employed (Figure 1.19b). The addition of ligand 19 
triggers the folding of the linker thereby causing the dissociation of the inhibitor, un-gating the 
activity of the thrombin. The enzyme can be subsequently deactivated by adding CB7 17 which 
sequesters the ligand, causing unfolding of the G4 and regeneration of the thrombin/inhibitor 
complex. In the same way as the original proof-of-concept outlined above, addition of 
adamantylammonium cation 18 reverses this process. 
 






Figure 1.19: Ligand-triggered regulation G4 structure to control the activity of an enzyme 
using a host/guest approach. (a) Chemical structure and cartoon representation of 
cucurbit[7]uril 17, an efficient molecular host for ammonium cations such as 19 and 
adamantylammonium 18. (b) Switchable control of thrombin activity by exploiting the 
host/guest chemistry of G4 ligand 19 and CB7 17.  Figure adapted from the author’s 
publication with permission © Wiley.1 
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1.4  Photo-control of G4 DNA 
The previous sections introduce the two main opportunities afforded by regulation of G-
quadruplex DNA: regulation of formation in vivo as a potential therapeutic strategy, or 
regulation of the structure in order to generate a mechanical or spectroscopic output as the 
basis of a functional system. In all of the systems discussed so far, the control over G4 is 
achieved using exclusively chemical triggers. Though this is not a problem in some cases, the 
reliance on chemical stimuli alone may lead to undesirable effects, impracticalities or 
limitations in real-word applications. In therapy, drugs are often administered intravenously 
and are therefore distributed throughout the whole organism, rather than just to the desired 
site of action, and this is partially responsible for side-effects due to off-target activity in other 
vital organs. In the case of functional applications, such as the development of sensors or 
other responsive materials, the sequential addition of chemical fuels must be precisely 
balanced in order to allow robust control over the system and, depending on the application, 
may not always be convenient or possible. Meanwhile, light offers several complementary 
advantages over chemical stimuli for the regulation of both biological and functional systems. 
In this section, the potential to regulate G-quadruplex structures using light towards 
therapeutic and functional applications is considered. 
 
1.4.1  Light as a stimulus for the regulation of biomolecule structure and function 
Upon the irradiation of an organic chromophore with light at appropriate wavelength, an 
electron is excited from the highest-occupied molecular orbital to the lowest-unoccupied 
molecular orbital. This transition allows various types of chemistry that are either not possible 
in the ground state, either on orbital symmetry grounds or because the thermal barrier to 
interconversion is too high. For example, the rotation about a stilbene double bond does not 
occur thermally at ambient temperature, meaning the E and Z isomers are stable and do not 
interconvert between one another in the ground state, but this barrier is easily surmounted in 
the photoexcited state, providing a pathway for thermal relaxation to the other isomer (Figure 
1.20).146 
Light is an attractive means for the regulation of both biological and functional systems since 
it can be administered with much higher spatiotemporal precision than chemical fuels.147–151 
By controlling the wavelength, intensity and irradiation time, both the energy and dose of 
photons can be controlled. Unlike chemical stimuli for which addition is, in practice, normally 
irreversible, irradiation does not contaminate the system (assuming no unwanted side-
reactions take place) and therefore is traceless once irradiation has ceased. 





Figure 1.20: Example of a molecular photoswitch – the isomerisation of E to Z stilbene. In 
the ground state (S0) the thermal barrier to thermal interconversion (blue trace) is too high 
for the transformation to occur at ambient temperature. Photoexcitation to the higher energy 
(S1) state allows this energy barrier to be surmounted. 
 
 
Figure 1.21: Approaches to the photocontrol of biomolecules. (a) the activity of the molecule 
is blocked (red) by conjugation to caging group by a photolabile linker. Photocleavage 
releases the active (green) form of the molecule; (b) the structure of the molecule is switched 
between a comparatively inactive (red) and active (green) form by light; in some cases, the 
process is thermally reversible. 
Chapter 1: Introduction 
29 
 
A variety of photoresponsive chemotypes have found application in different biological 
settings.151 These fall into two main categories: photocages and photoswitches (Figure 
1.21).147 In a photocaging strategy, the biological activity of the molecule is deactivated by 
conjugation by a photolabile group to a fragment which inhibits its activity. Photoirradiation 
cleaves the caging group, delivering the molecule in the active form (Figure 1.21a).  In the 
case of photoswitches, irradiation with light causes a change in the molecular structure. In 
many cases this can be reversed either thermally or with light of a different wavelength (Figure 
1.21b). This approach is particularly attractive since no waste products are generated and 
(assuming the two photoisomers have different activities in the system of interest) the activity 
of a molecule may therefore be switched reversibly without the need for sequential addition of 
chemical fuels, offering additional levels of control over the system. The deployment of 
molecular photoswitches in the regulation of biological systems has been extensively reviewed 
by others, and four primary scaffolds emerge as the most common: azobenzenes, stilbenes, 
diarylethenes and spiropyrans.151 The general structures and photoisomerisation reactions of 
these chemotypes are shown in Figure 1.22. The azobenzene (E-20/Z-20) and stilbene (E-
21/Z-21) chromophores undergo E/Z isomerisation, whilst the diarylethene (22o/22c) and 
spiropyran (23o/23c) scaffolds are converted between closed and open forms.  
 
 
Figure 1.22: Organic photoswitches most commonly deployed in biological applications. 
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Regarding the application of photochemistry towards the regulation of nucleic acid structures, 
two possible approaches can be considered. Either the photoresponsive functionality may be 
pre-incorporated in the biomolecule itself, or a ligand can be designed where binding activity 
can be controlled either by a photocaging or photoswitching strategy. The former example is 
particularly useful in the development of functional materials which need not rely on natural 
DNA structures and can be easily modified to include the necessary functionality. The latter is 
more relevant in biological contexts, such as therapy, where pre-modification of the target is 
not always possible, and control is instead exerted using small molecule ligands. These two 
strategies are considered below in the context of the opportunities afforded by the control of 
G-quadruplex structure. 
 
1.4.2  Photocontrol through incorporation of photoswitches  
To date, the majority of studies concerned with the photoregulation of nucleic acid structures 
focus the control of duplex DNA hairpins.149,152 Meanwhile, examples of photoresponsive 
control of G4 structures in a similar way are rather rare despite the proven applications of this 
alternative architecture in the development of functional materials. Ogasawara and Maeda 
demonstrated the photoresponsive formation and unfolding of G-quadruplex by installation of 
a modified guanine nucleobase decorated with the photoisomerisable 8- fluorenylvinyl group 
(E-24/Z-24, Figure 1.23).153 In the E state the G-quadruplex structure assembles, but 
isomerisation to the Z state using 410 nm light causes the unfolding of the structure. The 
folding and refolding process could be cycled several times, and in turn control the affinity of 
the DNA structure for thrombin. Thus, the system achieves a similar end to the hybridisation-
controlled catch-and-release of thrombin reported by Simmel (see Section 1.3.2.1),139 but is 
controlled simply by photoirradiation rather than requiring sequential addition of 
oligonucleotide fuels. Later, the Heckel group demonstrated the photoresponsive formation of 
an intermolecular G‐quadruplex by incorporation of azobenzene functionality into the 
backbone of guanosine tetramers (E-25/Z-25, Figure, 1.24).154 Very recently, the Tucker group 
engineered a complementary system where thrombin binding to G-quadruplex is modulated 












Figure 1.23: Photoswitching of G-quadruplex folding by incorporation of the 
photoresponsive 8-fluorenylvinyl group, developed by Ogasawara and Maeda. Structural 
figures reproduced with permission © Wiley.153  
 
Figure 1.24: Photoresponsive formation of an intermolecular G-quadruplex from 
azobenzene-linked nucleotides, developed by Heckel and co-workers.  
 






Figure 1.25: Control of G4/thrombin binding by anthracene photodimerisation, developed 
by Tucker and colleagues.  
 
Though many exciting applications of these elegant approaches to regulating G4 structure 
can be envisaged, the drawback in these cases is the need to rely on pre‐incorporation of 
unnatural functionality into the oligonucleotide, limiting their potential applications in biological 
setting. Complementary applications, where such a modification of the underlying DNA 
sequence is undesirable, could be achieved by using a supramolecular approach, through the 
design of photoresponsive small-molecule ligands. 
 
1.4.3  Photocontrol using photoresponsive ligands 
Regarding the development of photoresponsive small molecules for use in biological 
applications, much interest has been devoted to the development of photoswitchable inhibitors 
of proteins, towards the goal of achieving light-responsive therapeutic agents.148,156–158 This 
approach, known as photopharmacology, aims to reduce the off-target effects resulting from 
distribution of the drug around the whole organism by using light to activate the molecule 
specifically at the site of action, and subsequently deactivating the compound by light and a 
different wavelength, or a thermal process (Figure 1.26). This approach requires a 
photoswitchable ligand where there is a significant difference in bioactivity between the two 
isomers. For example, Feringa and colleagues developed a photoresponsive inhibitor of a 
histone deacetylase based on an azobenzene core, which was 39-fold more active in the Z  
versus the E state (E-26/Z-26, Figure 1.27) which led to increased toxicity to HeLa cells.159 
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Despite DNA being well-studied as a therapeutic target, photopharmacological approaches 
towards targeting DNA have barely been explored. The only examples to date consider duplex 
DNA binding. For example a photochromic spiropyran (27o/27c, Figure 1.28) developed by 
Andreasson and co-workers was shown to bind calf thymus DNA in the planar open (27o) 
zwitterionic state, whilst binding was deactivated upon photocyclisation to the closed (27c) 
state.160 In a subsequent study, the authors evaluated the uptake and cytotoxicity of the two 
isomers in HEK 293 cells, observing that in cellulo photoisomerisation of the compound led to 
significantly increased (52% versus 3%) cell death.161 
 
 
Figure 1.26: Concept of photopharmacology. (a) in traditional chemotherapy; (b) in situ 
control of activity through use of photoswitchable drugs. 
 











Figure 1.28: A spiropyran-derived photoresponsive ligand for duplex DNA, developed by 
Andreasson and colleagues.  
 
Though quadruplex DNA has long been studied as a therapeutic target, and significant 
therapeutic leads have been generated which demonstrate the benefit of targeting these 
structures selectively over duplex DNA (Section 1.3), to date no attempts have yet been made 
to explore the potential of these non-canonical structures as targets for photopharmacology. 
Two examples of photocaged G-quadruplex ligands have been reported, one based on 
pyridostatin (28)162 and the other based on a telomestatin mimic (29, Figure 1.29).163 In both 
cases, the G-quadruplex binding activity of the active compound is neutered by the presence 
of the nitroveratryl group which may be removed in cellulo by irradiation with UV-light, resulting 
in the unmasking of the compounds’ toxicity. However, the photocaging approach permits only 
one-way control of the ligand activity. 






Figure 1.29: Photocaged G-quadruplex ligands. The nitroveratryl caging group (shown in 
red) is removed by irradiation with 385 nm light. 
 
The only example of reversible control of G4 with a photoswitchable small molecules is 
azobenzene derivative 19 (previously introduced in Section 1.3.2) first reported by Wang and 
co-workers in 2010 (Figure 1.30).143 The compound was found to induce G4-folding in the 
absence of cations in water in the E form, whilst the Z isomer did not have such an effect. The 
unfolding and refolding of G4 could be cycled at least ten times without any appreciable photo-
fatigue by photoisomerisation of the ligand (Figures 1.30b and 1.30c). Subsequently, the 
authors applied the photoswitchable ligand to regulate the activity of thrombin in a manner 
analogous to the host-guest approach discussed in Section 1.3.2 (Figure 1.30d).164 
Meanwhile, the authors attempted to exploit this system in the presence of metal ions to mimic 
physiological conditions, presumably with biological applications in mind.165 Unfortunately, 
compound 19 was found to be ineffective in these studies. The authors do not specifically 
comment on why this system is adversely affected by the presence of metal ions, though 
perhaps the stabilisation of G4 folding topology induced by the metal cation is more difficult to 
overcome by ligand-driven effects. 
 




Figure 1.30: Photoswitchable control of G4 folding by azobenzene derivative 19. (a) ligand 
photoisomerisation between E and Z forms; (b)-(c) reversible G4 folding/unfolding triggered 
by ligand photoisomerisation monitored by circular dichroism spectroscopy; (d) application 
to photoregulation of thrombin activity; (e) second-generation analogues aiming to 
photocontrol G4 structure in the presence of metal ions. Figure (b) used with permission © 
Wiley.143  
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This led the authors to develop further analogues of 19 (30-32, Figure 1.30) which appeared 
to allow the photo-regulation of G4 topology in potassium-rich conditions to some extent. 
Based on apparent changes in the characteristic circular dichroism spectra, the authors 
proposed the E-forms of the ligands induced a switch in topology from hybrid to antiparallel in 
the presence of potassium ions. However, details about the nature of the ligand-induced 





Figure 1.31: Further azobenzene derivatives investigated as photoresponsive G-
quadruplex ligands. 
 
Further azobenzene-derivatives functionalised with amino acid side chains were recently 
reported by the Matczyszyn group, such as lysine derivative 33 (Figure 1.31).166 Though in 
these cases the formation of the G4/ligand complex could be controlled by the 
photoisomerisation process, the compounds appear to exert little effect on G4 topology and 
also appear to interact significantly with duplex DNA, perhaps indicating that applications of 
azobenzene derivates may be confined to situations where a high level of quadruplex/duplex 
selectivity is not required. A series of closely-related azobenzene-derived ligands conferred 
only very modest thermal stabilisation to G4 structures: even at high ligand concentrations (40 
μM) only 4 °C thermal stabilisation was induced in G4 for the most potent analogue reported 
(34, Figure 1.31) in potassium-rich conditions, indicating that this chemotype does not display 
high affinity for G4.167 Meanwhile, azobenzene derivatives are demonstrated to intercalate and 
stabilise duplex DNA at comparable concentrations,168 suggesting that this chromophore is 
more likely suited to intercalating DNA base pairs rather than targeting the specific features of 
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G4. Furthermore, at the time of writing, the potential of these compounds to target G4 for 
therapeutic effect has not yet been investigated.  
 
1.5  Conclusions and thesis aims 
The discussions in the previous sections highlight the myriad potential applications afforded 
by the control of G4, both in therapy and in the development of nanodevices. Though progress 
has been made towards both of these areas, opportunities for further development remain. In 
particular, photoresponsive G4 ligands would offer interesting means to control G4 topology 
in the development of molecular devices or as the basis of G4-targeted photopharmacology 
strategies. Though some progress has been made towards regulating G4 architectures with 
photoswitchable small molecules, this research area remains significantly underexplored. In 
particular, issues such as G-quadruplex/duplex selectivity and potency in physiological 
conditions require further investigation and development. Azobenzenes are the only 
photoswitches to date investigated for binding to G4 DNA, despite the availability of several 
other potential photoresponsive scaffolds which may furnish ligands that provide 
complementary effects.  
 
The overarching goal of this research project was therefore to explore the development of 
novel photoresponsive G4 ligands that function effectively in physiologically-relevant 
conditions and explore their potential as tools for G4-targeted photopharmacology or 
controlling G4-based nanodevices. The results of these endeavours are reported in the 
following chapters: 
Chapter 2 describes the design, synthesis, biophysical and cellular evaluation of a new class 
of amine-decorated G4 ligands derived from stiff-stilbene, the first example of DNA targeting 
molecules derived from this particular molecular photoswitch. This work acts as an initial proof 
of concept that this type of scaffold can be used to target G4 with good selectivity in 
biologically-relevant conditions. The chapter also serves to introduce the various techniques 
used to study G4/ligand interactions.  
In Chapter 3, the design of the stiff-stilbene ligands is developed to improve the ligand potency. 
The synthesis and evaluation of N-methylpyridinium derivatives is reported, which 
demonstrate improved G4 recognition properties compared to the first-generation amine-
decorated analogues. This work identifies the ligands as tools to perturb G4-folding in 
physiologically-relevant conditions and that the stilbene configuration is a critical determinant 
of G4 ligand activity. The ligands are screened for activity against a small panel of disease 
models, identifying correlation between G4 binding activity and toxicity. 
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In Chapter 4, the photochemistry of N-methylpyridinium G4 ligands is explored towards the 
goal of exploiting the difference in activity of the photoisomers in photopharmacology or control 
of G4 architectures. Whilst the ligand photochemistry in water was ultimately unsuited towards 
photopharmacological applications, the reversible folding and unfolding of a G4 structure is 
demonstrated in sodium-rich conditions. 
Chapter 5 reports on the design, synthesis, biophysical screening and cellular evaluation of 
G4 ligands designed from the dithienylethene chromophore. These ligands are found to 
undergo robust photoswitching between two photoisomeric states in buffered conditions, 
which in turn exhibit different binding modes to G-quadruplex DNA and toxicity to a cancer cell 
model. 
Chapter 6 summarises the results of the thesis, offering general conclusions and suggestions 
for future work. 
Chapter 7 contains details of experimental procedures, including compound synthesis and 
characterisation. 
 
A removable glossary of frequently-discussed ligands is included to assist the reader. This is 
also printed at the back of the thesis.
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2  Amine-decorated stiff-stilbene G4 ligands 
This chapter is based upon work published in Chemistry: A European Journal of which I am 
first author.169 I was responsible for all elements of ligand design, synthesis and biophysical 
studies, which were undertaken at the University of Bristol, UK. Compounds A and C were 
synthesised by Rosina S.L. Fisher, an MSc student working under my direct supervision. I 
performed the in vitro assays at the Institute of Parasitology and Biomedicine (CSIC), 
Granada, Spain, with assistance from Dr Pablo Peñalver. 
 
2.1  Introduction 
This chapter describes initial progress towards the development of a novel series of G4 ligands 
derived from a photoresponsive stiff-stilbene chromophore. The rationale for the choice of 
ligand scaffold is first explained in the context of previously reported small-molecule 
photoswitches, general G4 ligand design principles and the few reports of previous attempts 
to engineer photoresponsive G4 ligands. Subsequently, the synthesis of a library of 
compounds is reported, designed to test the general viability of the scaffold to serve as the 
basis of new G4 binding agents, and to evaluate the effect of ligand isomerisation on G4-
binding activity. The initial screening of the compound library for binding to G4 structures using 
a thermal melting assay is then described. These results provide preliminary indications of 
structure-activity relationships present in the new ligand series and identify a proof-of-concept 
ligand pair that indicates G4-binding activity is determined by the isomeric configuration of the 
central stilbene moiety. This promising ligand pair is then investigated in greater detail, using 
a combination of circular dichroism, UV/visible absorbance and NMR spectroscopies, to 
validate this preliminary result and gain further insight into the nature of G4 recognition by the 
novel ligand scaffold. Finally, the potential to exploit the difference in activity of the ligands 
towards therapeutic ends is explored by screening the compounds for anticancer and 
antiparasitic activity in in vitro assays.  
 
2.2  Ligand design and synthesis 
 
2.2.1  Consideration of ligand scaffolds 
The first step in the design of novel photoresponsive G4 binding agents was the selection of 
a photoresponsive chromophore that could be readily adapted to serve as the basis of a new  
series of high-affinity G4 ligands. Considering the photochromic scaffolds previously 
introduced in the context of general G4 ligand design principles (Section 1.3.1.4) the most 
promising scaffolds to explore as the basis of photoresponsive G4 ligands are the azobenzene 
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(E-20/Z-20) and stilbene (E-21/Z-21) photoswitches (Figure 1.22). These scaffolds undergo  
geometrical change upon isomerisation, adopting a planar arrangement in the E form whilst 
being non-planar in the Z form owing to steric repulsion between the ortho aromatic hydrogen 
atoms.170 Chemotypes derived from planar aromatic scaffolds are generally privileged in G4 
ligand development since, in many cases, they are found to effectively bind G4 through π-
stacking interactions with the planar G-tetrads.44  The change in geometry from planar to non-
planar forms triggered by photoisomerisation can therefore be expected to significantly alter 
the ability of the ligand to form such interactions. Other potential G4 ligand binding modes, 
such as loop and groove binding, are also likely to be affected by such changes in spatial 
arrangement of the ligand atoms. For these reasons, investigation of the G4 binding properties 
of diarylethene (22o/22c, Figure 1.22) derivatives was not initially pursued, since the molecule 
undergoes comparatively little structural change upon photoisomerisation.171 However, the 
diarylethene scaffold was studied at a later point in the project and delivered some promising 
results (Chapter 5). Spiropyrans (23o/23c, Figure 1.22) also have potential as 
photoresponsive G-quadruplex binding molecules, based on the difference in shape between 
the closed form (containing a tetrahedral carbon atom at the spirocentre) and open form (which 
adopts a more planar structure). This scaffold was not explored in the present project but could 
be investigated in future work. 
 
2.2.2  From azobenzene to stiff-stilbene 
As described previously (Section 1.4.3), work has previously been undertaken to deploy 
azobenzene derivatives as photoresponsive ligands to facilitate the responsive control of G4 
structure. Though promising results have been obtained,143,164 this approach suffers from 
several limitations that likely prevent the use of this system for in vivo applications (e.g. 
photopharmacology) of G4 targeting. Though the switching of G4 conformation functions 
effectively in the absence of metal ions, the compound is not effective in influencing G4 
topology cation-rich conditions that mimic the intracellular environment.165 Furthermore, a 
series of closely-related azobenzene-derived ligands conferred only modest thermal 
stabilisation to G4 structures: even at high ligand concentrations (40 μM) only 4 °C thermal 
stabilisation was induced in G4 for the most potent analogue in potassium-rich conditions, 
indicating that this chemotype does not display high affinity for G4 under physiologically-
relevant conditions of high ionic strength. These issues may explain why compound 19 (in the 
active G4-binding E configuration) does not demonstrate toxicity (EC50 > 125 μM) to HeLa 
cells.164 Meanwhile, azobenzene derivatives are demonstrated to intercalate and stabilise 
duplex DNA at comparable concentrations, suggesting that this chromophore is more likely 
suited to intercalating DNA base pairs rather than targeting the specific structural features of 
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G4.168 Considering the azobenzene core in the context of the best-in-class G4 ligands 
previously reported (e.g. PhenDC3 10, Figure 1.14), it was reasoned that the poor G4 affinity 
of azobenzenes is a result of comparatively weak stacking interactions between the ligand π 
system and the G-tetrads, the binding mode suggested by computational investigations in the 
original study.143 Whilst the E azobenzene can adopt a planar conformation, it possesses only 
two aromatic rings and hence a relatively small hydrophobic surface area. Furthermore, 
rotation about the N-aryl bonds permits conformational freedom in solution, resulting in an 
entropic penalty to adopt the active conformation to bind to the macromolecule. Therefore, 
stacking interactions between the azobenzene ligand and the G-tetrads can be expected to 
be weaker than those present in the more potent G4 ligands reported to date, many of which 
are derived from fused ring systems that provide greater hydrophobic stacking surface and 
increased rigidity. 
In light of the above considerations, it was reasoned that G4 binding could be markedly 
improved by extending the hydrophobic stacking surface and increasing the conformational 
rigidity of the ligand scaffold, whilst maintaining the feature of photoresponsive functionality. 
In pursuit of this goal, stilbenes presented an interesting opportunity, as the possibility of 
tetrasubstitution of the central double bond in these variants allows the generation of bicyclic 
systems that would feature both increased hydrophobic surface area and the additional rigidity 
that were anticipated to be beneficial for more effective recognition of G4 (Figure 2.1). 
The synthesis of such conformationally restricted stilbenes, colloquially termed stiff-stilbenes, 
has been previously reported.172 Commonly, the McMurry coupling is employed (Scheme 
2.1).173 In this reaction, titanium(IV) is reduced in situ by zinc to generate a low-valent Ti(II) 
species, which acts as the reducing agent of a carbonyl compound. In one proposed 
mechanism, single electron reduction of the carbonyl group of compound 35 generates a ketyl 
radical 36, which subsequently dimerises to form pinacol-type product 37.174 Elimination of the 
oxo-titanium species furnishes the desired products (E-38 and Z-38), normally as a mixture of 




Figure 2.1: Design concept: from azobenzenes to stiff-stilbenes. 
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The photophysical and photochemical behaviour of a range unfunctionalised stiff-stilbene 
compounds with varying bridging unit lengths was comprehensively characterised by 
Tomoda175 and Inoue.176 Through a combination of X-ray crystallography and computational 
studies, the E isomer of a methyl-substituted variant (E-39) was found to be almost fully planar, 
whilst the ethylene bond of the Z-isomer (Z-39) is twisted by approximately 5.7° (Figure 2.2).175 
This isomer therefore displays helical chirality, discussed further below. 
Stiff-stilbenes have already found application in the design of light-triggered supramolecular 









Figure 2.2: X-ray crystal structures of substituted stiff-stilbenes E-39 and Z-39. Structural 
figures reproduced with permission.172  
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Wezenberg and Feringa recently reported a bis-urea functionalised stiff-stilbene derivative 
E/Z-40 for which the affinity for acetate and phosphate anions could be tuned by reversible 
photoisomerisation between the E and Z forms. Indeed, the association constant for 
phosphate of the Z state (2.0 x 103 M-1) was approximately 25 times greater than the molecule 
in the E form (Figure 2.3).178 In a later study considering binding to chiral anions, the authors 
found that the two helical forms of the Z-isomer interconvert rapidly (on the NMR timescale) 
at room temperature, and temperatures below -55 °C were required to resolve the resonances 
of the diastereomeric complexes of the two helices with the single enantiomer of a BINOL-
derived phosphate salt. In agreement with the experimental observations, the barrier to 





Figure 2.3: Previous applications of a stiff-stilbene derivative in the design of a 
photoresponsive anion receptor. 
 
Recently, Feringa and co-workers incorporated a hindered stiff-stilbene-based molecular 
motor into a duplex DNA hairpin in order to allow the photocontrol of duplex stability.182 
However, the use of stiff-stilbenes as the basis of selective DNA-targeting molecules that may 
be eventually applied in biological circumstances, such as photopharmacology (Section 1.4.3) 
has not yet been explored. Therefore, as an initial proof-of-concept, the first goal of this project 
was to design and synthesise a set of stiff-stilbene based DNA ligands and evaluate the 
potential of the E and Z forms to selectively target G4 DNA in physiologically-relevant 
conditions.  
 
2.2.3  Synthesis of a proof-of-concept ligand pair 
As a first step to evaluate the potential of photoresponsive stiff-stilbene compounds as G4-
targeting molecules, a prototype ligand pair was required that featured appropriate 
substituents to confer aqueous solubility and potent DNA-binding properties to the 
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photoresponsive scaffold. A common approach in G4 ligand design that simultaneously 
addresses both these issues involves the tethering of basic amine moieties to the aromatic 
scaffold using flexible linking chains (e.g. as in the case of NDI derivative MM41 9, Figure 
1.14). As well as rendering the ligand soluble in water, these groups are sufficiently basic (pKa 
≈ 9)183 to be protonated under physiological conditions (pH = 7.4). The resulting cationic 
moieties participate in electrostatic interactions with the negatively charged DNA phosphate 
backbone which complements the π-stacking of the ligand chromophore and G-tetrads. The 
flexible orientation of these pendant groups afforded by the spacer unit allows them the 
freedom to interact with loop and groove residues. Previously, methyl piperazine moieties 
have been demonstrated as effective for conferring excellent G4 recognition properties to 
naphthalene diimide scaffolds,122,124 with spacer units of two or three atoms in length being 
sufficiently long to allow the capping amines to target groove and loop residues whilst the 
aromatic component participates in end-stacking interactions with the G-tetrads. This 
precedent pointed to the design of ligands E-41 and Z-41 as an initial pair to consider the 
general DNA-recognition ability of the stiff-stilbene scaffold and also examine the effect of the 




Figure 2.4: Prototype stiff-stilbene G4 ligands to investigate the ligand design hypothesis. 
 
The synthesis of ligands E-41 and Z-41 is shown in Scheme 2.1. The preparation of the bis-
bromide derivatives E-43 and Z-43 from 6-bromo-1-indanone 42 had previously been 
reported, employing the aforementioned McMurry coupling reaction for the formation of the 
hindered tetrasubstituted double bond.178 This reaction proceeded in 77% overall yield to 
afford E-43 and Z-43 as a 2:1 mixture, which were separated by precipitation of the less-
soluble E-isomer. With bis-bromides E-43 and Z-43 in hand, the target compounds were 
furnished by Buchwald-Hartwig C-N cross coupling of these intermediates with commercially 
available 3-aminopropyl-4-methylpiperazine. An initial attempt to employ Pd(OAc)2 as the 
catalyst was unsuccessful, but a system comprising BrettPhos184 Pd G3 in dioxane with 
sodium tert-butoxide as the base generated the desired products E-41 and Z-41.  






Scheme 2.1: Synthetic route to prototype stiff-stilbene ligands E-41 and Z-41. Reagents 
and conditions: (a) Zn, TiCl4, THF, 16 h, 65 °C; (b) 3-aminopropyl-4-methylpiperazine, 
BrettPhos Pd G3 (5-10 mol%), NaOtBu, dioxane, 2 h, 80 °C. 
 
 
Scheme 2.2: General mechanism of Buchwald-Hartwig C-N cross-coupling. L = ligand, B = 
base. 
 
The Buchwald-Hartwig amination proceeds via a Pd(0) catalytic cycle (Scheme 2.2).185 
Oxidative addition of the aryl bromide coupling partner to the metal centre generates a Pd(II) 
species. Displacement of the bromide ligand by the amine coupling partner followed by 
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deprotonation by the base generates the final Pd(II) intermediate, from which reductive 
elimination forms the arylated amine product and regenerates the active Pd(0) species which 
can participate in further catalytic cycles. The products were purified by HPLC as their 
trifluoroacetate salts and characterised by NMR spectroscopy. 
 
2.2.4  Synthesis of a compound library 
Whilst the prototype ligand couple E/Z-41 would allow an initial assessment of the potential 
differences in G4 recognition between the isomeric forms of the stiff-stilbene scaffold, further 
analogues were desired to elicit possible structure-activity relationships that may be present 
in the ligand series. Several points of difference were considered: 
(a) variation in the length of the spacer unit, in order to determine the optimal length of this 
component: spacers of three to seven atoms in length were considered. 
(b) variation in the chemical functionality of the aryl substituent, in order to examine the 
electronic influence of the aryl substituent and the effect of increased rigidity in the spacer unit: 
the effect of substituting the amine linkage for a urea linkage was explored. 
(c) variation in aryl substitution pattern, noting that the electronics of the compound are 
different depending on the position of the electron-donating nitrogen substituent relative to the 
central stilbene moiety: 5-substituted (para to stilbene olefin) and 6-substituted (meta to 
stilbene olefin) derivatives were considered. 
(d) variation in the nature of the terminal basic moiety, since previous studies have shown that 
this can have a marked effect on G4 binding properties: the difference between methyl 
piperazine and morpholine termini was investigated. 
 
Figure 2.5 summarises the compound library synthesised to investigate the above effects.  





Figure 2.5: Overview of stiff-stilbene compounds synthesised, showing the various points 
of structural difference from E-41. The compounds in the library are identified A-N, with 
compound E-41 identified as B in this series.  
 
Preparation of the 5-substituted isomers required bis-bromide E-45, which was prepared using 
the same procedure used for the synthesis of the 6-substituted bromide (Scheme 2.2) from 5-
bromo-1-indanone 44. As before, a mixture of E and Z isomers were formed, and the E isomer 
separated by precipitation. Though this isomer could reasonably be expected to be the less 
soluble isomer due to its planarity, the stereochemistry of the products was verified by 
comparing the NOESY spectra of the two isomers, which confirmed the spatial proximity of 
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the aromatic H4 and H7 hydrogen atoms and bridging methylene groups in the E isomer 
(Figure 2.6).  
With this key intermediate in hand, the amine-linked derivatives were readily accessed using 
the same Buchwald-Hartwig approach used for the synthesis of E-41 using the appropriate 
bromide and commercially-available primary amine (Scheme 2.3).  
Unfortunately, though 5-substituted derivatives L, M and N were successfully synthesised, 
isolated and characterised, they began to decompose in aqueous solution overnight 
(Appendix, Figure A2.1) and were therefore not considered suitable candidates for biophysical 
screening. This unwanted reactivity was rationalised to arise from activation of the stilbene 
double bond by the mesomeric electron donating effect of the para amine substituent. 
Fortunately, decomposition was not observed for the other analogues, even after several days 




Scheme 2.2 Synthesis of novel bis-bromides E/Z-45. Reagents and conditions: (a) Zn, 




Scheme 2.3: Synthesis of amine-linked stiff-stilbene G4 ligands A,C,G,H,L,M,N. Reagents 










Figure 2.6: Assignment of E/Z stereochemistry in novel bromides by nOe analysis. The 
isomers are differentiated by the absence of nOe between H7/H2 in the Z-isomer. 
 
Meanwhile, the urea derivatives were accessed using the procedure shown in Scheme 2.4. 
Buchwald-Hartwig amination of the appropriate bromide (E-43 or E-45) with benzophenone 
imine following a previously-reported procedure178 afforded intermediates E-46 and E-47, 
which are subsequently hydrolysed under acidic conditions to furnish amines E-48 and E-49 
in good yield (57-72%) over two steps. Activation with triphosgene followed by reaction with 
the appropriate amine afforded the required urea derivatives in yields of 30-46% following 
purification by reverse-phased HPLC. 






Scheme 2.4:  Synthesis of urea-linked stiff-stilbene G4 ligands D,E,F,I,J,K. Reagents and 
conditions: (a) benzophenone imine, Pd(OAc)2 (10 mol%), DPPF (15 mol%), NaOtBu, 
PhMe, 90 °C; (b) 2 M HCl (aq), THF, r.t.; (c) triphosgene, Et3N, DCM, r.t., then R-NH2. 
 
 
2.3  Biophysical studies 
With the prototype ligand pair (E-41 and Z-41) and the rest of the compound library (A-H) in 
hand, efforts turned to evaluating the efficacy of these compounds as G4 binding ligands 
through a variety of biophysical screening assays. 
 
2.3.1  FRET thermal melting assays 
 
2.3.1.1 Introduction to FRET 
The fluorescence resonance energy transfer melting assay is an invaluable means to rapidly 
screen small molecules for interaction with biological targets.108 This assay measures the 
effect of a small molecule on the thermal stability of the biomolecular secondary structure. 
Ligand binding is an energetically favourable process, meaning there is a greater energetic 
penalty for the denaturation process and higher temperatures are needed to induce unfolding. 
In this case, the biomolecule of interest is obtained conjugated to a fluorescent donor at one 
end and a fluorescence acceptor at the other. The FRET pair is chosen such that the 
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absorption of the donor does not overlap with that of the acceptor. The donor can then be 
excited specifically, and since the emission spectra of the two species are also distinct, the 
fluorescence of only one species can be monitored. The well-established FAM (50)/TAMRA 
(51) pair is most commonly employed in the design of fluorescent nucleotides for G4 studies 
(Figure 2.7). In the absence of the TAMRA acceptor, excitation of the FAM donor at its 
absorbance wavelength (495 nm) results in fluorescence emission at longer wavelength (520 
nm). However, if the acceptor is present in close proximity, the resonance between the donor 
emission and acceptor excitation allow non-radiative energy transfer to the acceptor, 
effectively quenching the fluorescence of the donor (520 nm) and resulting instead of the 








Chapter 2: Amine-decorated stiff-stilbene G4 ligands 
53 
 
Since the efficiency of FRET depends strongly on the distance between the acceptor and 
donor, monitoring the donor fluorescence therefore allows the denaturation of the secondary 
structure to be followed (Figure 2.8a). In the folded form of the biomolecule the fluorophores 
are in close proximity leading to efficient quenching of donor (FAM) fluorescence. As the 
secondary structure denatures upon raising the temperature the fluorophores move apart, 
resulting in an increase in observed fluorescence. Normalisation of this signal and 
determination of the temperature at which the donor fluorescence is half of the maximum 
indicates the characteristic melting temperature of the secondary structure (Tm), which can be 
compared in the presence and absence of ligand (ΔTm) to indicate the ability of the ligand to 
bind to and stabilise the folded structure (Figure 2.8b). 
Compared to the other biophysical techniques available during this project for the study of 




Figure 2.8: Schematic overview of the FRET melting assay. (a) thermal denaturation of the 
secondary structure causing the fluorophore pair to move further apart in space, leading to 
increased donor fluorescence as the temperature is increased; (b) example melting curves 
and representation of ΔTm. 
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of the secondary structure can be followed by a range of other techniques (e.g. UV/visible 
absorbance spectroscopy), fluorescence is particularly useful since the sensitivity of this 
technique only requires very small quantities of the biomolecule. Furthermore, the assay is 
readily amenable to the 96-well plate format, allowing a large number of compounds to be 
screened rapidly against a panel of DNA sequences. However, a disadvantage of the method 
is that the introduction of the artificial fluorophores into the oligonucleotide models may lead 
to the generation of artefacts, for example by interaction of the ligand with the components of 
the FRET pair rather than the oligonucleotide. Furthermore, since the assay is temperature 
dependent, the association of the ligand for the biomolecule under physiological conditions 
cannot be quantified, since this is in itself a temperature-dependent parameter.186 Therefore, 
whilst the assay provides a rapid means to screen molecules for binding to DNA structures, 
promising compounds must later be validated using further techniques to gain confidence in 
the results. 
 
2.3.1.2 Library screen 
The ability of all E-configuration compounds (A-H) to induce thermal stability in G4 and duplex 
DNA was first assessed, in order to provide an initial assessment of the potential of the stiff-
stilbene scaffold to serve as the basis of DNA-binding agents. For this initial screen the human 
telomeric sequence (F21T) in potassium-containing buffer was selected as the G4 model, 
owing to the physiological relevance of this G4 sequence and that this model is almost 
ubiquitously employed in the G4 ligand binding studies previously reported.108 For the duplex 
model, a self-complementary hairpin (F10T) comprising ten base pairs separated by a 
hexaethyleneglycol (HEG) linker was employed, being of comparable size to the G4 
sequence.122 Compounds were screened at 5 μM and 10 μM ligand concentration in order to 
identify meaningful hits; compounds that do not display induce significant thermal stabilisation 
at these concentrations are not considered effective ligands. The results are shown in Table 
2.1 and representative raw data in the Appendix A2 (Figures A2.2-A2.12). 




Table 2.1: FRET thermal stabilisation values (ΔTm) induced by ligands A-K in G4 (F21T-
K+) and duplex (F10T) sequences. DNA concentration = 200 nM. Further experimental 
details are provided in Section 7.3.1. 
Ligand 
ΔTm / °C 
F21T-K+ G4  F10T duplex 
10 μM 5 μM  10 μM 5 μM 
A 12 ± 0.9 5 ± 0.5  0 ± 0.1 0 ± 0.1 
B (E-41) 12 ± 0.5 6 ± 1.1  0 ± 0.1 0 ± 0.2 
C 9 ± 1.2 5 ± 1.8  0 ± 0.3 0 ± 0.4 
D 11 ± 0.8 4 ± 0.3  0 ± 0.2 -1 ± 0.1 
E 8 ± 0.7 1 ± 0.3  0 ± 0.1 -1 ± 0.1 
F 7 ± 0.5 1 ± 0.5  0 ± 0.1 -1 ± 0.2 
G -4 ± 0.7 -8 ± 0.3  -1 ± 0.1 -1 ± 0.2 
H -2 ± 0.6 -6 ± 0.4  -1 ± 0.1 -1 ± 0.1 
I -4 ± 0.7 -5 ± 0.1  -1 ± 0.1 -1 ± 0.1 
J -4 ± 0.5 -5 ± 0.2  -1 ± 0.1 -1 ± 0.2 
K -4 ± 0.5 -5 ± 0.8  -1 ± 0.1 -1 ± 0.1 
      
Pleasingly it was observed that all compounds bearing pendant methylpiperazine moieties (A-
F) induced significant thermal stabilisation (ΔTm = 7-12 °C) in the G4 model at 10 μM ligand 
concentration (Table 2.1). Whilst stabilisation of the G4 structure remains evident at 5 μM 
ligand concentration, the stabilisation temperatures at this concentration are rather weak (ΔTm 
= 1-6 °C), which suggested that further optimisation of this ligand series was likely required to 
improve G4 affinity for the purposes of biological applications. However, it should be noted 
that the stabilisations achieved at 10 μM are higher than those reported for previously reported 
azobenzene derivatives (ΔTm 1-3 °C) studied at higher (40 μM) concentration.167 This 
comparison suggests that the high conformational rigidity and large hydrophobic surface area 
of the stiff-stilbene scaffold is an important feature that furnishes this scaffold with good G4-
targeting properties.  
Within the methylpiperazine compound class, the effect of ligand structural variation of G4 
stabilisation appears to be rather modest, though some tentative relationships can be inferred. 
Compounds with shorter spacer units appeared to stabilise G4 slightly more strongly, for 
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example compound B, featuring a 4-atom spacer confers higher thermal stability (ΔTm = 12 
°C) than compound C bearing a longer spacer unit (ΔTm = 9 °C). Similarly, comparing the urea 
derivatives, E (containing 6-atom spacer) induces a slightly higher thermal stabilisation than 
F which features an additional methylene group in each linking chain. The substituent position 
of the aromatic core also appears to affect the G4 stabilisation, with compound D (6- 
substituted) displaying a higher (ΔTm = 11 °C) stabilisation than 5-substituted analogue E (ΔTm 
= 8 °C). This effect could result from slightly better presentation of the side-chains towards the 
quadruplex grooves (assuming an end-stacking binding mode for the central  aromatic core) 
in the 6-substituted variant, or could result from the influence of the substituent on the 
electronics of the stilbene core, since the nitrogen lone pair is in conjugation with the central 
stilbene double-bond in the 5-substituted isomers. It should be noted that whilst these minor 
structure-activity effects are discernible they are not sufficiently striking, nor the compound 
library sufficiently large, to make wider inferences about the optimal features of 
methylpiperazine-based stiff-stilbene ligands. Whilst the synthesis and evaluation of additional 
analogues would provide more convincing evidence for some of the structure-activity 
relationships emerging in this compound class, efforts towards this goal were not pursued 
because, at least based on the results obtained in this initial screen, these relatively minor 
modifications were unlikely to lead to the dramatic improvement in G4 binding activity that was 
ultimately sought. 
Whilst only small changes in activity appear to result from the structural modifications in the 
methylpiperazine compound series, the nature of the terminal basic residue appears to exert 
a much more dramatic effect on the interaction of these stiff-stilbene derivatives with G4 DNA. 
All compounds in the morpholine series (G-K) appear to induce a reduction in the thermal 
stability of the G4, of ~ 5 °C, relative to the melting temperature of the G4 in the absence of 
ligand. This surprising effect has also been observed by others but never fully investigated.33 
Whilst further exploration of this apparent destabilisation was not undertaken during the 
present project, further studies are warranted to understand the true origins of this effect. 
 
2.3.1.3 G4/duplex selectivity 
Critically, no stabilisation of the duplex DNA hairpin is observed for any of the compounds, 
indicating that the stiff-stilbene scaffold is effective at discriminating against duplex DNA 
binding in favour of targeting G4. To verify the selectivity of the scaffold against duplex, the 
lead compound B (E-41) was investigated in a competition assay, in which increasing 
concentrations of a non-fluorescent duplex DNA sequence are added to the solution of the 
G4/ligand complex. In this case, competitive off-target binding to the duplex sequence 
diminishes the concentration of the G4/ligand complex, observed as an apparent depression 
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in the induced thermal stabilisation of the fluorescent G4 species (Figure 2.9). Though a 
gradual depression of the ΔTm caused by off-target binding is evident, indicating the G4/duplex 
discrimination is not perfect, the thermal stabilisation remains significant (ΔTm = 9 °C) even in 
the presence of 10 μM duplex DNA competitor, corresponding to 50 equivalents of duplex 
hairpins versus quadruplex (0.2 μM) strands. That 75% of the G4 thermal stabilisation 
potential of the ligand is retained in the presence of a high concentration of duplex competitor 
demonstrates the preference of the ligand for the four-stranded structure that corroborates the 
initial result of the initial screen, where no stabilisation of the duplex strand was observed.  
 
 
Figure 2.9. FRET competition assay examining the effect of increasing concentrations of 
non-fluorescent duplex competitor (ds26) on E-41 induced thermal stabilisation of F21T-K+ 
G4. 
 
2.3.1.4 Difference in activity of E-41 and Z-41 stiff-stilbenes 
Having demonstrated methyl-piperazine decorated stiff-stilbene ligands can selectively target 
G4 DNA in the initial screen of the compound library, efforts moved towards exploring possible 
differences in the E/Z-41 ligand pair on G4 recognition in pursuit of the eventual goal of 
photoswitchable control of the ligand activity. Since E-41 already demonstrated affinity for G4 
in the initial screen, a wider panel of G4 structures were included in the comparative study of 
these two compounds. Compounds were also screened at concentrations down to 1 μM to 
provide a clearer indication of their potency at low micromolar concentrations. In addition to 
the F21T telomeric G4 model in potassium-rich buffer previously discussed, E-41 and Z-41 
were screened against the same sequence in sodium-containing buffer, since telomeric G4 is 
observed to form an alternative antiparallel G4 topology under these conditions.27 Two further 
G4s were included relevant to the ultimate potential therapeutic applications of the ligands. A 
sequence corresponding to the G4 found in the promoter region of the c-myc oncogene was 
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included, as a model of a further potential anticancer target (see Section 1.3.1.2).187 Finally, a 
G4 sequence found in T. brucei parasite genome was studied, owing to the potential of G4 
ligands to serve as antiparasitic agents (see Section 1.3.1.3). The detailed structure of this 
sequence is not fully characterised, but preliminary CD experiments by Belmonte-Reche et al. 





Figure 2.10.  Concentration-dependent FRET thermal stabilisation values (ΔTm) induced 
by ligands E-41 and Z-41 in G4 and duplex sequences: (a) F21T-K+; (b) F21T-Na+; (c) 
FmycT; (d) FebrT; (e) F10T. 
 
 
The results of the study are shown in Figures 2.10 and representative raw data in Appendix 
A2 (Figures A2.12-2.13). The most striking feature of the results is that the isomeric 
configuration of the stiff-stilbene core exerts a large effect on the activity of the ligand. Indeed, 
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for the F21T-K+ (Figure 2.10a) and FmycT G4 (Figure 2.10c), whilst E-41 induces thermal 
stability of up to 12 °C for both sequences at 10 μM concentration, Z-41 is ineffective and does 
not induce any effect on G4 stabilisation over the concentration range examined. The thermal 
melting curves for F21T-K+ clearly show this difference in activity (Figures 2.11a and 2.11b). 
The curves obtained for the experiments with F10T duplex are also shown, indicating no 
stabilisation of the hairpin structure by either ligand (Figures 2.11c and 2.11d). The positive 
shift in the thermal melting curves induced by ligand E-41 is clearly visible whilst the G4 melting 
curve remains comparatively unperturbed by ligand Z-41. E-41 also appears to stabilise the 
Ferb1T quadruplex more effectively than Z-41, although the difference in activity is less 
pronounced in this case (Figure 2.10d). The difference in activity observed between the E-41 
and Z-41 appears to validate the design hypothesis which proposed the E derivative should 
be the more active ligand, since the central aromatic core adopts a planar geometry and can 
therefore be expected to interact with the G4 tetrads better than the twisted Z isomer.  
 
Figure 2.11. FRET thermal melting curves for (a)-(b) F21T-K+ G4 and (c-(d) F10T duplex 




A further noteworthy feature of these results is that though E-41 appears to stabilise the F21T-
K+ (hybrid), FmycT (parallel) and FebrT (mixed) G4 topologies, this ligand induces negligible 
stabilisation of the F21T-Na+ (antiparallel) G4 (Figure 2.10b). This indicates that, in addition to 
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selectivity against duplex DNA, the stiff-stilbene scaffold may also display some discrimination 
between different types of G4 folded structure. This interesting observation was further 
investigated by UV/visible and NMR titration studies (vide infra). 
Taken together, the results of the FRET assays demonstrated the promise of the new stiff-
stilbene ligand series. The ligand design appears to result in affinity for G4 and promising 
binding selectivity between different DNA topologies. Critically, regarding the eventual aim to 
control the activity of the ligands by photoisomerisation, the two isomers display differing G4 
binding activity. However, it should be noted that the FRET assay only serves to provide a 
preliminary insight into the association of the compounds with G4 DNA. As discussed earlier, 
this assay is susceptible to artefacts such as the interaction of the ligands with the fluorescent 
dyes, which could generate false positive or false negative results. Additionally, ligand binding 
may itself perturb the DNA folding topology and therefore results obtained cannot be 
unambiguously attributed to stabilisation of the native structure formed in the absence of 
ligand. Moreover, the FRET assay provides no structural information on G4/ligand complexes 
that would validate the binding mechanisms proposed to result in the observed activities. 
Therefore, further investigation of the G4 binding of the ligands was necessary to confirm the 
key results and provide additional information to guide further ligand design. The following 
sections report the more detailed investigation of the E/Z-41 couple using additional 
techniques, including circular dichroism, UV/visible absorbance spectroscopy and NMR 
spectroscopy. 
 
2.3.2  UV/visible absorbance titrations 
 
2.3.2.1 Introduction to the technique 
The electronic structure of molecules with delocalised π-systems results in characteristic 
UV/visible absorbance spectra. In simple terms, a photon at resonance with the energy 
difference between an occupied and unoccupied molecular orbital is absorbed, causing the 
excitation of the molecule to a higher energy state if the transition is permitted on quantum 
mechanical grounds.188 The Beer-Lambert law states that the observed absorbance (at a path 
length of 1 cm) of a solution of species 𝑌, 𝐴 , is proportional to the concentration, [𝑌].189 The 
constant of proportionality is the molar extinction coefficient at the wavelength in question, 𝜀 : 
 
 
𝐴 =  𝜀 ∙ [𝑌] (2.1) 
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In the case of a titration of ligand (𝐿) with DNA (𝐷), complex formation (𝐷. 𝐿) occurs according 
to the equilibrium:  
The affinity of the two species, i.e. the degree of complex formation at equilibrium at a 
particular concentration of 𝐷 and 𝐿, is quantified by the association constant (𝐾 ),186 defined 
as:  
In a typical UV/visible absorbance titration, the total concentration of ligand is held constant, 
whilst the concentration of DNA is varied. Assuming the Beer-Lambert law is valid, the 
absorption spectrum of a mixture is a linear combination of the spectra of the constituent 
species weighted by their respective concentrations. The observed spectrum (𝐴[ ]) at a 
particular titration point (i.e. concentration of DNA) is therefore given by: 
Outside of the range of DNA absorption (λ > 320 nm) 𝜀  is zero and the observed spectrum is 
simply a combination of that of the free ligand and bound ligand: 
Complexation of the ligand and DNA is therefore detected by a change in the observed ligand 
absorbance spectrum upon addition of DNA, as the concentration of free ligand decreases 
and the bound complex forms. The spectra of the free and bound ligand are almost invariably 
different, since the intermolecular forces between the macromolecule and ligand perturb the 
ligand’s electronic structure. For example, stacking interactions between the π systems of the 
DNA bases and aromatic ligand scaffolds decrease the energy gap between the π and π* 
ligand molecular orbitals, resulting in a bathochromic (red) shift in the absorbance spectrum.  
 









𝐴[ ] = 𝜀 [𝐷] + 𝜀 [𝐿] +  𝜀 . [𝐷. 𝐿] (2.4) 
 
 
𝐴[ ] = 𝜀 [𝐿] + 𝜀 . [𝐷. 𝐿] (2.5) 
 






Figure 2.12. Example ligand UV-titration spectrum showing spectral changes on 
complexation with DNA. 
 
Binding to DNA may also induce hyperchromic or hypochromic shifts owing to changes in the 
ligand structure on binding (Figure 2.12).190 UV/visible absorbance titrations therefore allow 
the formation of DNA/ligand complexes to be investigated without the requirement to modify 
the biomolecule with artificial fluorophores. Furthermore, unlike the FRET melting assay, the 
temperature is kept constant and therefore the association constant under physiologically- 
relevant conditions may be determined. Specifically, the change in absorbance may be 
expressed in terms of the association constant through Eqn. (2.6) (derived in the Appendix 
A1):186 
Values for 𝜀∆ .  and 𝐾  may be therefore obtained by monitoring the change in absorbance of 
a solution of fixed total ligand concentration on increasing the concentration of DNA and fitting 
the observed absorbance changes to Eqn. (2.6) using non-linear regression.  
The binding of E-41 and Z-41 to the hybrid (telo23-K+) and antiparallel (telo22-Na+) forms of 
telomeric DNA were investigated by monitoring the absorbance changes of the ligands upon 
titration with the relevant G4 model. The changes to the absorbance spectra observed during 
the titrations are displayed in Figure 2.13. 
 
 
∆𝐴 = 𝜀∆ .  ∙  
[𝐷] +  [𝐿] +
1
𝐾
− [𝐷] + [𝐿] +
1
𝐾
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2.3.2.1 Titrations with hybrid (telo23-K+) G4 
Comparing first the binding of ligands E-41 and Z-41 to hybrid telo23-K+ G4, clear differences 
can be observed between the two ligand systems (Figures 2.13a and 2.13c). Upon increasing 
the concentration of telo23 during the titration, binding of the ligand E-41 is clearly evidenced 
by a 15% hyperchromicity in the 365 nm absorbance maximum and a bathochromic shift of 
approximately 7 nm (Figure 2.13a). The emergence of such red-shifted features is suggestive 
of π stacking between the ligand and G4 bases. Though it is not possible to draw definitive 
conclusions about the binding mode, the interaction between E-41 and hybrid telo23 DNA 
observed in the FRET assay is clearly confirmed.  
In contrast, the addition of telo23 to a solution of Z-41 barely perturbs the ligand spectrum 
(Figure 2.13c). Indeed, a weaker hypochromicity (< 10%) and bathochromic shift (3 nm) are 
observed. Plotting the isotherm at 390 nm indicates the difference in affinities of E-41 and Z-
41 for the G4 structure (Figure 2.13e). The curvature observed in the E-41 isotherm indicates 
that the complete binding of this ligand to the G4 structure is approached over the 
concentration range studied. Meanwhile, the small perturbations to the Z-41 spectrum vary 
linearly over the course of the titration, indicating that that saturation of ligand binding is not 
approached and that ligand has weaker affinity, as previously indicated the FRET assays. 
The hyperbolic isotherm was well-described by the 1:1 binding model and the blue curve in 
Figure 2.13e is the result of fitting the observed data points to Eqn. (2.6) by non-linear 
regression. This allowed the association constant to be estimated as (9.1 ± 1.7) x 104 M-1. In 
comparison with the association constants of previously optimised G4 ligands this affinity is 
not particularly high, and association constants of 106 or greater are reported to be necessary 
for therapeutically-relevant G4 ligands.78 However, the value obtained is in the range expected 
from the FRET results, where ligand concentrations comparable to those employing the 
UV/visible titration studies (10 μM) were required to observe stabilisation of the G4 structure. 
Because of the very small perturbations of the UV/visible spectrum of Z-41 by telo23-K+, the 
ligand dissociation constant could not be measured at this concentration range. In order to 
measure the dissociation constant for this ligand, the concentration must be increased in order 
that binding saturation is observed over the course of the titration. However, given the large 
quantities of DNA required for such experiments this was not pursued. 





Figure 2.13: UV/visible titration studies of ligands E-41 and Z-41 with G4 DNA. (a)-(d): 
titrations of 10 μM (a),(b) E-41 and (c),(d)  Z-41 with (a),(c) hybrid (telo23-K+) G4 and (b),(d) 
antiparallel (telo22-Na+) G4; (e)-(f): extracted 390 nm binding isotherms for  E-41 and  E-41 
with (e) hybrid (telo23-K+) and (f) antiparallel (telo22-Na+) G4. 
 




Table 2.2: Summary of spectral changes observed for ligands E-41 and E-41 (10 μM) after 
addition of 2.5 equiv. G4 DNA. 
 Hypochromic shift / %  Bathochromic shift / nm 
 E-41 Z-41  E-41 Z-41 
Hybrid 
(telo23-K+) 
15 9  7 3 
Antiparallel 
(telo22-Na+) 
11 8  1 0 
      
2.3.2.2 Titrations with antiparallel (telo22-Na+) G4 
Titrations with the antiparallel G4 model (telo22-Na+) were conducted over the same 
concentration range. Under these conditions, though the hypochromic shifts observed are 
similar (though slightly lower) than those seen upon titrations with the hybrid G4 model, a 
significant difference is the absence of the bathochromic shift upon addition of telo22 (Figures 
2.13b and 2.13d). This can clearly be observed for the active E-41 isomer by inspection of the 
titration curves for the two quadruplexes (Figures 2.13a and 2.13b) and also by comparison 
of the 390 nm isotherms (Figure 2.13f) with those obtained from the telo23 titrations (Figure 
2.13e). Therefore, it appears that the hybrid G4 offers a specific binding mode for ligand E-41 
that is comparatively inaccessible in the antiparallel form. This result appears to confirm the 
selectivity observed in the thermal melting assay, which indicate E-41 preferentially stabilises 
hybrid G4 (F21T-K+) over the antiparallel (F21T-Na+) model. The comparable hypochromic 
shifts may arise from non-specific electrostatic interactions with the external regions of the G4 
that are less likely to depend specifically on the folding topology. In subsequent NMR 
experiments, differences in binding modes to the two G4 structures are also demonstrated 
(Section 2.3.4). 
 
2.3.3  Circular dichroism titrations 
 
2.3.3.1 Introduction to circular dichroism 
In the previous section, absorbance spectroscopy was introduced as a way to examine G4 
ligand binding, since the interaction of molecules perturbs the electronic structures and leads 
to observable changes in the respective spectra. This technique is insensitive to the chirality 
of the absorbing species, since unpolarised light does not itself have a chiral sense. However,  
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using a combination of a polarising filter and quarter-wave plate, circularly-polarised light may 
be produced in which the magnitude of the electromagnetic field remains constant but rotates 




Figure 2.14. Fundamentals of circular dichroism. (a) generation of circularly-polarised light 
from unpolarised light via linearly polarised light; (b) definition of ellipticity based on the 
interaction of linearly polarised light with a chiral sample. Figure (a) by Thomas W Cronin, 
distributed under a CC BY-SA 4.0 license. 
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The helical sense of the rotation can either be left- or right-handed, and the two helical forms 
interact differently with chiral matter due to stereospecific coupling of the transition dipole 
moments with the rotational sense of the radiation (discussed further below).191 
Linearly polarised light can be considered a superposition of left- and right-handed circularly 
polarised light with equivalent amplitude of electric field (EL = ER), resulting in oscillation of the 
field vector in a plane perpendicular to the direction of propagation (Figures 2.14a and 2.14b). 
Following transmission of linearly polarised light through a chiral sample, differential 
absorption of the left- and right-handed components means that EL and ER are no longer 
equivalent and the superposition of the two components results in an elliptical polarisation, 
defined by the angle θ (Figure 2.14b). The difference in absorbance of the left- and right- 
handed components (∆𝐴 = 𝐴 − 𝐴 ) commonly measured by spectropolarimeters is related 
directly to this angle of ellipticity by Eqn. (2.7), which is derived based on the basis of 
geometrical and physical arguments.192 
The observed ellipticity can be expressed as the molar ellipticity of the sample through Eqn. 
(2.8) to yield an intrinsic value independent of concentration and path length. 
Circular dichroism in an invaluable technique for the study of G-quadruplex structures, since 
different folded topologies gives rise to diagnostic spectral signatures.111,193–195 The physical 
origin of circular dichroism in G4 is complex, but in broad terms arises from the coupling of the 
transition dipole moments (exciton coupling) of the stacked guanine residues (Figure 2.15). 
The chiral sense of this coupling is determined by the relative orientation of neighbouring 
bases in the helical arrangement, in turn influenced by the conformations of the glycosidic 
bond angles (syn/anti) of the two nucleotides and hence the overall folding topology. Figure 
2.15a shows and example of the displacement of the transition dipole moments of two stacked 
guanine residues which arises when both are in the anti conformation. This exciton coupling 
results in non-degenerate states with opposite rotational strength (R), arising from the 
combined effect of the electronic and magnetic transition moments which results in a helical 
charge redistribution (Figure 2.15b). These states are therefore populated differently by left- 
and right-handed circularly polarised light, resulting in the observed spectral effect (Figure 
2.15c). 
 















Figure 2.15. Origin of circular dichroism in G-quadruplexes. (a) Simplified representation of 
two stacked G-tetrads showing the helical displacement of the transition dipole moments 
for two guanine residues GA and GB; (b) exciton coupling of the two transitions leads to non-
degenerate states with opposite rotational strength (R) resulting in differential absorption of 
left- and right-handed circularly polarised light; (c) the resulting CD spectral signature of the 
exciton coupling represented in (b). 
 
The combination of many such effects over all the guanine-guanine base-steps in the G4 
structure gives rise to the characteristic CD signatures of each G4 topology.195 
CD may therefore be used to examine the effects of ligands on G4 folding, by monitoring the 
effect of increasing ligand concentration on the characteristic CD bands. Hyperchromic shifts 
in the bands indicate stabilisation of the folded structure by the ligand,106 whilst disappearance 
of spectral features and emergence of new dichroic features can indicate structural 
rearrangement, such as disruption of the G4 fold or re-folding to an alternative topology.144,196 
Furthermore, since achiral ligands enter a chiral environment upon binding to the G4, CD-
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activity may be induced in the ligand-only region of the spectrum which may indicate particular 
modes of binding.106 
 
2.3.3.2 CD investigations of binding of E-41 and Z-41 to G4 structures 
Given the different effects of E-41 and Z-41 observed in the FRET melting assay and 
confirmed by UV/visible titration studies, circular dichroism titrations were conducted to 
examine the possible effects of the ligands on different G-quadruplex topologies in 
physiologically-relevant buffers. Three G4 models were selected: the hybrid (telo23-K+)37 and 
antiparallel (telo22-Na+)27 G4 models were used as in the UV/visible titrations. The promoter 
region of the c-myc oncogene (Pu27) was also selected as a model of a parallel G4.197 
In the titration experiments, the spectrum of the G4 was first recorded in the absence of ligand 
and subsequently in the presence of increasing stoichiometric equivalents of ligand up to a 
maximum of 10 molar equivalents (Figure 2.16). The spectra obtained in the absence of ligand 
(black traces) display the diagnostic features expected for respective G4 sequences. The 
hybrid G4 (telo23-K+) is characterised by a positive band at 290 nm with a shoulder at 260 nm 
and a negative band at 240 nm (Figures 2.16a and 2.16b). Meanwhile the antiparallel form 
(telo22-Na+) displays a positive band at 290 nm and a negative band a 260 nm (Figures 2.16c 
and 2.16d). The parallel form  (Pu27) features a strong positive band at 260 nm and negative 
feature at 240 nm (Figures 2.16e and 2.16f).111 Only very weak perturbations of the G4 spectra 
are induced upon the addition of ligand E-41 and Z-41. The perturbations of the ellipticity do 
appear to be slightly larger for ligand E-41, consistent with the observations of the FRET 
assays and UV/visible titration studies, which indicate this to be the active form of the ligand. 
For example, in the titration with Pu27, the parallel G4, a hypochromicity in the positive band 
at 260 nm is observed for ligand E-41 (Figure 2.16e) whilst CD spectrum of the same G4 is 
comparatively unperturbed by ligand Z-41 (Figure 2.16f). However, overall, the results indicate 
that ligand binding to G4 occurs without perturbation of the native folding topology, since all 
the main spectral features of each G4 topology are preserved upon increasing the ligand 
concentration. Therefore, whilst the difference in G4 binding activity between the two ligand 
forms was still considered worthy of further investigation towards photopharmacological 
applications, it was concluded that the E-41 and Z-41 couple did not show strong potential as 
a means for the ligand-mediated photocontrol of G4 topology for the development of 
nanodevices, since the ligand is not able to influence the folding dynamics of the DNA 
structure necessary for such applications. 
 





Figure 2.16: CD titrations of (a)-(b) telo23-K+ hybrid G4, (c)-(d) telo22-Na+ antiparallel G4  
and (e)-(f) Pu27 parallel G4 with (a),(c),(e)  E-41 and (b),(d),(f) Z-41.  Black trace: DNA CD 
spectra in absence of ligand; dark grey trace: CD spectra in the presence of 10 equiv. ligand. 
Intermediate titration points are shown as pale grey traces. [θ] = molar ellipticity. DNA 
concentration: 4.2 μM. 
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2.3.4  NMR studies 
Given the inconclusive results of the CD studies regarding the binding modes of the ligands, 
further investigation of the G4/ligand interactions by 1H NMR spectroscopy was warranted in 
order to help rationalise the results of the UV/visible titration studies and FRET assays. As 
well as enabling DNA/ligand complex formation to be more directly observed, these 
experiments can provide indications of the binding mode of the ligands to the G4 
structures.109,198 In particular, perturbations of the chemical shifts of specific guanine residues 
are indicative of G-tetrad stacking interactions, whilst line broadening of Hoogsteen-bonded 
NH (imino) proton resonances without such perturbations suggests binding to regions 
elsewhere on the quadruplex, such as in the loops or grooves.106,109  
 
2.3.4.1 Studies with hybrid (telo23-K+) G4 
First the interaction of E-41 and Z-41 with hybrid (telo23-K+) G4 was investigated, since the 
FRET and UV/visible titration studies indicated E-41 selectively associates with this form of 
the telomeric G4 (as opposed to the antiparallel G4 formed in sodium conditions) whilst ligand 
Z-41 remained comparatively ineffective. The NMR spectra of this G4 was reported by Phan 
et al. in 2006 and the sequence was found to exist as a mixture of major (~ 70%) and minor 
(~ 30%) conformations under the NMR conditions.37 This makes it rather difficult to monitor 
chemical shifts in the aromatic region of the spectrum as many resonances are overlapped, 
but the imino resonances were confidently assigned in accordance with the reported data. 
Upon titration with ligand E-41, significant changes to the telo23 imino resonances were 
observed (Figure 2.17a). At 1:1 G4/ligand stoichiometry, whilst several resonances remain 
distinct (most clearly G10, G9, and G21, indicated by numbered resonances), other 
resonances appear almost absent (especially G3, G15 and G23, indicated with asterisks) and 
at 2:1 stoichiometry appear to have disappeared entirely. The apparent loss of imino 
resonances could result from a number of factors. One possibility is precipitation of the 
complex at the high concentrations (~ 200 μM) required for NMR experiments, but since the 
intensity of several imino resonances are preserved throughout the titration this possibility can 
likely be discounted. Another possible explanation is that intermediate exchange between free 
and bound ligand states on the NMR timescale (resulting in the case of strong binding ligands 
which exhibit slow dissociation kinetics from the biomolecule) results in line broadening that 
ultimately leads to the apparent disappearance of the signals (Figure 2.18 and caption). 






Figure 2.17: 1H NMR titration studies (Hoogsteen NH imino region) of hybrid G4 (telo23-
K+) titrated with (a) E-41 and (b) Z-41. The cartoon representation in each case labels 
perturbed imino resonances in green and disappearing resonances in red. DNA 
concentration: 185 μM. 
 






Figure 2.18: Possible exchange broadening effects in NMR titrations. A strongly bound 
ligand exhibits slow dissociation kinetics from the DNA on the NMR timescale, meaning the 
koff rate is slower than the difference in frequency (Δν) between the resonances 
corresponding to the free DNA (νfree) and bound complex (νbound). The free and bound DNA 
states are therefore distinct on the NMR timescale, and both resonances are observed with 
intensity proportional to the mole fraction of each species. In the fast exchange regime, 
exhibited by weakly bound ligands with fast dissociation kinetics, the free and bound states 
rapidly interconvert on the NMR timescale and the position of the chemical shift appears as 
weighted average of those of the free and bound species. In the intermediate regime the 
free and bound complexes interconvert on the NMR timescale, resulting in line broadening 
accompanied by a change in chemical shift. Figure adapted with permission © Elsevier.199 
 
In this case, it should be possible to observe the recovery and sharpening of signals 
corresponding to the bound complex as the concentration of bound complex increases (Figure 
2.18). That no such recovery is observed at high ligand concentration suggests that that the 
disappearance of imino signals may not be the result of exchange broadening. The remaining 
possibility is that E-41 interacts with hybrid G4 through an intercalative mechanism, which 
requires partial disruption of the G-tetrad network leading to the disappearance of certain 
resonances. It should be noted that the circular dichroism experiments did not indicate 
disruption of the folded structure (Figure 2.16a). However, the concentrations required for the 
NMR experiments are approximately 50-fold higher than those employed in the CD studies.  
Meanwhile, the comparatively small effects on the telo23 imino resonances observed upon 
titration with Z-41 (Figure 2.17b) are consistent with the previous results that indicate this 
ligand interacts less strongly with the G4 than the E-41 counterpart. Indeed, all imino 
resonances remain distinct throughout the titration. Instead, only minor chemical shift 
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perturbations can be observed for G10, G16 and G15 resonances, indicating weak interaction 
with this specific region of the G4. The NMR results therefore support the results of the other 
biophysical assays and confirm that the stilbene configuration is an important determinant of 
ligand binding mode and therefore for the affinity observed for the hybrid G4.  
 
2.3.4.2 Studies with antiparallel (telo22-Na+) G4 
The binding of the E-41 and Z-41 ligands to antiparallel telo22-Na+ G4 was also examined. 
Though the ligand affinity for this G4 sequence observed in the FRET and UV/visible titration 
assays appeared to be rather low, the concentrations required for NMR experiments are much 
higher (~180 μM versus ~10 μM) meaning complexation can be observed even for 
comparatively weak-affinity ligands. Moreover, since telo22-Na+ adopts a single folded 
conformation in solution, assignment and interpretation of the spectra, including the aromatic 
and carbohydrate resonances is much more straightforward.27 
The binding of E-41 to the antiparallel G4 was first examined (Figure 2.19). In comparison to 
the effect of this ligand on the hybrid telo23 G4, only minor changes in the imino region of the 
spectrum were detected. Rather than the disappearance of specific resonances, a gradual 
change in chemical shift of the imino resonances is observed throughout the titration, 
indicative of fast exchange. Specific perturbations of the G8 and G4 resonances were 
observed (Figures 2.19a and 2.19c) with the other imino resonances only comparatively 
weakly affected. Owing to the comparative simplicity of the telo22 spectra, many of the 
aromatic signals could be resolved in 2D NOESY data using the assignments reported by 
Wang and Patel.27 This reveals specific chemical shifts in the aromatic protons of the two 
lateral loops, particularly the A19H8 and A7H8 protons, and the H2’/H2’’ sugar ring protons of 
T6 (Figures 2.19b and 2.19c, full spectrum in Appendix A2, Figure A2.14). Meanwhile, no 
significant chemical shift perturbations are observed for residues corresponding to the middle 
or lower G-tetrads, nor the diagonal loop (Figure 2.19d). Taken together, these data indicate 
the ligand specifically targets the top face of telo22, perhaps stacking with the G-tetrad owing 
to its planar structure. 
Meanwhile, weaker chemical shift perturbations are observed for the same G4 sequence on 
titration with ligand Z-41 (Figure 2.20 and Appendix A2, Figure A2.15). Though the imino 
resonances experience weak perturbation (Figure 2.20a), the effect is more subtle than for 
the E-41 counterpart. Furthermore, the specific perturbation of the A7 and A19 residues of the 
lateral loops is not observed (Figure 2.20b). Again, these results demonstrate the importance 
of ligand planarity in activating the specific binding mode of the stiff-stilbene ligand. 
 




Figure 2.19: 1H NMR titration studies examining the binding of E-41 to antiparallel (telo22-
Na+) G4. (a) stacked imino spectra; (b) relevant regions of the 2D NOESY spectra of the 
free DNA (blue) and with 2 equiv. E-41 (pink); (c) chemical shift perturbations of imino and 
aromatic resonances of DNA upon addition of 2 equiv. E-41; (d) cartoon representation of 
the antiparallel G4 with chemical shift perturbations > 0.05 ppm highlighted in green. 




2.4  In vitro assays 
The results of the biophysical assays demonstrated that the stiff-stilbene ligands can 
selectively target G4 in physiologically-relevant conditions. Importantly, the E/Z-41 ligand pair 
 
Figure 2.20: NMR titration studies examining the binding of Z-41 to antiparallel (telo22-Na+) 
G4. (a) stacked imino spectra; (b) chemical shift perturbations of imino and aromatic 
resonances of DNA upon addition of 2 equiv. Z-41. 
 
Chapter 2: Amine-decorated stiff-stilbene G4 ligands 
77 
 
acts as a proof-of-concept that isomerisation of the stilbene core could act as a means to 
control G4 ligand affinity. However, despite differences in activity of the ligand pair, the affinity 
of the active E-41 ligand for the preferred hybrid G4 (Ka ≈ 104) is not particularly high. This 
raised the question of whether the ligands developed in this chapter were sufficiently potent 
DNA binding molecules for the promising activities observed in the binding studies to translate 
into corresponding activities in biological systems. Before embarking upon efforts to study the 
photochemistry of E/Z-41, it was considered more worthwhile to evaluate the toxicity of these 
ligands in in vitro cellular and parasitic models in order to establish the potential of the E/Z-41 
pair as a photopharmacological strategy, or whether further optimisation of the G4-binding 
properties was first necessary to progress towards this goal. 
Ligands E-41 and Z-41 were therefore screened for activity against two mammalian cell lines: 
HeLa (a cervical cancer cell line) was chosen as a tumoral model whilst MRC-5 (lung 
fibroblasts) was selected as a non-cancerous model. Meanwhile, to evaluate the potential of 
the compounds as antiparasitic agents, toxic activity was measured in the protozoan parasites 
T. brucei and L. major.52 
 
 
Figure 2.21. Chemical basis of (a) MTT and (b) alamarBlue cell viability assays. The 
products generated by the reducing environments of normally functioning cells are detected 
by absorbance (formazan) or fluorescence (resorufin) and the readout is proportional to the 
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2.4.1 Basis of the viability assays 
The MTT and resazurin (alamarBlue) assays use redox processes to measure cellular viability. 
Live cells maintain a reducing environment owing to the production of reducing agents (such 
as NADH) during metabolism.200 Both MTT (52) and resazurin (53) are susceptible to reduction 
by these species, generating products (formazan 54 and resorufin 55) which may be detected 
through fluorescence or absorbance spectroscopy (Figure 2.21).201,202 The respective 
readouts are therefore proportional to the quantity of viable cells under the experimental 
conditions. To measure compound toxicity, cells and parasites were incubated with increasing 
concentrations of compound for 72 hours and the viability under each set of conditions was 
measured using alamarBlue (mammalian cells and T. brucei) or MTT (L. major). Normalisation 
against a negative control (cells not treated with compound) allows the toxic effect of the 
compound to be quantified as the concentration which results a 50% reduction in viability 
relative to the control, known as the EC50 (effective concentration). 
 
2.4.2 Toxicity studies in cells and parasites 
First the activity of the pair or ligands E-41 and Z-41 was inspected against a small panel of 
mammalian cells and parasites (Figure 2.22 and Table 2.3). Though a 5-fold difference in EC50 
between the E-41 (EC50 = 46 ± 8 μM) and Z-41 (EC50 = 9 ± 3 μM) isomers is observed against 
HeLa cells, it is the Z isomer which is more efficacious. In light of the biophysical assays, which 
demonstrate this to be the poorer G4 ligand, this suggests that the mechanism of toxicity is 
unlikely to be related to G4 binding for these two compounds. Furthermore, the toxicity of both 
ligands to the non-tumoral cell line is similar to that observed in the cancerous model (e.g. for 
Z-41, EC50 (HeLa) = 9 ± 3 μM, EC50 (MRC5) = 9 ± 1 μM). Since more potent G4 ligands have 
previously been demonstrated to selectively target tumoral cells through a variety of proposed 
mechanisms (Section 1.3.1), the similarity in toxicity between the different cell lines tentatively 
suggest alternative mechanisms of action that are not G4-dependent. Therefore, it appears 
that the G4-binding activity of the E/Z-41 couple is not sufficiently strong for the trends 
observed in the biophysical assays to translate into in vitro performance.  
Turning attention to the activity of the compounds against the parasitic strains, significantly 
higher toxicity against T. brucei is observed, with EC50 values recorded in the nanomolar range 
(e.g. EC50 Z-41 = 12 ± 5 nM). Whilst promising, these do not correlate at all with the G4-binding 
affinity of the molecules.  
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The Z-41 isomer is the more active form against both parasitic strains (between three- and 
seven- fold decrease in EC50 compared to E-41), again suggesting that the biological activity 
is not a result of a G4-mediated pathway. Nonetheless, the compounds are both significantly 
more toxic to T. brucei than non-tumoral cells (up to 750-fold in the case of Z-41) and further 
 
Figure 2.22: Dose-response curves for ligands E-41 and Z-41 against (a) HeLa and (b) 
MRC5 cells, and (c) T. brucei and (d) L. major parasites. Exposure time: 72 h. 
 
Table 2.3: EC50 values for compounds E-41 and Z-41 against the cellular and parasitic 
models studied. Selectivity index = EC50 (MRC5) / EC50 (HeLa/T. brucei/L. major) 
Ligand 
EC50 / μM  Selectivity index 




















1.0 750 3.9 
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investigations into the mechanism of the activity of these compounds would be worthwhile to 
explore their potential as a new class of potential anti-trypasonomal agents. The compounds 
are less efficacious against the L. major organism, but nonetheless Z-41 displays a 4-fold 
selectivity against the non-tumoral model. 
 
Figure 2.23: Toxicity screen of the compound library A and C-H against HeLa cells. 
Exposure time: 72 h. 
 
Finally, the remainder of the compound library (compounds A and C-H) was screened for 
toxicity against HeLa cells to further examine the influence of the ligand structure on biological 
activity (Figure 2.23). Com pounds A and C, direct analogues of E-41 only differing in the 
length of the alkyl spacer chain, displayed similar activities (EC50 ≈ 50 μM). The only other 
toxic compounds appeared to be D, E and H and therefore no correlation with the G4 binding 
properties observed in the FRET assay was found. For example, E and F differ only in length 
of the spacer unit, which does not much impact the thermal stabilisation of G4 in the FRET 
assay but appears to significantly impact the toxicity. Again, these results highlight that the 
biologically activity of the compound series developed in this chapter is unlikely to result from 
G4 binding. 
 
2.5  Chapter conclusions 
The work described in this chapter details the initial efforts of this research project towards the 
development of a new series of photoresponsive G4 ligands with the overall aim of achieving 
a G4-targeting ligand that can be regulated in physiological conditions towards the 
development of G4-targeted photopharmacological agents. The limitations in the current state-
of-the-art (azobenzene derivatives) have been critiqued, leading to the design of a new family 
of ligands based on the stiff-stilbene photoswitch. A model photoswitchable ligand pair (E-41 
and Z-41) was conceived and synthesised, and the binding of the two isomeric derivatives 
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was investigated using a suite of spectroscopic methods. This demonstrated that the stiff-
stilbene scaffold is a promising fragment for the design of G4 ligands. Indeed, this first attempt 
to engineer a G4 ligand derived from this scaffold yielded an active compound (E-41) with 
affinity at the micromolar level and selectivity against duplex DNA. Critically, the Z-41 isomer 
was shown to be inactive as a G4 ligand, indicating that the G4 binding activity of this 
compound series could conceivably be controlled by photoisomerisation. NMR spectroscopy 
confirmed differences in binding modes between the two ligands. Meanwhile, investigations 
into the structure-activity relationships were undertaken (compounds A-H), though 
unfortunately these did not return any significant increase in G4-stabilising ability. 
Unfortunately, the biological activity of the isomeric forms, whilst of interest (particularly the 
potency of the compounds against parasitic organisms) did not match the ability of the ligands 
to bind G4. It was concluded that improvements to the G4-recognition properties in this 
compound series were needed in order to build more convincing evidence that stiff-stilbene 
derivatives may eventually target G4 in vivo. 
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3  N-methylpyridinium-decorated stiff-stilbene G4 ligands 
This chapter is based upon work published in Angewandte Chemie International Edition203 and 
Chemistry: A European Journal169 of which I am first author. I was responsible for all elements 
of ligand design, synthesis and biophysical studies, which were undertaken at the University 
of Bristol, UK. The DFT calculations were performed by Miss Marta Duchi in Dr. Thomas A.A. 
Oliver’s group at the University of Bristol. I performed the biological assays at the Institute of 
Parasitology and Biomedicine (CSIC), Granada, Spain, with assistance from Dr Pablo 
Peñalver. Dr Peñalver also collected the microscopy images. The molecular dynamics studies 
were performed by Dr Susanta Haldar in Professor Adrian J. Mulholland’s group at the 
University of Bristol. 
 
3.1  Introduction 
The previous chapter described a proof-of-concept study of the design of G4 ligands derived 
from stiff-stilbene with the goal of achieving photocontrol of ligand activity in physiological 
conditions. Promising activities were achieved: the first-generation compounds E-41 and Z-41 
selectively bound G4 in preference to duplex, and the affinity of the ligand for G4 was shown 
to depend on the geometric configuration of the stilbene moiety, suggesting photocontrol of 
the ligand activity could ultimately be achieved. However, the relatively modest affinity of the 
active molecule for G4 did not appear sufficient for G4-mediated toxic effects in mammalian 
cells and parasites to be observed in vitro. Optimisation of the ligand design was therefore 
desired, in order to create a more potent class of compound that could compete with high-
affinity compounds previously reported. This chapter describes the design of a second 
generation of stiff-stilbene ligands bearing N-methylpyridinium cationic moieties in contrast to 
the flexible amine-terminated side-chains featured in the prototype E/Z-41 ligands. The 
rationale for the compound design is first explained and the synthesis of a set of analogues is 
briefly described. The results of the biophysical assays are then discussed which reveal this 
class of compounds display markedly improved G4 binding properties and also dramatic 
effects on G4 folding topologies. As well as the suite of biophysical techniques described in 
the previous chapter, results of binding simulations from molecular dynamics and 
metadynamics studies (conducted by Dr Susanta Haldar) are presented in light of NMR data 
gathered by the author. Finally, the toxicity of the new compounds in cellular and parasitic 
models is reported, which suggests that the improved G4-targeting properties of the new 
ligands translate into promising selective effects against disease models and indicate a role 
for stiff-stilbene ligands in photopharmacology. 
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3.2  Ligand design and synthesis 
 
3.2.1  Design concept 
In search of a means to increase the G4-binding ability of the stiff-stilbene scaffold, it was 
noted that N-methylated aromatic moieties are commonly found in G-quadruplex ligands that 
are reported to display high binding activity (see Section 1.3.1). For example, TMPyP4 (4, 
Figure 3.1), bearing four N-methyl pyridinium groups, is known as a potent G4 ligand but also 
targets duplex DNA.104 It was thus reasoned that the combination of the N-methylpyridinium 
moiety with the stiff-stilbene core may improve G4 ligand binding potency by extending the 
ligand surface area and cationic charge, whilst possibly retaining the selectivity of the scaffold 




Figure 3.1. TMPyP4 (4), a potent G4 binding chemotype containing four N-
methylpyridinium moieties. 
 
3.2.2  Structural considerations 
To examine the design hypothesis, the pyridinium ligands E-56 and Z-56 were sought as direct 
analogues of the prototype amine-decorated E/Z-41 pair (Figure 3.2a). The molecular 
structures of these ligands were examined by DFT calculations (Figure 3.3) to assess the 
effect of the new substituent on the ligand geometry. From the computational results, it 
appears that the presence of the pyridinium moieties confers a distortion from planarity in the 
E isomer (Figure 3.3c), though the molecule nonetheless possesses a large extended surface 
that could be expected to stack or intercalate the G-tetrad. The increased ligand surface area 
can be seen by comparison of the dimensions of E-56 (Figure 3.3d) with the unfunctionalised 
stilbene core (Figure 3.3b), and appear more suited to overlap with the surface of a G-tetrad 
(Figure 3.3a). Meanwhile, Z-56 adopts a V-shaped conformation, with a ~ 20° bite angle 
between the two halves (Figure 3.3e). This geometry suggests that only one half of the 
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molecule can be expected to stack with the planar G-tetrads at any one time, and the structure 




Figure 3.2. Ligand optimisation strategies pursued in this chapter. (a) Replacement of 
flexible transiently-charged side-chains with rigid cationic N-methylpyridinium moieties; (b) 
effect of substitution pattern on ligand shape and electronics. 
 
 




Figure 3.3: Investigation of candidate ligand structures by DFT. (a) Dimensions of a G-
tetrad; (b) dimensions of the unsubsituted stiff-stilbene core; (c)-(h) calculated ground-
state strucuture of (c)-(d) E-56, (e)-(f) Z-56 and (g)-(h) E-57 shown (c),(e),(g) side-on and 
(d),(f),(h) top-down. 
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In Chapter 2, the position of the amine-derived substituents on the stilbene core was varied 
(e.g. ligand D vs. ligand E). This modification appeared to exert little effect on the G4 binding 
properties as measured in the thermal melting assay, but this is perhaps unsurprising given 
the conformational freedom of the alkyl spacer units, which may allow the terminal 
methylpiperazine moieties to adopt a favourable orientation irrespective of the connectivity to 
the central scaffold. However, the pyridinium ligand variants contain only one rotatable bond 
(between the stiff-stilbene core and the N-heterocycle) and therefore the position of the 
substituent exerts a much greater influence on the molecular shape of the ligand. In particular, 
installing the pyridinium moiety para to the stilbene olefin (at the 5-position), rather than meta 
(at the 6-position) renders a more rod-like shape to the molecule (ligand E-57) which could 
reasonably be expected to modulate the affinity of the ligand to DNA structures (Figure 3.2b). 
DFT optimisation of the ground state molecular geometry indicates the molecule to be fully 
planar, unlike E-56 (Figures 3.3g and 3.3h). This difference is proposed to arise from the 
difference in electronics between the two isomers (Figure 3.2b). In E-56 the positive charge 
may be delocalised over the two halves of the molecule since the pyridinium moiety is 
conjugated to the central olefin, and therefore the planar conformation is likely favoured to 
maximise orbital overlap of the two π-systems. This extended delocalisation is not possible in 
the 6-substituted isomer E-56, resulting in a distortion from planarity being favoured on steric 
grounds. 
 
3.2.3  Synthesis of the target compounds 
With a prototype set of target compounds identified to test the design hypotheses, efforts 
turned towards their synthesis. The synthetic route to the pyridinium-substituted compounds 
was undertaken starting from the same bis-bromides (E-43, Z-43 and E-45) previously 
prepared for the synthesis of the amine-derived analogues in Chapter 2 (Scheme 3.1). In this 
instance, the pendant pyridine moieties were attached by a double Suzuki coupling to 4-
pyridinylboronic acid to furnish the bis-pyridinium compounds (E-58, Z-58 and E-59) in 
moderate to good yields. Like the Buchwald-Hartwig coupling introduced in Chapter 2, the 
Suzuki reaction is also promoted by a Pd(0) catalytic cycle (Scheme 3.2).204 In this case, 
following oxidative addition of the aryl bromide, transmetallation between the Pd(II) species 
and the boronic acid partner occurs, generating the bis-aryl palladium(II) intermediate which 
undergoes reductive elimination to form the cross-coupled product and regenerate the active 
palladium(0) catalyst. The transmetallation is promoted by the presence of base, which 
generates the active boron-ate complex from the boronic acid. 
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From the bis-pyridinium compounds, alkylation with iodomethane furnished the desired 
compounds as bis-iodide salts. Full synthetic details are provided in the experimental section 




Scheme 3.1. Synthetic route to N-methylpyridinium stiff-stilbene ligands E-56, Z-56 and E-
57. Reagents and conditions: (a) 4-pyridylboronic acid, Ph(PPh3)4 (20 mol %), Na2CO3, 




Scheme 3.2: General mechanism of the Suzuki reaction 
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3.3 Biophysical studies 
With the compound library in hand, efforts turned to evaluating the potential of the compounds 
as new G4 binding molecules using a similar panel of techniques as described in Chapter 2.  
 
3.3.1  FRET thermal melting assays 
DNA binding activity of the three compounds was initially assessed using the FRET thermal 
melting assay as previously introduced in Chapter 2 (Section 2.3.1). All ligands were screened 
against the four G4 models previously described, namely the human telomeric sequence (in 
potassium- and sodium- containing buffer) the c-myc oncogene model and the EBR1 G4 from 
the T. brucei genome, alongside the duplex DNA hairpin. 
 
3.3.1.1 Ligand screening 
The results of the ligand/G4 FRET screen are shown in Tables 3.1-3.5 and representative 
curves for F21T-K+ G4 and F10T duplex DNA are shown in Figure 3.4 (additional data are 
shown in the Appendix A3, Figures A3.1-A3.3). These data demonstrate the superiority of the 
N-methylpyridinium ligands E-56, Z-56 and E-57 compared to the first-generation amine 
derivatives E-41 and Z-41 introduced in Chapter 2. Indeed, whilst only modest stabilisation 
(ΔTm = 12 °C) of F21T-K+ G4 was achieved with ligand E-41 even at high ligand concentration 
(10 μM), the N-methylpyridinium analogue of this compound (E-56) induces significantly 
higher thermal stabilisation (ΔTm = 21 °C, Table 3.1) at lower ligand concentration (1 μM). 
Considering the FRET data as a whole, ligand E-56 emerges as the lead compound of this 
series, inducing the highest thermal stability in all G4 sequences. As in the case of the amine-
derived analogue E-41, the most effective stabilisation was observed for the F21T-K+ G4 (ΔTm 
= 21 °C at 1 μM, Table 3.1). More modest stabilisation values were observed for the F21T-
Na+ G4 (ΔTm= 12 °C, Table 3.2), FmycT G4 (ΔTm = 16 °C, Table 3.3) and Febr1T G4 (ΔTm = 
13 °C, Table 3.4). These results suggest that the preference of the stiff-stilbene core for the 
hybrid G4 topology observed in the first-generation compounds (Chapter 2) is retained to 
some degree in the new compound series.  
The effect of ligand structure on activity was next examined. Whilst Z-56 demonstrates some 
stabilisation of the G4 sequences, the affinity appears to be significantly lower than for the E-
56 counterpart. In general, the thermal stabilisation values induced in all G4 by ligand Z-56 
are at least two-fold lower than those observed for E-56 (e.g. at 1 μM, ΔTm  F21T-K+ = 21 °C 
for E-56, 10 °C for Z-56, Table 3.1). Therefore, the effect of stilbene configuration observed 
for the first-generation compounds (where the more planar E stilbene configuration rendered 
the ligand more active) appears to be retained in the second-generation N-methylpyridinium 
compounds. 
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Table 3.1: F21T-K+ FRET thermal stabilisation values for ligands E-56, Z-56 and E-57 
Ligand 
ΔTm / °C 
2 μM 1 μM 
E-56 26 ± 0.3 21 ± 0.3 
Z-56 13 ± 0.6 10 ± 0.5 
E-57 21 ± 0.6 15 ± 0.8 
     
Table 3.2: F21T-Na+ FRET thermal stabilisation values for ligands E-56, Z-56 and E-57 
Ligand 
ΔTm / °C 
2 μM 1 μM 
E-56 19 ± 0.7 12 ± 0.6 
Z-56 7 ± 1.3 5 ± 1.0 
E-57 11 ± 1.2 6 ± 0.9 
     
Table 3.3: FmycT FRET thermal stabilisation values for ligands E-56, Z-56 and E-57 
Ligand 
ΔTm / °C 
2 μM 1 μM 
E-56 23 ± 1.1 16 ± 0.8 
Z-56 10 ± 0.9 5 ± 1.4 
E-57 23 ± 0.3 16 ± 0.6 
     
Table 3.4: Febr1T FRET thermal stabilisation values for ligands E-56, Z-56 and E-57 
Ligand 
ΔTm / °C 
2 μM 1 μM 
E-56 19 ± 0.1 13 ± 0.5 
Z-56 6 ± 0.4 4 ± 0.3 
E-57 15 ± 0.2 7 ± 0.1 
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Comparing E-56 with E-57, it is interesting to note that whilst both molecules induce high 
thermal G4 stabilisation, ligand E-56 appears more effective. Indeed, whilst ligand E-56 
induces a thermal stabilisation of 21 °C for F21T-K+ at 1 μM, the stabilisation of ligand E-57 is 
6 °C lower (ΔTm = 15 °C) under comparable conditions (Table 3.1). This effect appears to be 
general to the majority of the G4 sequences, with the exception of the Febr1T sequence where 
comparable ΔTm values are observed for the two ligands (Table 3.4). Therefore, it suggests 
that the more compact S-shape geometry of ligand E-56 is beneficial to G4 affinity when 
compared with the more linear rod-like arrangement of ligand E-57. It is notable that E-56 is 
more effective at stabilising the G4 sequences despite the DFT calculations suggesting this 
molecule is not fully planar, in contrast to ligand E-57. Superficially, this result could be 
expected on the basis that the dimensions of the S-shaped ligand are better suited to overlap 
with G-tetrads than the linear counterpart E-57 (Figure 3.3). However, from the FRET results 
alone, it cannot be discounted at this stage that ligands E-56 and E-57 interact with G4 through 
mechanisms other than end-stacking, such as groove binding, and further investigations into 
the binding mode of the ligands will be later discussed. 
  
3.3.1.2 G4/duplex selectivity 
Importantly, in addition to the second-generation ligands displaying markedly more potent G4 
binding activity than the amine-decorated ligands discussed in Chapter 2, the selectivity for 
G4 over duplex DNA appears to be retained. Indeed, the ligands induce virtually no 
stabilisation in the duplex DNA model (ΔTm < 3 °C, Table 3.5). In conjunction with the results 
of Chapter 2, these data provide further evidence that stiff-stilbene core appears a promising 
chemotype for the development of G4-selective binding molecules. 
Table 3.5: F10T FRET thermal stabilisation values for ligands E-56, Z-56 and E-57 
Ligand 
ΔTm / °C 
2 μM 1 μM 
E-56 2 ± 0.2 1 ± 0.2 
Z-56 1 ± 0.1 0 ± 0.1 
E-57 1 ± 0.3 0 ± 0.2 
 




Figure 3.4: Representative FRET curves for (a)-(c) F21T-K+ G4 and (d)-(f) F10T duplex in 
presence of 1 μM and 2 μM  ligands (a),(d) E-56; (b),(e) Z-56; (c),(f) E-57. 
 
To further interrogate the G4/duplex selectivity of the pyridinium compounds, competition 
assays were conducted in which the thermal stabilisation induced in the G4 structures at 1 μM 
ligand concentration was monitored under conditions of increasing concentration of a non-
fluorescent duplex DNA competitor. As mentioned previously (Section 2.3.1), off-target 
binding is detected by a depression in the induced thermal destabilisation caused by ligand 
association to the duplex competitor diminishing the concentration of the G4/ligand complex. 
Results of the competition assays are displayed in Figure 3.5. Pleasingly, the selectivity of the 
lead compound E-56 for the G4 structures is confirmed (representative melting curves shown 
for F21T-K+ in Figure 3.5a, data represented as black bars in Figures 3.5b-3.5e). At a 
concentration of 5 μM duplex competitor (25 molar equivalents of duplex to G4 strands), over 
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70% of the induced thermal stabilisation is retained against F21T-K+ (Figure 3.5b) and FmycT 
G4 (Figure 3.5d), demonstrating preferential association with the 4-stranded hybrid and 
parallel G4 structures. The fact that a measurable depression in the melting temperature is 
observed indicates however that the discrimination is not complete, unlike for some of the best 
G4 ligands reported to date, such as PhenDC3 (10, Figure 1.14) which resists duplex 
competitors almost totally up to 10 μM concentration.130 Nonetheless, the observed results 
represent a promising selectivity that could be optimised in the development of future 
generations of stiff-stilbene G4-targeting compounds.  
Meanwhile, the discrimination between the F21T-Na+ antiparallel G4 and duplex appears 
much less effective (Figure 3.5b). At 5 μM duplex competitor, only ~ 30% stabilisation of the 
G4 is retained compared to that observed in the absence of competitor. This reflects the 
weaker affinity for this G4 model indicated by the lower ΔTm values obtained for F21T-Na+ 
(Table 3.2). The selectivity between FebrT G4 and duplex is as also expected based on the 
initial FRET results (Figure 3.5e). A similar selectivity profile is observed for ligand E-57 
(Figures 3.5b-3.5e, dark-grey bars), though the discrimination between G4 and duplex 
appears to be slightly poorer than for compound E-56, consistent with this compound being 
the weaker of the two ligands. 
Finally, the Z-56 ligand displays the weakest discrimination between the G4 and duplex DNA 
structures (Figures 3.5b-3.5e, light-grey bars). Though the selectivity for hybrid G4 appears 
comparable to E-56 and E-57, the ligand-induced thermal stabilisation for the all other G4 
sequences is clearly depressed even at low concentrations of competitor. This effect is 
particularly noticeable in the experiments involving FmycT (Figure 3.5d), where a gradual 
reduction ΔTm is observed on increasing the concentrations of duplex competitor, with only 
19% stabilisation retained under these conditions at 5 μM duplex (compared to the 74% 
stabilisation retained for the E-56 counterpart under comparable conditions).  
The results of the FRET experiments indicate the N-methylpyridinium ligands outperform the 
amine-derived ligands reported in the previous Chapter 2. Fortunately, the desired activity 
difference between the E and Z ligand forms (that suggested activity could eventually be 
controlled by photoisomerisation) was retained and G4/duplex discrimination for the most 
active compound remained good, demonstrating that increasing the ligand potency did not 
come at great expense to selectivity. Having identified this new ligand class, subsequent work 
focused on a more in-depth investigation of the ligand binding modes of the three compounds 
alongside evaluation of their potential as therapeutic agents using the battery of techniques 
introduced in the previous chapter. 





Figure 3.5. FRET competition assay data. (a) Representative melting curves for F21T-K+ in 
the presence of E-56 (1 μM) and increasing concentrations of ds26 duplex DNA; (b)-(e) 
retained thermal stabilisation induced by ligands E-56, Z-56 and E-57 (1 μM) under 
increasing concentrations of ds26 duplex DNA for (b) F21T-K+ G4; (c) F21T-Na+ G4; (d) 
FmycT G4; (e) Febr1T G4 sequences. 
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3.3.2  UV/visible absorbance titrations 
Quantification of the binding affinity of ligands E-56, Z-56 and E-57 to hybrid telo23-K+ G4 was 
attempted using UV/visible titration studies in a similar manner as described in Chapter 2 for 
the amine-derived ligands (Section 2.3.2). The resulting titrations and representative 
isotherms are shown in Figure 3.6 in which the absorbance spectrum of the ligand was 
measured upon titration with telo23-K+ G4. Qualitatively, the changes in the isotherms confirm 
the strong association of ligands E-56 and E-57 to G4. The isotherms were not well-described 
by the 1:1 binding model presented in Chapter 2 (Section 2.3.2). Indeed, saturation of binding 
for ligands E-56 and E-57 is clearly observed before one stoichiometric equivalent of DNA is 
added (Figures 3.5b and 3.6c) indicating higher binding stoichiometries. Binding of more than 
one ligand per host quadruplex is more challenging to model owing to co-operative effects, 
where the binding of the first ligand molecule to the DNA influences the binding of subsequent 
molecules.186 Whilst software is available to model such systems, the large number of fitting 
parameters in the associated equations requires very high-quality, information-rich isotherms 
in order to obtain reliable fits. Unfortunately, attempts to fit the data that could be obtained to 
co-operative binding models gave nonsensical results in most cases. The apparent 
dissociation constants were therefore estimated by fitting the observed isotherms in Figure 
3.6 to an independent-and-equivalent sites model, Eqn (3.1) as previously employed by others 
in the treatment of multi-site G4 ligand binding.205,206 N, the stoichiometry of the complex is the 
assumed number of ligand binding sites per G4, and was chosen as the lowest value that 
adequately described the data, with the quality of fit indicated by the R2 value. 
Though these assumptions are likely rather crude, the apparent dissociation constants (Figure 
3.6) mirror the trends observed in the thermal melting assays with compound E-56 emerging 
again as the most potent G4 ligand (Ka = 3.8 x 106 M-1). The 3:1 binding stoichiometry of this 
ligand was also supported by circular dichroism studies (see below, Figure 3.7a) as ligand E-
56 induces increasing hyperchromicity in the telo23-K+ bands up to a 3:1 ligand:G4 ratio. 
These results reinforce the observations of the FRET assay that stilbene configuration is 
important for G4 recognition, with Z-56 displaying lower apparent affinity (Ka = 1.7 x 105 M-1) 
than the E-56 counterpart, by an order of magnitude. 
 
∆𝐴 = 𝜀∆ .  ∙  
𝑁 ∙ [𝐷] +  [𝐿] +
1
𝐾
− 𝑁 ∙ [𝐷] +  [𝐿] +
1
𝐾
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Figure 3.6: G4 binding studies of ligands (a,b) E-56, (c,d) Z-56 and (e,f) E-57 monitored by 
UV/visible absorbance titrations. (a,c,e): spectra of 10 μM ligand (black traces) titrated with 
increasing concentration of telo23-K+ hybrid G4 (grey traces); (b,d,f) determination of the 
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3.3.3  Circular dichroism titrations 
As previously mentioned, circular dichroism (CD) is a useful technique for the study of 
G4/ligand complex formation, since the effects of the ligand on G4 topology can be detected 
through changes in the characteristic dichroic absorbance bands. Moreover, induction of CD 
signals in otherwise CD-transparent systems on association with a chiral macromolecule 
provides a clear indication of binding. To this end, CD titrations were performed for ligands E-
56, Z-56 and E-57 against different G4 models: the telo23 sequence in both sodium- and 
potassium-containing buffer (hybrid G4), telo22 in sodium buffer (antiparallel G4) and Pu27 
(parallel G4). 
This section discusses the differences in CD spectral perturbations induced in the respective 
G4 signatures by each ligand. In certain cases, these differences are sufficiently striking to 
confidently conclude that the ligand induces a global change in the DNA conformation. 
However, there are several instances where more minor changes occur. Though these 
changes are significant and possible binding modes may be ventured by comparison with data 
reported for previous systems, the complex origin of CD signals means that it is not possible 
to draw robust conclusions on the structures of the complexes from CD data alone, since 
effects are difficult to generalise between different chemotypes. Therefore, in addition to 
analogy with previous reports, these discussions are also informed by the information gained 
from NMR spectroscopy and molecular dynamics simulations (Section 3.3.4). Since 
interpretation of NMR spectra of G4/ligand complexes is itself also complicated by several 
factors (such as exchange broadening of signals), the combination of both techniques is 
needed to build evidence for the proposed ligand binding modes.   
Examining first ligand E-56, strikingly different behaviour can be observed between the 
different G4 topologies examined (Figure 3.7). No major conformational change appears to 
be induced in the hybrid G4 conformation of telo23 under potassium conditions (Figure 3.7a), 
though binding of the ligand is clearly evidenced by the ligand-induced hyperchromicity in the 
positive band at 290 nm consistent with stabilisation of the native hybrid G4. Plotting the 
ellipticity against the equivalents of ligand E-56 added indicates a 3:1 binding stoichiometry 
(Figure 3.8). Small induced circular dichroism (ICD) signals are visible in the ligand region (λ 
> 320 nm). The origin of ICD signals is complex and difficult to generalise, but small ICD bands 
have previously been attributed to arise from interaction with the 3-dimensional G4 grooves 
rather than by end stacking with the planar G-tetrads.106 Subsequent NMR experiments 
provided additional evidence that association of ligand E-56 occurs through a groove-binding 
mode of interaction.  Ligand E-56 induces little perturbation to the spectral signature of the 
parallel Pu27 G4 and no induced CD bands can be detected (Figure 3.7d). This could indicate 
an alternative mode of binding to the parallel structure compared with the hybrid type. 
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However, in the absence of further structural information regarding binding to the parallel 
sequence (not obtained in the present study) this inference is rather speculative. 
Of perhaps greater interest is the effect of ligand E-56 on the G4 sequences examined in 
sodium buffer (Figure 3.7b). Though the CD spectrum of telo23 in sodium-rich conditions is 
different from the same sequence in potassium-containing buffer (Figure 3.7b), it was recently 
demonstrated by detailed structural investigations that the same hybrid topology of telo23 is 
observed under Na+ and K+-rich conditions.207 However, despite the similarity in G4 secondary  




Figure 3.7. CD titrations of studies of ligand E-56 against (a) telo23-K+ (hybrid G4); (b) 
telo23-Na+ (hybrid G4); (c) telo22-Na+ (antiparallel G4); (d) Pu27 (parallel G4). Black trace: 
DNA CD spectra in absence of ligand; dark grey trace: CD spectra in the presence of 7 
equiv. E-56. Intermediate titration points are shown as pale grey traces. [θ] = molar ellipticity. 
DNA concentration = 4.2 μM. 
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Upon titration with ligand E-56, all of the characteristic bands associated with the native G4 
fold of telo23-Na+ disappear and the emergence of new spectral features can clearly be seen, 
specifically a positive band at 270 nm and a large induced CD signal in the ligand region (> 
320 nm). These changes indicate the ligand disrupts the G4 fold and induces rearrangement 
to an alternative structure. The CD spectra of the telo23-Na+/E-56 complex does contain any 
features corresponding to archetypal G4 signatures and, on the basis of the CD data, all that 
can be concluded is that significant structural perturbation is caused by the ligand. However, 
subsequent NMR experiments and computational studies provide further evidence that the 
ligand induces denaturation of the G4 folding under these conditions (Section 3.3.4). 
Similar spectral changes are induced in the telo22 sequence in the same buffer conditions, 
which forms instead an antiparallel G4 topology (Figure 3.7c). However, the effect is much 
less pronounced than in the case of telo23, and at the final titration point the CD spectrum 
reveals a mixture of antiparallel G4 and the remodelled species. Specifically, the maximum at 
290 nm can still be observed in addition to ligand-induced positive band at 273 nm; in the 





Figure 3.8: Molar ellipticity at 290 nm of telo23-K+ hybrid G4 upon titration with ligand E-56, 
indicating 3:1 binding stoichiometry. 
 
To provide further evidence that the spectra changes induced by ligand E-56 were indeed the 
result of global conformational rearrangement, a kinetic experiment was performed (Figure 
3.9). The emergence of the new positive feature at 270 nm was monitored following the mixing 
of the telo23-Na+ G4 and 10 equiv. ligand E-56. This revealed the spectral changes to take 
place in the order of minutes, suggesting a global structural rearrangement. A characteristic 
unfolding time (τ) of 245 seconds was extracted from fitting of the data to the first-order rate 
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Eqn. (3.2). This timescale is consistent with ligand-induced G4 topological changes reported 
by others. For example, similar rearrangement times were reported by Chaires and co-workers 




Figure 3.9: CD kinetic study of telo23-Na+ refolding after addition of 10 equiv. ligand E-56, 
monitoring the emergence of the positive feature at 270 nm with time. 
 
Next, the effect of the Z-56 ligand on the various G4 structures was examined under analogous 
conditions (Figure 3.10). The ligand interacts very differently with the G4 topologies compared 
to E-56. Considering first the telo23-K+ hybrid G4, whereas titration of the quadruplex with E-
56 preserves and increases the intensity of the characteristic G4 bands, addition of ligand Z-
56 causes attenuation of the shoulder band at 260 nm characteristic of the native equilibrium 
(Figure 3.10a) and, unlike for ligand E-56, no ICD signals are observed in the ligand region. 
Subsequent NMR experiments (Section 3.3.4) provided further evidence that the CD spectral 
changes result from ligand-induced perturbation of the conformational equilibrium of G4. Only 
very minor changes are seen in the spectrum of the parallel G4 structure (Figure 3.10d), 
though a small induced CD in the ligand region (330 nm) indicates binding between the two 
structures. 
Examining the two G4s formed in sodium-rich conditions, interesting differences are again 
observed, both between telo22 and telo23 G4 in this buffer and in the behaviour of ligand Z-
56 compared to ligand E-56. Virtually no perturbations to the antiparallel G4 signature are 
caused by the addition of ligand Z-56 (Figure 3.10c), indicating persistence of the antiparallel 
 
𝜃 = 𝑎 − 𝑏𝑒 /   (3.2) 
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topology. In surprising contrast, the telo23-Na+ hybrid G4 signature is significantly perturbed 
by the addition of ligand E-56 and at the end of the titration the spectrum resembles exactly 
that of the telo22 antiparallel G-quadruplex, suggesting that Z-56 may induce this structure 
from the hybrid type found in the absence of ligand. Most strikingly, the disruption of the 
quadruplex structure induced in both telo22-Na+ and telo23-Na+ by E-56 is not observed for 
the Z-56 counterpart; in both cases, a characteristic G4 spectral signature is preserved 
throughout the titration.  
 
 
Figure 3.10: CD titrations of studies of ligand Z-56 against (a) telo23-K+ (hybrid G4); (b) 
telo23-Na+ (hybrid G4); (c) telo22-Na+ (antiparallel G4); (d) Pu27 (parallel G4). Black trace: 
DNA CD spectra in absence of ligand; dark grey trace: CD spectra in the presence of 7 
equiv. Z-56. Intermediate titration points are shown as pale grey traces. [θ] = molar ellipticity. 










Figure 3.11: CD titrations of studies of ligand E-57 against (a) telo23-K+ (hybrid G4); (b) 
telo23-Na+ (hybrid G4); (c) telo22-Na+ (antiparallel G4); (d) Pu27 (parallel G4). Black trace: 
DNA CD spectra in absence of ligand; dark grey trace: CD spectra in the presence of 7 
equiv. E-57. Intermediate titration points are shown as pale grey traces. [θ] = molar ellipticity. 
DNA concentration = 4.2 μM. 
 
Finally, the activity of ligand E-57 was investigated (Figure 3.11). The binding mode to the 
hybrid telo23-K+ G4 appears similar to that for ligand E-56 (Figure 3.11a), with similar spectral 
changes (namely hyperchromicity at 290 nm and ICD signals in the ligand region) observed 
during the titration. Interaction of the ligand with the parallel Pu27 sequence is also evidenced 
by perturbation of the positive band and negative ICD signal in the ligand region (Figure 
3.11d). Interestingly, a large bisignate ICD is observed in the ligand in both telo23-Na+ (Figure 
3.11b) and telo22-Na+ (Figure 3.11c). Conveniently, this blue-shifted ligand absorption band 
does not overlap with the absorption spectrum of the DNA, so perturbations in the G4 spectral 
signature can be detected more easily than in the case of E-56. In the case of telo22-Na+, 
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hypochromicity is observed in the G4 bands at 240 nm and 260 nm, indicative of some 
disruption of the fully folded structure, but the effect is not as pronounced as for ligand E-56. 
The behaviour of the hybrid telo23-Na+ sequence is more complex. Initially, the ligand induces 
hyperchromicity in both the negative band a 260 nm and positive bands at 290 nm, but at 
higher ligand concentrations the intensity of these bands becomes depleted, suggesting E-57 
is also capable of disrupting the G-tetrads of telo23-Na+ at higher concentrations. 
 
3.3.4  NMR and molecular dynamics studies 
Though the CD experiments are useful to examine qualitative differences in the interaction of 
the ligands with the different G4 structures, more direct structural information was needed to 
build more additional evidence of the proposed binding modes and ligand effects on G4 
structure. NMR experiments were therefore conducted on the hybrid (telo23-K+) and 
antiparallel (telo22-Na+) for the three ligands to examine the structural effects on these 
different G4 topologies in more detail. 
 
3.3.4.1 Studies with telo23-K+ hybrid G4 
The binding of the ligands to hybrid G4 in potassium-containing buffer was first investigated. 
Whilst CD indicated the folded G4 structure was preserved upon the addition of all three 
ligands E-56, Z-56 and E-57, different binding modes were observed between for the E-56 
and Z-56 ligands (Section 3.3.3). Furthermore, this is the more biologically-relevant G4 owing 
to the high intracellular concentration of potassium209 and the ligands induced the highest 
stabilisation values in this sequence in the thermal melting assay (Section 3.3.1). As discussed 
in Chapter 2, the telo23 sequence adopts a mixture of a major and minor folded species under 
the NMR conditions, meaning only the imino resonances could be straightforwardly assigned 
due the spectral complexity in the aromatic region. Nonetheless, the behaviour of the imino 
signals during the titration provides some information about the nature of the G4/ligand 
interactions to complement the CD data.  
Examining first ligand E-56 (Figure 3.12), severe line broadening of the imino resonances can 
be observed during the titration. All imino signals broaden to a similar degree and remain 
distinguishable, suggesting that interactions with specific G-tetrad residues do not dominate 
in the association of ligand E-56 with G4, providing additional evidence for the groove-binding 
mode inferred from the CD titrations. Furthermore, end-stacking with G4 bases would likely 
result in chemical shift perturbations of specific resonances due to ring-current effects,106 
which are not observed.  






Figure 3.12: NMR titration of telo23-K+ hybrid G4 with ligand E-56. DNA concentration = 
185 μM.  
 
 
Figure 3.13.  NMR titration of telo23-K+ hybrid G4 with ligand E-57. The shift in G9/G10 
resonances is indicated with an arrow and the disappearance of G15/G23 resonances is 
indicated *. DNA concentration = 185 μM 
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Ligand E-57 (Figure 3.13) also induces spectral line broadening at 1:1 stoichiometry though 
unlike for ligand E-56 the G9/G10 signals shift significantly at 2:1 stoichiometry, whilst signals 
associated with the lower G-tetrad (G15/G23) disappear entirely, suggesting specific 
interactions with these parts of the G4, possibly stacking or intercalation, are also important in 
the binding of ligand E-57. 
For ligand Z-56 (Figure 3.14), all imino resonances are resolved at 2:1 ligand:G4 stoichiometry 
unlike what was observed for ligands E-56 and E-57. Notably, whilst the unbound G4 
sequence exists as a mixture of major and minor conformations, complexation with ligand Z-
56 appears to favour a single conformation, with only 12 distinct imino signals visible at 2:1 
stoichiometry versus the more complex spectrum for the G4 sequence observed in the 
absence of the ligand. This structural perturbation may explain the disappearance of the 




Figure 3.14.  NMR titration of telo23-K+ hybrid G4 (imino region) with ligand Z-56. DNA 
concentration = 185 μM. 
 
In conjunction with the data obtained in the CD titrations, it can be inferred that ligand E-56 
interacts with hybrid telo23-K+ G4 primarily through groove binding without association with 
specific G-tetrad bases, whilst stacking interactions with G-tetrad regions are also important 
in the binding of ligands E-57 and Z-56. 
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It should be stated that though the NMR experiments and CD experiments together provide 
evidence of certain binding modes, unambiguous determination is not possible based on the 
current data, and more involved future structural work will be necessary to prove the exact 
mechanisms of interaction. 
 
3.3.4.2 Unfolding of G4 in Na+ conditions by E-56 
The CD studies (Section 3.3.3) indicated the whilst the hybrid G4 form was stable to the 
binding of ligand E-56 in potassium-rich conditions (Figure 3.7a), the same ligand induces 
dramatic changes in G4 folding conformation in sodium-containing buffer (Figure 3.7b). Since 
the preservation of the G4 fold of telo23-K+ upon titration with ligand E-56 was also 
demonstrated by NMR (despite the line broadening, the presence of signals consistent with 
Hoogsteen-bonded G-tetrads remains clearly visible) the effect of ligand E-56 was next 
examined against the same sequence in sodium-containing buffer (Figure 3.15a).207 Upon 
titration with ligand E-56, line broadening is initially observed, but at 2:1 stoichiometry, the 
imino resonances almost completely disappear, indicating the disruption of the Hoogsteen 
network of the G-tetrads by the addition of ligand. It was concluded that effects observed in 
the CD studies result from the E-56 induced denaturation of telo23-Na+ structure. That the 
aromatic resonances persist, albeit broaden considerably, indicates the loss of imino 
resonances is not simply a result of precipitation.  
The same experiment was attempted on telo22-Na+ (antiparallel G4) but the evidence for G4 
unfolding was not as conclusive as for the telo23-Na+ hybrid model (Figure 3.15b). 
Nonetheless, this behaviour correlates with the CD data which indicate that the antiparallel 
telo22-Na+ G4 is more resistant to unfolding by ligand E-56 than the hybrid telo23-Na+ 
structure (compare Figure 3.7b and 3.7c). 
To provide further insight into the unfolding of the G4 structure by ligand E-56, computational 
studies were conducted by Dr Susanta Haldar and Adrian Mulholland (Figures 3.16 and 3.17).  






Figure 3.15.  NMR titrations of (a) telo23-Na+ hybrid G4 and (b) telo22-Na+ antiparallel G4 
with ligand E-56. DNA concentration = 185 μM. 
 
The ligand was first docked to the G4 structure to predict the likely binding poses, and the 
lowest-energy pose was then subjected to 1 μs molecular dynamics simulations. In these 
simulations the ligand samples a range of binding poses, which energetically favourable 
orientations being sampled more frequently, thus indicating the preferred binding orientations 
(Figure 3.16). In the case of ligand E-56 the MD simulations indicate three preferred ligand 
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conformations on the top face of the G4 (Figure 3.16a and 3.16c). However, MD simulations 
do not allow the system access states outside these local minima, such as the alternative 
binding events that would trigger DNA unfolding. These issues may be addressed by 
employing well-tempered metadynamics, an advanced modelling technique that biases the 
system towards exploring rarely sampled configurations (Figure 3.17). This provides a more 
detailed picture of ligand binding and unbinding events, and allowed longer-term effects, such 




Figure 3.16. Molecular dynamics simulations of telo22-Na+ and E-56. (a) probability 
histogram of ligand orientations sampled, characterised by the dihedral angle between 
ligand and G4; (b) stability of the G4 backbone co-ordinates over the time course of the 
simulation (c) binding poses corresponding to maxima A, B and C in Figure (a). Figures 
prepared by Dr Susanta Haldar. 
 
The ligand binding and unbinding events observed by the metadynamics simulations are 
visible in Figure 3.17a, which plots the separation distance between the centre of mass of the 
central G-tetrad that of the ligand against the timescale of the simulation. The corresponding 
molecular visualisation is shown below (Figure 3.17b). From the starting docking pose from 
the molecular dynamics simulations (Pose A), the ligand unbinds from the G4 within the first 
~15 ns and samples the solvated state. To dissociate from the G4, the ligand firsts slides on 
top of the DNA and interacts with the capping residues (Pose B) which then interacts open 
towards the solvent (pose C). Finally, the ligand dissociates from these bases and enters the 
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solvated state (pose D). The process of intercalation and unfolding of the G4 can be followed 
during the remainder of the simulation. 
 
Figure 3.17: Well-tempered metadynamics studies examining the unfolding mechanism of 
telo22-Na+ G4 by ligand E-56. (a) binding/unbinding events characterised by distance 
between ligand and G4 centres of mass; (b) representative structures corresponding to 
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After 90 ns, the ligand re-enters the groove and then intercalates the G4 structure, partially 
rupturing the G-tetrads (Pose E). In the later stage of the simulation (150 ns) full intercalation 
takes place (Pose F). The ligand is then seen to sample bound and dissociated states. At 
~525 ns, the ligand again enters the binding pocket and intercalates with G21, G8, G15, G2 
and G14 (Pose G). Finally, at ~580 ns, the telo22 G4 begins to unfold within the next 100 ns 
(pose H). These results provide a plausible mechanism of how the binding mode of ligand E-
56 results in the structural perturbations observed in the experimental studies. 
 
3.3.4.3 Stability of telo22-Na+ G4 to Z-56 
Whilst the metadynamics studies supported the unfolding of G4 prompted by ligand E-56 as 
observed in the CD and NMR experiments, it was also necessary to characterise the binding 
of the Z-56 ligand to telomeric G4 using the same methods to gain confidence that the 
simulations accurately represent the behaviour of the G4/ligand systems. Ligand Z-56 did not 
appear to induce unfolding of either telo23-Na+ or telo22-Na+ in the CD studies, and hence 
should not be seen to induce G4-unfolding in the simulations if the model offers a reliable 
description of the binding process. 
The theoretical calculations were performed by Dr Haldar and Dr Mulholland using the same 
procedures employed for the E-56 system (Figures 3.18 and 3.19). The molecular dynamics 
simulations from the initial docking poses indicated a stable binding pose of the ligand at the 
top of the G4, associating with the A7, T18 and A19 bases on the lateral loops (Figures 3.18a 
and 3.18c). The overall RMSD of the DNA backbone is found to be constant at ~0.3 nm (Figure 
3.18b) indicating that G4 is stable during the MD simulation. Next, the stable binding pose was 
subjected to well-tempered metadynamics simulations in order to more thoroughly understand 
the binding process to the G4 and confirm the stability of the folded structure to ligand binding 
(Figure 3.19). In accordance with the experimental results, the folded G4 is found to be stable 
to the binding of Z-56 and the simulations fully converge after ~800 ns. This convergence 
allows the free energy surface (FES) of ligand binding to be computed and information 
regarding the binding mechanisms can be inferred by inspection of the local energy minima. 
The FES is shown in Figure 3.18, expressed as a function of d (distance) and T (torsion) 
collective variables, which reflect the ligand orientation and distance from the centre of mass 
from the G4. Four principle free energy minima are observed, where Basin A is the global  
minimum. 
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In this pose, the ligand interacts with the top face of the G4, by sandwiching in between T6, 
A7, A19 and T18 bases. In Basin D, one of the pyridinium rings stacks with the A7 base, but 
both indane rings partially interact with the G8 and G20 bases which belong to the top G-
tetrad. In order to sample this binding pose from the global minimum (Basin A) the ligand 
slides from T18 to interact with the A7 base. These results suggest that the binding of the 
ligand involves the top face of the G4. In Basin B and C, the ligand is partially exposed to the 
solvent and therefore these local minima likely represent intermediate states of binding and 





Figure 3.18:  Molecular dynamics simulations of telo22-Na+ and Z-56. (a) probability 
histogram of ligand orientations sampled, characterised by the dihedral angle between 
ligand and G4 axes; (b) stability of the G4 backbone co-ordinates over the time course of 
the simulation (c) binding poses corresponding to maxima A and B in Figure (a). Figures 
prepared by Dr Susanta Haldar. 
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In order to obtain physical evidence of the binding modes indicated by the calculations, the 
telo22/Z-56 complex was investigated by NMR spectroscopy (Figure 3.19). Since the binding 
to this quadruplex is rather weak, a fast-exchange regime is observed where the chemical 
shift perturbations of the DNA resonances vary gradually throughout the titration (Figure 
3.20a), since they appear as the weighted average of the chemical shifts of the free and bound 
states (see discussion in Section 2.3.4, Figure 2.19). Furthermore, as the secondary structure 
of the G4 is preserved upon addition of the ligand, the resonances several of the aromatic and 
ribose protons could be assigned in addition to the imino signals corresponding to the bases 
of the G-tetrads from 2D NOESY spectra (Figures 3.20b and 3.20c, full spectrum in Appendix 
A3, Figure A3.4). 
Key binding residues can be inferred from the chemical shift perturbations induced by ligand 
Z-56. The G20 and G4 imino resonances (Figure 3.20a and Figure 3.20c) and the G16H8 
proton (Figure 3.20c), corresponding to the top G-tetrad, are clearly perturbed. Further 
significant chemical shift perturbations are seen for the A7H1’ (anomeric) proton and the 
A19H8 (aromatic) proton corresponding to residues in the lateral loops (Figures 3.20b). 
 
 
Figure 3.19: Free-energy surface of the telo22-Na+ / Z-56 binding process computed as a 
function of ligand distance and torsion angle. Representations of ligand poses in the local 
minima are shown (Poses A-D).  
 




Figure 3.20: NMR invesitgations of telo22-Na+/Z-56 complex. (a) titration of telo22-Na+ 
(imino region) with Z-56; (b) overlayed NOESY spectra (aromatic/carbohydrate region) of 
telo22-Na+ in the absence (blue) and presence (pink) of 2 equiv. Z-56; (c) chemical shift 
perturbations of imino and aromatic resonances of telo22-Na+ upon addition of 2 equiv. Z-
56. 
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Moreover, an intermolecular NOE correlation is observed between the ligand N-methyl group 
(δ = 4 ppm) and A19H8 and A7H1’ protons in the DNA ligand complex (asterisks, Figure 
3.20b), providing further evidence for binding to the top fact of the G4 as observed in the 
computational studies. However, whilst the computational results indicate the ligand to be 
stacked atop the capping residues of the lateral loops, the fact that G8 and G4 imino 
resonances are also specifically perturbed suggest stacking interactions with these bases, 
suggesting that the ligand may open the capping residues to access the top G-tetrad. 
Meanwhile, resonances corresponding to other regions of the telo22 G4, particularly the lower 
G-tetrad and diagonal loop are comparatively unperturbed (e.g. G9, as shown in Figure 3.20b), 
indicating the ligand does not associate with these regions of the G4. These experimental 
observations support the binding modes identified in the computational studies, which also 
reveal binding to the top face of the G4, and especially the importance of the A7 and A19 
bases in ligand binding.  
 
3.3.4.4 Binding of ligand E-57 
Finally, ligand E-57 was investigated using molecular dynamics (Figure 3.21) and NMR 
(Figure 3.22) studies. In the dynamic simulations, the dihedral distribution (Figure 3.21a) 
identified three stable conformations. Poses A and B show different orientations of the ligand, 
but in both cases it appears to bind to the groove of the G4 where it partially interacts with 
bases from the G-tetrads (G4, G8 and G9), and one of indane residues stacks with the T5 
base in the lateral loop. As the simulation progresses however, a further binding pose is 
observed (Pose C) where the ligand intercalates into the major groove, rupturing the hydrogen 
bonds in the G-tetrad. In this pose, the ligand is intercalated in between G2, G3 and G15 
bases from the middle and lower G-tetrad.  Following a further 500 ns simulation, the DNA 
backbone RMSD (Figure 3.21b) begins to fluctuate between 3.0 to 5.0 Å which suggests a 
loss of stability of the DNA fold due to rupturing of the G-tetrad hydrogen bonds caused by the 
intercalation. Ligand E-57 can therefore be expected to induce instability in telo22 G4 DNA, 
perhaps explaining the attenuation of spectral features observed in the CD titrations (Figure 
3.11c). NMR studies confirmed the proposed effect of the ligand more directly, since titration 
of telo22 with the ligand induced loss of intensity of G4 imino protons and that could be 
expected to arise from the breakage of the Hoogsteen network. Indeed, at 2 equiv. ligand, the 
G8 resonance is not visible at all and a new signal in the Watston-Crick region of the NMR 
spectrum (12.5 ppm) is observed, indicating the ability of ligand partially disrupt the G4 
structure, as suggested by the circular dichroism experiments. 
 
 






Figure 3.21: Molecular dynamics simulations of telo22-Na+ and ligand E-57. (a) probability 
histogram of ligand orientations sampled, characterised by the dihedral angle between 
ligand and G4 axes; (b) stability of the G4 backbone co-ordinates over the time course of 
the simulation (c) binding poses corresponding to maxima A, B and C in Figure (a). Figures 
prepared by Dr Susanta Haldar. 
 
3.3.5  Conclusions of the biophysical studies 
From the biophysical assays, it can be concluded that the new N-methylpyridinium derivatives 
interact strongly with different types of G4 DNA and this structural modification offers 
significant improvement over the more flexible amine-decorated compounds introduced in 
Chapter 2. The nature of the DNA/ligand interactions depends both on the overall G4 folding 
conditions and topology, as well as the ligand structure. Towards the aims of this thesis, the 
different effects of the E-56 and Z-56 ligands on G4-folding in sodium-rich conditions suggest 
an application for this ligand pair as a photoresponsive chaperone to allow the reversible 
formation/disruptiuon of G4 under these conditions, as a possible tool in the development of 
new nanodevices. This possibility is further investigated in Chapter 4. 






Figure 3.22:  NMR titration telo22-Na+ antiparallel G4 with ligand E-57. The disappearance 
of G8 (11.9 ppm) and the appearance of a new signal in the Watson-Crick region (12.4 ppm) 
are indicated with asterisks. DNA concentration = 185 μM 
 
Meanwhile, towards possible biological applications, it was confirmed that G4 structures were 
stable in the presence of both E-56 and Z-56 in physiologically-relevant potassium-buffered 
conditions, as evidenced by CD spectroscopy and NMR studies. However, the more planar E- 
56 is a significantly more potent ligand, evidenced by FRET thermal melting assays and the 
UV/visible titrations, whilst NMR and CD studies demonstrated different binding modes for the 
two compounds. Since the G4 affinity of the more active compound (E-56) is significantly 
higher than the amine-decorated compound E-41 reported in Chapter 2, but the selectivity 
against duplex is retained, the difference in activity of E-56 and Z-56 offered new grounds for 
optimism that the ligand may ultimately be deployed as a tool for the photoresponsive control 
of G4 stability in vivo as the basis of a photopharmacological strategy. To validate this 
approach, an initial assessment of the toxicity of the two distinct ligand forms in cellulo was 
undertaken before embarking upon photochemical studies. 
 
3.4 In vitro assays 
To gain an estimation of the therapeutic potential of the N-methylpyridinium G4 ligands, the 
compounds were screened against a small panel of mammalian cell line and parasitic 
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organisms. As in Chapter 2, HeLa cervical cancer cells were chosen as a cancerous cell model 
and MRC5 lung fibroblasts as the non-tumoral model. Compounds were also assessed as 
antiparasitic agents in T. brucei and L. major parasites owing to the recent identification of G4  
in the genomes of these organisms. Finally, the uptake of a representative compound was 
studied by confocal microscopy. 
 
3.4.1  Toxicity assays 
 
3.4.1.1 Mammalian cells 
Compounds E-56, Z-56 and E-57 were initially tested for activity in mammalian cells after 72-
hour exposure. The dose-response curves are shown in Figure 3.23 and the corresponding 
EC50 values from the fitted curves in Table 3.6. These initial results appeared rather 
disappointing, with the compounds appearing to be only weakly toxic to HeLa cells. 
 
 
Figure 3.23:  Dose-response curves for ligands E-56, Z-56 and E-57 against (a) HeLa and 
(b) MRC5 cells at 72 h exposure, measured by the alamarBlue cell viability assay. 
 
Table 3.6: EC50 values and selectivity indices for compounds E-56, Z-56 and E-57 against 
mammalian cells at 72 h exposure. 
Ligand 
EC50 / μM  Selectivity index 
(72 h) HeLa MRC5  
E-56 77 ± 4 3.1 ± 1  < 1 
Z-56 82 ± 2 12 ± 1  < 1 
E-57 16 ± 3 0.35 ± 0.1  < 1 
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Moreover, the compounds appeared to be more toxic (~ 10-50-fold) to the non-tumoral MRC5 
cell-line. This poor discrimination was not initially considered promising given the ultimate 
desire to deploy these compounds as anticancer agents. However, previous work by others 
has identified that a longer exposure time to G4-binding compounds is sometimes necessary 
to observe toxic effects, since a mechanism of action involving telomere shortening 
theoretically requires several population doublings to take effect.118,210 For example, BRACO-
19 (7, Figure 1.14) was demonstrated to show antiproliferative activity consistent with telomere 
shortening at sub-cytotoxic doses at 15-day exposure.118 Therefore, the toxicity of the 
compounds after longer (7 day) exposure were measured (Figure 3.24 and Table 3.7). 
Strikingly, whilst the toxicity towards MRC-5 was comparable with that observed at shorter-
term exposure (EC50 = 10-100 μM), the cancerous cells became more susceptible to lower 
doses of compound E-56 (EC50 = 62 nM), the strongest G4 ligand in the compound series. 
This increase in potency returns a selectivity index of 29 between the cell lines at long-term 
exposure. That the toxicity to MRC-5 cells does not significantly depend on ligand exposure 
time for could be attributed to the telomerase-negative nature of this cell line, rendering this 
model less susceptible to effects of telomeric G4 binding ligands. The comparable toxicity 
observed for MRC5 at 3-and 7-day exposure may therefore result from an alternative 
mechanism of action not related to telomere shortening. 
Meanwhile, whilst the toxicity of the comparatively Z-56 is slightly increased at longer exposure 
times, the effect is much less pronounced than for compound E-56. The longer exposure 
increases the activity of E-56 by three orders of magnitude, whilst the potency of Z-56 
increases by only one order of magnitude. This difference in effect correlates with the G4 
binding properties of the ligands. The net result is that at 7-day exposure, E-56 appears 
approximately 85 times more potent (EC50 = 62 nm) than the Z-56 isomer (EC50 = 5.2 μM). 
This result is particularly relevant in light of the goal to deploy the ligand as a 
photopharmacological agent, since it suggests that the biological activity of the G4-interactive 
compounds may ultimately be controlled by photoisomerisation. 
 





Figure 3.24:  Dose-response curves for ligands E-56, Z-56 and E-57 against (a) HeLa and 
(b) MRC5 cells at 7d exposure, measured by the alamarBlue cell viability assay. 
 
Table 3.7:  EC50 values and selectivity indices for compounds E-56, Z-56 and E-57 against 
mammalian cells at 7-day exposure. 
Ligand 
EC50 / μM  Selectivity index 
(7 day) HeLa MRC5  
E-56 0.062 ± 0.01 1.8 ± 0.5  29 
Z-56 5.2 ± 2 20 ± 5  3.8 
E-57 0.11 ± 0.3 0.46 ± 0.1  4.2 
     
 
3.4.1.2 Parasitic organisms 
Next, efforts turned to considering the potential of the G4 ligands as antiparasitic agents. 
Activity was first measured against both T. brucei and L. major, with MRC-5 cell lines chosen 
as non-tumoral cell model for comparison (Figure 3.25 and Table 3.8). Pleasingly, compounds 
E-56, Z-56 and E-57 exhibited a potent toxicity to T. brucei with EC50 values in the nanomolar 
range. Critically, the compounds are much less toxic against the non-tumoral MRC-5 cells with 
selectivity index of up to 280-fold, suggesting a promising therapeutic window for these 
compounds as anti-trypasonomal agents. Though the compounds appear to exert a lower 
toxicity to the L. major parasite, ligands E-56 and E-57 show sub-micromolar efficacy against 
this organism, suggesting a potential role for G4 recognition in their mechanism of action in 
this case. The selectivity index is significantly lower than observed in the case of T. brucei, but 
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the values are comparable to those observed for other G4 ligands screened against this 
organism.52 
 
3.4.2  Confocal microscopy 
As a step towards investigating the mechanism of action of ligands E-56, Z-56 and E-57 the 
uptake and localisation of the compounds by mammalian cells and parasites was examined 
through microscopy studies. Unfortunately, lead compound E-56 was not sufficiently 
fluorescent to visualise using this technique. Studies therefore focused on compound E-57, 
which has photophysical properties (λem = 550 nm) much better suited to visualisation in cells 
(Figure, 3.26). After 30 min incubation at 37 °C, significant uptake of compound E-57 in both 
HeLa cells (Figure 3.27) and T. brucei parasites (Figure 3.28) was observed. The ligand E-57 
was mainly localised in the nucleolus and the cytoplasm of HeLa cells. In T. Brucei, the same 
 
 
Figure 3.25.  Dose-response curves for ligands E-56, Z-56 and E-57 against (a) T. brucei 
and (b) L. major parasites at 3d exposure, measured by the alamarBlue cell viability assay 
(T. brucei) or MTT assay (L. major). 
 
Table 3.8: EC50 values and selectivity indices for compounds E-56, Z-56 and E-57 against 
parasitic organisms at 72 h exposure.  
Ligand 
EC50 / μM  Selectivity index (72 h) 
T.brucei L.major  T.brucei L.major 
E-56 0.0029 ± 0.0005 0.64 ± 0.1  110 4.8 
Z-56 0.043 ± 0.0001 11 ± 2  280 1.1 
E-57 0.0061 ± 0.002 0.11 ± 0.03  60 3.2 
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ligand was mainly found in the nucleus and the kinetoplast. These results suggest that 
pyridinium stiff-stilbene G4-ligands can reach DNA harbouring sites and therefore possibly 
target G4 structures. Indeed, G4 DNA structures have recently been directly observed in the 
nucleoli of live cells.211 Further investigations into  the therapeutic mechanism  of  stiff-stilbene  
ligands  is  warranted  in  order  to interrogate the true biological targets and obtain more 
conclusive evidence regarding the potential G4-mediated mode of activity. 
3.5  Chapter conclusions 
The work reported in this chapter built upon the results of Chapter 2 and further develops the 
stiff-stilbene ligand core into a system more suited to biological applications through 
optimisation of the G4 binding properties. These studies led to the identification of N-
methylpyridinium stiff-stilbene compounds as potent G4-binding agents, demonstrating 
significant improvements over the first-generation amine-based ligands. In particular, the new 
compounds exhibit higher affinity for G4 structures, demonstrated through a variety of 
biophysical assays, an effect which appears to translate into biological effects that correlate 
to some degree with the G4 binding properties, though the mechanism of action remains to 
be rigorously elicited. Towards the overall goal of developing a photoresponsive G4 binding 
agent as the basis of a molecular fuel or photopharmacology, the very different activities of 
the E-56 and Z-56 ligand pair, both in terms of toxicity and of their effect on G4 folding 
topologies were particularly significant, suggesting the potential to control ligand activity 
through photoisomerisation. Efforts therefore turned to attempts to investigate the 




Figure 3.26:  Emission spectrum of ligand E-57 in water (0.5% DMSO). λex = 450 nm. Ligand 
concentration = 50 μM.   
 






Figure 3.27:  Fluorescence microscopy images of HeLa cells after incubation with 0.5 μM 
ligand E-57 for (a) 30 min or (b) 120 min. Control (c) cells without added compound are also 
displayed. Visualisation panes from left to right: mitochondria (Mitotracker Red), ligand E-








Figure 3.28:  Fluorescence microscopy images of T.brucei parasites after incubation with 
1 μM ligand E-57 for (a) 30 min or (b) 120 min. Control (c) parasites without added 
compound are also displayed. Visualisation panes from left to right: mitochondria 
(Mitotracker Red), ligand E-57, nucleus (DAPI), co-localisation image, bright-field image. 
Scale bar: 5 μm. 
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4  G4 photocontrol with stiff-stilbene ligands 
This chapter is based upon work published in Angewandte Chemie: International Edition of 
which I am first author.203 I was responsible for all elements of experiment design and data 
collection. All experiments were all undertaken at the University of Bristol, UK. Assistance with 
sample irradiation was provided by Dr Thomas A.A. Oliver and Miss Marta Duchi. 
 
4.1  Introduction 
The overarching goal of this project was the design of a new class of photoresponsive G4 
ligand which allowed activity to be controlled by light in physiologically-relevant conditions. 
Towards this end, the previous chapters report the development of a set of ligands designed 
from the stiff-stilbene photoswitch, indicating that the G4 binding properties, effect on G4 
structure and cytotoxicity may be determined by the configuration of the central stilbene double 
bond of the E/Z-56 ligand pair. Given that stiff-stilbenes have previously been demonstrated 
to undergo reversible E/Z isomerisation upon photoirradiation,172,178 the E/Z-56 ligand couple 
looked very promising as a tool to allow G4 regulation by light with a ligand-driven strategy, 
as summarised in Figure 4.1. In the current chapter, investigations of the photochemistry of 
the E/Z-56 ligand couple are reported, and the observed photoresponse is used as a tool to 





Figure 4.1: Proposed concept of photoresponsive G4 ligand control. 
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4.2  Ligand photochemistry 
As a starting point towards applying the E/Z-56 pair as a tool for the photoregulation of G4 
DNA, the photochemistry of the ligand was first characterised in organic and aqueous 
environments. These studies were required in order to developing an understanding the 
behaviour of the ligand upon photoirradiation that could ultimately be deployed to regulate the 
G4 DNA structure. 
 
4.2.1 Photochemistry in DMSO 
The photochemistry of ligand Z-56 was initially investigated in DMSO-d6. Though this solvent 
is ultimately unsuitable for the DNA-based applications of the photoresponsive ligand, the 
ligand was significantly more soluble in this medium allowing higher concentrations to be 
achieved, meaning the photochemistry could be conveniently monitored via 1H NMR 
spectroscopy. 400 nm was selected as the irradiation wavelength since a bright 
monochromatic light source was available at this wavelength and it is towards the blue-shifted 
end of the absorbance of E-56 and Z-56 (see UV/visible spectra in Section 3.3.2) and therefore 
more suited to biological application, since high-energy UV light is deleterious to cells. Upon 
irradiation of a 1 mM sample of Z-56 in DMSO-d6, photoisomerisation to the E-56 form is 
clearly observed in the 1H NMR spectra (Figure 4.2). The isomerisation appears to proceed 
cleanly, since all new resonances can be assigned to the formation of the E isomer, and no 
by-products are detected. The conversion was monitored at intervals up to 90 minutes, by 
which time no further conversion was detected indicating the 400 nm photostationary state 
(PSS) had been achieved. This PSS consists of an approximately 1:1 mixture of E and Z 
ligand forms. Though this does not represent complete conversion, that the E-56 isomer is 85-
fold more toxic than the Z-56 form in the cellular assays (see Section 3.4) suggests that even 
this partial conversion could result in suitable in situ activation of the molecule if delivered at 
a suitable concentration. However, though this initial study was promising, such an effect 
would need to be achieved in aqueous cell-like media to be of clinical utility. Efforts therefore 
turned to investigating the behaviour of the ligand in buffered aqueous solutions. 
 
 






Figure 4.2. Photogeneration of ligand E-56 by irradiation of Z-56 with 400 nm light, 
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4.2.2 Photochemistry in buffered aqueous solution 
In order to understand the ligand photochemistry in the aqueous conditions relevant to G4 
folding, photoirradiation of Z-56 was performed at 10 μM concentration in 100 mM sodium 
phosphate buffer, at which concentrations both forms of the ligand are water-soluble and the 
photoreaction can be monitored by UV-absorbance spectroscopy (Figure 4.3). Surprisingly, 
when a sample of Z-56 was irradiated under these conditions, the UV spectra instead indicate 
the conversion of the ligand to a new photoproduct rather than isomerisation to E-56 (Figure 
4.3a). Specifically, the absence of isosbestic points (which would be expected for direct 
conversion between two species without the formation of a stable intermediate) and the  
attenuation of absorption at λ > 325 nm indicate an alternative reaction pathway. The same 
phenomenon was observed both in pure H2O (Figure 4.3d) and irradiation of the E-56 isomer 
under the same conditions generated the same UV/visible signature (Figures 4.3b and 4.3e), 
indicating that both ligand isomers ultimately form the same photoproducts. It should be noted 
that in control experiments, the stability of the ligand in solution in the dark proved that the 
reaction pathway is light-mediated rather than a result of inherent instability of the ligand in 
aqueous conditions (Appendix A4, Figure A4.1). 
To determine the fate of ligand Z-56 under the reaction conditions, the photoproduct was 
analysed by mass spectrometry and NMR spectroscopy. Mass spectrometry analysis (Figure 
4.4) indicated evidence of the oxidative decomposition of the ligand. In particular, a signal was 
observed for a species with m/z = 224.1 which corresponds to both ketone 61 and dioxirane 
60 (Figure 4.5). A signal corresponding to a molecular ion m/z = 210.1, consistent with 
demethylation of the pyridinium moiety to form product 62 was also observed. 
Formation of a ketone was clearly visible in the NMR spectra of the photoproduct (Figure 4.6). 
In particular, the presence of a carbonyl group is indicated in the 13C NMR spectrum, δ = 206 
ppm (Figure 4.6b). Surprisingly, the NMR spectrum also indicated the loss of the N-methyl 
group, though trace amounts of N-methylated products were visible in the 1H NMR spectrum 
(δ = 4.25 ppm). Owing to the difficulty of performing this reaction on a practical scale due to 
the low solubility of the ligand under the reaction conditions, efforts to purify and characterise 
these minor by-products were not pursued. 





Figure 4.3. Photoresponse of ligands E-56 and Z-56 (10 μM) irradiated at 400 nm in (a-c) 
100 mM sodium phosphate buffer, pH 7.4 and (d-f) pure H2O. (a),(d) irradiation of Z-56 (solid 
blue trace) for 30, 60 and 90 min (grey traces); (b),(e) irradiation of E-56 (solid red trace) for 
30, 60 and 90 min (grey traces);  (c),(f) comparison of spectra of E-56 and Z-56 (solid traces) 
and the spectra of the respective photoproduct (dotted traces) after 90 min irradiation 
indicating the formation of the same species from both ligands. 
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In order to confirm the identity of the major product, a pure sample of this material was 
synthesised by Suzuki coupling of bromide 42 with 4-pyridylboronic acid (Scheme 4.1). The 





Figure 4.4: Mass spectrometry analysis of the photoproduct after irradiation of Z-56 in 100 




Figure 4.5: m/z values of possible photoproducts of ligand Z-56 
 






Scheme 4.1: Synthesis of ketone 62. Reagents and conditions: (a) 4-pyridylboronic acid, 






Figure 4.6: NMR analysis of the Z-56 photoproduct and comparison with a reference 
sample of ketone 62. (a) 1H NMR spectra; (b) 13C NMR spectra. 
 
4.2.3 Mechanistic comments 
In-depth mechanistic studies of the photoreaction of ligand Z-56 were not undertaken during 
the course of this project. However, the observations discussed above can be considered in 
the context of precedent reported in the literature to rationalise the observed reactivity. 
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Reaction with ground state triplet oxygen is forbidden on spin conservation grounds, and 
therefore the ligand must act as a photosensitiser to generate the reactive species if this 
mechanism is to be possible.212 Addition of singlet oxygen across the stilbene olefin of E/Z-56 
generates endo-peroxide 60 and subsequent fragmentation yields two equivalents of ketone 
61. Loss of the methyl group is surprising, but demethylation of related systems has previously 
been observed, albeit under basic conditions;213 possibly this moiety becomes more labile 
during the photoreaction. Subsequent to the publication of this work, a similar self-sensitised 
reaction pathway was also proposed by Boulatov and co-workers for a related stiff-stilbene 
system, 64, where the dependency of the reaction on oxygen concentration was ultimately 
employed in the development of a sensor for intracellular oxygen levels (Scheme 4.2).214 In 
this case, the authors observed the generation of singlet oxygen by using scavenging 
experiments with TEMP 68 to generate TEMPO 69, which may be detected by electron spin 




Scheme 4.2: Photosensitised pathway for oxidation of stiff-stilbenes recently proposed by 
Boulatov et al. towards the generation of an oxygen sensor (a) mechanism of self-sensitised 
generation of singlet oxygen by intersystem crossing and energy transfer from a 
photosensitiser (P); (b) oxidation and fragmentation to form the ketone products; (c) use of 
TEMP to detect formation singlet oxygen. 
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4.3  Phototriggered control of G4 folding 
Though the eventual fate of ligands E-56 and Z-56 upon photoirradiation in water was a 
disappointment regarding the ultimate application of the ligand pair as a tool for reversible in 
situ control of G4, the observed photoreactive pathway was nonetheless considered a 
possible means to fuel repeated switched in G4 conformation by employing the ligand as a 
photoresponsive fuel.  
To examine this hypothesis, the telo23-Na+ structure was selected since the unfolding effect 
of ligand E-56 is most effective under these conditions, as previously demonstrated by CD 
spectroscopy (Section 3.3.3) and NMR spectroscopy (Section 3.3.4). The ability of E-56 to 
fuel repeated conformational switches in G4 DNA was demonstrated (Figure 4.7). First, the 
CD was recorded in the absence of ligand (Figure 4.7a, green trace) demonstrating the 
characteristic signature of the hybrid G4 fold. Addition of 10 equiv. E-56 induced the 
conformational switch to the unfolded form of the DNA (Figure 4.7a, blue trace) as previously 
investigated by the CD, NMR and metadynamics simulations. Pleasingly, the CD spectrum 
acquired following irradiation of the sample with 400 nm light exactly resembled the original 
spectrum of the G4 in the absence of the ligand (Figure 4.7a, red trace). Therefore, exposure 
to blue light deactivates ligand E-56 and causes the regeneration of the original G4 folded 
topology. To examine the reversibility of this process, a further aliquot of E-56 was added to 
the same DNA solution and the CD spectrum of ligand‐bound unfolded telo23-Na+ was 
restored almost completely (Figure 4.7a, blue trace). This fuelling/irradiation cycle was 
repeated several times, and the conformation of the G4 was switched between folded and 
unfolded states at least five times before significant fatigue of the system was observed 
(Figure 4.7b). Nonetheless, further partial reversibility continued to be observed to some 
extent up to 8 times (Figure 4.7c).  Further evidence for the reversible unfolding of G4 was 
obtained by NMR analysis (Figure 4.7d), which show the recovery and sharpening of the imino 









Figure 4.7: Reversible switching of telo23-Na+ G4 folding/unfolding by ligand E-56 (a) 
spectra of telo23-Na+ generated by exposure to 400 nm light in the presence of E-56; (b) 
Plot of the change in ellipticity at 273 nm and 340 nm over several dose/irradiation cycles 
(c) superimposed CD spectra of eight switches showing the eventual photofatigue of the 
system; (d) unfolding/refolding of telo23-Na+ monitored by 1H NMR spectrsocopy. 
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This reversible folding/unfolding of G4 could be considered as a primitive nanodevice, where 
the photoresponsive ligand induces the metastable unfolded state in the DNA system allowing 
the G4 structure formation to be triggered on-demand (Figure 4.8).  
4.4  Chapter conclusions 
In this chapter, the photochemistry of the E/Z-56 ligand couple was investigated with the aim 
of moderating the G4 binding activity in situ towards the development of a G4-targeted 
photopharmacology or as means to control G4 folding for the development of oligonucleotide-
based nanodevices. Unfortunately, the present system is not suitable for 
photopharmacological applications, since the inactive form of the ligand cannot be converted 
to the active form in aqueous conditions, instead undergoing irreversible oxidative cleavage. 
Nonetheless, the ligand permits the photoregulation of G4 folding in the presence of sodium 
ions without the requirement to pre‐incorporate photoresponsive functionality into the 
biomolecule, suggesting potential applications in the control of natural G4 systems. The 
approach is complementary to the azobenzene system previously reported,143 in that the 
ligand is able to exert dramatic effects on G4 folding in the presence of metal salts and induces 
unfolding against the cation-stabilised structure, rather than templating G4 folding in the 
absence of cations. It would however be much more desirable for the system to function 




Figure 4.8: Reversible switching of telo23-Na+ G4 folding/unfolding by ligand. 
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products. Efforts therefore turned to the identification of an alternative chromophore as the 
basis of a fully photoreversible G4 ligand that functions in physiologically-relevant conditions. 
The results of these endeavours are reported in the next chapter. 
 
 
   
Chapter 5: Dithienylethene G4 ligands 
135 
 
5  Dithienylethene G4 ligands 
This chapter is based upon work published in Chemical Communications.215 I  was responsible 
for all elements of compound design and synthesis for compounds 77o/77c and 79o, all 
photochemistry and biophysical assays, and the writing of the manuscript. The synthesis of 
compound 78o was performed by Dr Javier Ramos-Soriano. The cytotoxicity studies of 
77o/77c were performed by Miss Sadiyah Sheikh. All experiments were undertaken at the 
University of Bristol, UK. 
 
5.1  Introduction 
The previous chapters reported progress towards the design of stiff-stilbene based 
photoresponsive G4 ligands. This scaffold proved highly effective as the basis of new G4-
targeting molecules, achieving high binding affinity and selectivity for G4 over duplex DNA in 
the best cases. Critically, the olefin geometry of the stilbene core proved a crucial determinant 
of the G4 binding activity and biological activity, particularly in the N-methylpyridinium 
compounds E-56 and Z-56. Unfortunately, in the derivatives examined thus far, photooxidative 
cleavage of the stilbene core (rather than the desired photoisomerisation) was found to 
dominate and hence the current stiff-stilbene system cannot yet be deployed towards the 
proposed biological applications. A ligand to regulate G4 in physiologically-relevant conditions 
that could be reversibly switched with light, without the generation of by-products, was still 
sought. Towards this end, this chapter describes the work undertaken to investigate the 
potential of dithienylethene (DTE) derivatives as supramolecular agents for the 
photoregulation of G4 structures. The molecular photoswitch is briefly introduced and previous 
attempts to deploy these derivatives to target DNA-based systems are outlined. The synthesis 
of a small set of DTE derivates is then reported, and studies of the photochemistry of these 
derivatives in the absence and presence of G4 and duplex DNA are described. The G4 binding 
properties of the ligands were investigated using FRET thermal melting assays, UV/visible 
absorbance spectroscopy, circular dichroism, and NMR spectroscopy. These studies 
demonstrated that the bistable states of the photoswitchable ligands associate to G4 with 
different binding modes. Finally, the cytotoxicity of the two states of the photoswitchable ligand 
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5.2  Ligand design rationale 
 
5.2.1  Dithienylethene as a bistable photoswitch 
Dithienylethenes are a subset of diarylethene photoswitches, the first of which was reported 
by Irie and Mohri in 1988.216,217 The design of these switches evolved from the observation 
that a common side-reaction in the photoisomerisation of stilbenes E/Z-21 is photocyclisation 
to the dihydrophenanthrene derivative (Figure 5.1a). Whilst barrier height for the thermal 
disrotatory ring closure in the ground state prevents this reaction from occurring at ambient 
temperature, the energy barrier is significantly lower in the photoexcited state. In this case, 
the ring closure proceeds in a conrotatory fashion (on orbital symmetry grounds) to form trans-
dihydrophenanthrene 70. Under ambient conditions, rapid oxidation of this species occurs to 
generate phenanthrene 71 as the final product, rendering this reaction pathway irreversible 




Figure 5.1: Development of dithienylethene photoswitches. (a) limitations to application of 
stilbene photoswitches: photocyclisation competes with E/Z isomerisation which is 
irreversible owing to oxidation of the dihydrophenanthrene 70; (b) design features of 
dithieylethenes as molecular photoswitches to circumvent the limitations of stilbene-derived 
systems. 
 
This limitation is circumvented by substitution of the ortho positions of the aromatic ring with 
methyl (or other alkyl) groups to prevent oxidation (Figure 5.1b). However, the lifetime of the 
cyclised form remains short in the stilbene system, since the aromaticity of the open isomer 
renders this form more stable, resulting in a low barrier height to cycloreversion. To address 
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this issue, the benzene rings are replaced with heterocycles of lower aromaticity, such as 
furans or thiophenes. This modification renders the open and closed isomers closer in energy 
and increases the energy barrier of the thermal disrotatory cycloreversion process. However, 
the barrier to the conrotatory cycloreversion in the photoexcited state remains low, meaning 
the reverse reaction can be triggered on-demand by irradiation in the absorbance window of 
the closed species. Indeed, another ideal feature of the DTE system is that the open forms 
absorb mainly in the UV, whilst the closed form possesses a distinct visible absorbance band. 
Photostationary states consisting of almost entirely open or closed isomers can therefore be 
achieved. Finally, to prevent competitive olefin isomerisation, the central double bond is most 
often constrained into a cyclic system to lock the molecule into the Z configuration and prevent 
conversion to the E form upon photoirradation.217 These design features render DTE 
derivatives almost perfect molecular photoswitches and significant effort has been devoted to 
tune their behaviour towards a huge number of applications.217–220  
 
5.2.2  Dithienylethenes as DNA-targeting molecules 
Unlike the stiff-stilbene scaffold developed in the previous chapters, the possibility of deploying 
DTE as a scaffold for photoresponsive DNA-binding molecules has been explored briefly by 
others (Figure 5.2). However, to date, all these studies have focused exclusively on duplex 
DNA and the possibility of using DTE-based ligands to target G-quadruplexes has not yet 
been considered, despite the particular opportunities afforded by these particular nucleic acid 
structures.  
In 2011, Feringa and co-workers reported the binding properties of the open and closed forms 
of DTE derivative 72 to self-complementary DNA hairpins.221 The DTE core was derivatised 
with amine-terminated side chains which, when protonated at physiological pH, form 
electrostatic interactions with the DNA phosphate backbone. Both isomers were shown to bind 
duplex DNA, evidenced by induced circular dichroism in the absorbance bands of the open 
and closed ligand forms. These spectral features were used to monitor the reversible 
photoswitching between the ligand states in the presence of DNA upon alternate irradiation 
with UV and visible light. The binding of both ligand forms was shown to depend strongly on 
pH, with dissociation of the DNA/ligand complex observed at alkaline pH indicating poor 
association of the deprotonated ligand species for the DNA. This led the authors to propose 
that the ligands interact with DNA primarily through electrostatic binding modes to the DNA 
phosphate backbone, rather than intercalation with the base pairs. Though the chiroptical 
properties of the system were reversibly switched, this spectroscopic output only serves to 
demonstrate that the DTE can be isomerised in the presence of DNA. Evidence of 
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photocontrol of ligand activity (e.g. a change in binding mode and/or binding affinity) necessary 
for functional applications was not observed. 
Andreasson and colleagues investigated the binding of DTE derivatives functionalised with N-
methylated aromatic moieties (compounds 73 and 74) to calf-thymus DNA.222 Binding 
constants in the order of 105 M-1 were obtained in 5 mM NaCl solution. That the affinity was 
found to be weaker (though not explicitly quantified) in the presence of higher salt 
concentrations indicated electrostatic binding modes which are supressed in media of higher 




Figure 5.2: Examples of DTE switches investigated for binding to duplex DNA. 
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pyridinium analogue 73 suggesting that electrostatic interactions, rather than ligand size and 
shape, is the key determinant of binding affinity. A change in ligand binding mode upon 
photoisomerisation of 73o to 73c was inferred from linear dichroism experiments: the open 
form displayed a signature characteristic of intercalation, whilst the closed form appeared bind 
in the DNA groove. 
Another interesting example came from the Yi group who exploited both the self-association 
and DNA binding properties of the thiazole orange dye to develop a DNA-gated photochromic 
DTE derivative, 75. In the absence of DNA, the sandwiching of the thiazole moieties locks the 
molecule in the parallel conformation, both quenching the fluorescence and preventing the 
photocyclisation. Binding to DNA requires the molecule to adopt the photo-reactive antiparallel 
conformation, activating fluorescence, which can be switched off on-demand by isomerisation 
to the non-fluorescent closed form. This device was used to image DNA inside cells, with 
higher fluorescence observed in DNA-harbouring regions (the nucleus) versus locations were 
less DNA is present (the cytoplasm). Some inferences of the binding mode of 75 to self-
complementary DNA duplexes were made using UV and CD spectroscopy, but the possible 
differences in binding modes between the open and closed forms were not part of the scope 
of this study. 
Finally, Gamez studied the DNA binding of the open/closed forms of the DTE platinum 
complex 76 (Figure 5.2).223 Through a fluorescence intercalator displacement assay, binding 
constants of the open and closed forms were estimated, with the closed form appearing to be 
5-fold more affine for calf-thymus DNA (through comparison of the Stern-Volmer quenching 
constants). The increased affinity was proposed to result from the increased planarity and 
more compact structure of the closed isomer which translated into approximately 2-fold 
increase in cytotoxicity lung carcinoma cells. 
 
5.2.3  Dithienylethenes as potential photoresponsive G4 ligands 
Whilst the potential of DTE derivatives to act as photoresponsive DNA binding molecules has 
been considered previously, to date only binding to duplex DNA has been investigated. 
Surprisingly, no attempts to investigate DTE binding to G4 DNA structures have yet been 
made, despite the differences in secondary structure suggesting possibilities of additional 
binding modes where the state of the DTE photoswitch may exert more influence on binding. 
For example, the more rigid planar structure of the closed DTE isomers could be expected to 
stack more efficiently with G-tetrads than the conformationally flexible open isomers. As 
reported in Chapter 3, it was found that N-pyridinium stiff-stilbene ligands were particularly 
effective G4 binders, while discriminating effectively against duplex DNA, but the one-way 
photoresponse of the ligand ultimately limited the potential applications. In light of these 
Chapter 5: Dithienylethene G4 ligands 
140 
 
results, it was hypothesised that N-methylpyridinium DTE ligand 77 may combine the high G4 
affinity demonstrated by the analogous stiff-stilbene compounds with more favourable 
photoswitching properties (Figure 5.3a).  
Moreover, the possible influence of the cationic moieties appended to the DTE core in 
influencing G4 binding was also considered. Larger heterocyclic systems (e.g. quinolinium 
moieties) have been shown to be beneficial for G4 binding efficiency since they increase the 
surface area of the ligand, which is favourable for forming selective stacking interactions with 
G-tetrads. In particular, PhenDC3 (10) is a particularly effective and selective G4 ligand. 
Analogues of DTE 77 bearing quinolinium side-chains, 78 and 79, were therefore desired to 
test examine the effects of the N-heterocycle on ligand activity (Figure 5.3b). 
. 
 
Figure 5.3: Design hypotheses explored in this chapter. (a) Rationale for investigation of N-
methylpyridinium DTE as a G4 binding ligand based on previous results; (b) extension of N-
methylated heterocycles to more closely mimic the structure of a known selective G4-
binding chemotype. 
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5.3  Compound synthesis 
 
5.3.1 Synthesis of the open ligand forms 
The DTE derivatives were synthesised using established procedures to access key 
intermediate 83 (Scheme 5.1).224 The synthesis of compound 77o has been reported 
previously towards the development of imaging agents,224 whist derivatives 78o and 79o are  
novel compounds. Friedel-Crafts acylation of 2‐chloro‐5‐methylthiophene 70 with glutaryl 
chloride 81 afforded intermediate dione 82 in quantitative yield. Intramolecular McMurry 
coupling, discussed previously in Chapter 2, afforded the cyclised intermediate 83. The 
pendant aryl fragments were then attached by Suzuki coupling (mechanistic discussion 
provided in Chapter 3) to the appropriate aryl bromide after in situ generation of the boronic 
ester 84. The low yields obtained in the case of 85 and 87 were a result of the difficulty of 
removing the triphenylphosphine oxide impurity remaining after the coupling reaction. Finally, 
the compounds were methylated with iodomethane to afford the target compounds 77o-79o 
as bis-iodide salts. The quinoline derivatives 86 and 87 appeared less reactive than pyridine 
85, requiring elevated temperatures to affect methylation whilst the pyridine compound 
reacted rapidly at room temperature.  
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5.3.2  Photogeneration of the closed isomers 
With the open forms of the ligands 77o-79o in hand, samples of the closed ligand forms were 
generated by irradiation of the samples using a domestic 320-400nm UV lamp. Though 
ultimately this light source was not suitable for experiments involving DNA, it proved an 
expedient and easily accessible way to perform the photoreaction on sufficient scale to allow 
the conversion to be determined accurately by NMR spectroscopy. These samples of known 
concentration and composition could then be used as stock solutions for the DNA binding 
 
 
Scheme 5.1: Synthetic route to DTE G4 ligands 77o-79o. Reagents and conditions: (a) 
AlCl3, DCM, r.t. 18 h; (b) Zn, TiCl4, THF, 65 °C, 4 h; (c) nBuLi, THF, 0 °C, 30 min, then 
B(OnBu)3, THF, r.t. 1 h; (d) ArBr, Pd(PPh3)4 (10 mol%), K2CO3, THF, 70 °C, 18 h; (e) MeI, 
DCM, r.t.; 3 h (f) MeI, MeCN, 70 °C, 16 h; (g) MeI, DCM, 50 °C, 16 h.  Compounds 86 and 
78o synthesised by Dr Javier Ramos Soriano. 
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assays in order to compare the G4 binding activity of both isomers without the complication of 
performing the photoreactions in the presence of DNA in the first instance. 
Under these conditions, a 1 mM solution of the open form of pyridine derivative (77o) cyclised 
very readily on exposure to UV light (Figure 5.4). 45 seconds irradiation was sufficient to 





Figure 5.4. Cyclisation of 77o to 77c in D2O upon exposure to UV (320 – 400 nm) light, 
monitored by 1H NMR spectroscopy. 
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The novel quinolinium derivative 78o was poorly soluble in water, so was instead isomerised 
in DMSO-d6. Interestingly, the photocyclisation kinetics were much slower than those 
observed for the pyridinium analogue 77o (Figure 5.5). Indeed, after 30 minutes irradiation 
only 18% conversion was detected and the sample had to be irradiated overnight to reach the 
photostationary state, corresponding to approximately 90% conversion to the closed form. 





Figure 5.5. Cyclisation of 78o to 78c in DMSO upon exposure to UV (320 – 400 nm) light, 
monitored by 1H NMR spectroscopy. 
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5.4  Photoswitching studies 
With reference samples of known composition of 77o/77c and 78o/78c (determined by NMR) 
in hand, efforts could turn to examining the photoswitching behaviour of the compounds in 
conditions relevant to DNA-based applications, namely 100 mM phosphate buffer at pH 7.4. 
First the photochromic behaviour of the compounds was investigated in the absence of DNA 
in order to develop suitable irradiation protocols compatible with DNA-based studies, before 
the effect of the DNA on the switching process was examined.  
 
5.4.1  Reversible visible-light photoswitching in buffered aqueous solution 
Since the broad-spectrum UV lamp used to perform the preparative photocyclisation of 77o 
and 78o was ultimately incompatible with irradiation of DNA samples and biological 
applications, photoirradiation experiments in buffered conditions were conducted using 
monochromatic visible light using 4.5 mW laser diode modules. Samples were irradiated under 
identical conditions (50 μM ligand in 100 mM sodium phosphate buffer, pH 7.4, 2 mL sample 
volume in a 3 mL cuvette, path length 10 mm) so that the systems could be compared under 




Figure 5.6: Attempted cyclisation of 79o in DMSO upon exposure to UV (320 – 400 nm) 
light monitored by 1H NMR spectroscopy. This demonstrates photostability of the open form 
even after long irradiation times. 
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These concentrations were too low for NMR analysis to be practical, so the systems were 
monitored by UV/visible absorbance spectroscopy (Figure 5.7). Photocyclisation of both 77o 
and 78o was found to be promoted by 450 nm blue light, whilst 635 nm red light prompted the 
respective cycloreversion (Figure 5.7). The degree of conversion between the open and 
closed forms was estimated from the intensity of the red-shifted absorbance band of the closed 
isomer (λ ≈ 650 nm). Since the open isomers do not absorb in this region, the intensity of this 
absorbance band could be normalised against spectra of samples of known composition in 
order to estimate the proportion of the closed isomer in the mixture, allowing the kinetics of 
the two photoswitches to be compared (Figure 5.8). In agreement with the NMR experiments 
in DMSO, the pyridinium-derived compound 77o displays significantly faster photocyclisation 
kinetics, with full cyclisation prompted by 450 nm light in less than ten minutes (Figure 5.8a, 
 
Figure 5.7. Reversible photoswitching of (a,c) 77o/77c and (b,d) 78o/78c in sodium 
phosphate buffer. (a-b) superimposed UV visible spectra of the samples obtained after 
alternate irradiation with 450 nm and 635 nm light; (b) photoswitching between open and 
closed forms monitored by red-shifted absorbance band of the closed isomers over five 
alternate switches. Ligand concentration 50 μM in 100 mM sodium phosphate buffer. 
 
Chapter 5: Dithienylethene G4 ligands 
147 
 
blue trace). Meanwhile, the quinolinium isomer 78o required approximately 4 hours irradiation 
in order to generate a spectrum resembling the photostationary state in DMSO, (Figure 5.8a, 
red trace). In this case however, quantification of the extent of the ring closure reaction was 
complicated by the aggregation of the closed isomer under the buffered conditions. This effect 
led to a distortion in the reference spectrum obtained by diluting the 10 mM DMSO stock 
solution to 50 μM in buffer (Figure 5.7b, dotted trace). This effect was attributed to self-
association of the ligand in aqueous conditions at the concentration range studied and was 
also observed in circular dichroism experiments (Section 5.5.2). 
Figure 5.8. Kinetics of the (a) photocyclisation of 77o and 78o and (b) photocycloreversion 
of 77c and 78c in sodium phosphate buffer. The conversion was approximated by 
monitoring the formation/disappearance of the closed isomer and normalising the 
absorbance against a reference sample of the appropriate closed isomer. Ligand 
concentration 50 μM in 100 mM sodium phosphate buffer. 
 
 
For both ligand pairs, the cycloreversion prompted by red light was slower than the 
corresponding ring closure (Figure 5.8b). Samples of pyridinium 77c required approximately 
six hours irradiation to achieve near complete cycloreversion, though approximately 75% ring 
opening was observed after 3 h irradiation (Figure 5.8b, blue trace). Meanwhile, the 
quinolinium isomer 78c demonstrated only 30% conversion after 3 h and required overnight 
irradiation to achieve complete ring opening (Figure 5.8b, red trace). Though these response 
times are rather slow, it should be noted that only low power (4.5 mW) irradiation sources were 
employed in these studies, and faster response times could easily be achieved by obtaining 
brighter light sources. 
Finally, the reversibility of the switching process was examined by subjecting the ligands to 
alternate irradiation with 450 nm and 635 nm light (Figures 5.7c and 5.7d). Pleasingly, robust 
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and reversible photoswitching of the pyridinium analogue 77o/77c was achieved. The spectra 
of the respective isomers remain virtually superimposable over irradiation cycles and a sharp 
isosbestic point is preserved indicating clean photoisomerisation between the two ligand 
states without decomposition. Reversible photoswitching of the quinolinium derivative 78o/78c 
was also achieved, but the switching did not appear as efficient as for pyridinium derivative 
77o/77c. It is possible that the prolonged irradiation periods necessary to promote the 
isomerisation allow the accumulation of photodecomposition products, but the analysis is also 
complicated by the spectral distortion from the aggregation of ligand 78c under the 
experimental conditions. Nonetheless, reversible switching between the two ligand forms is 
still demonstrated, even if it is not as efficient as for the pyridinium couple 77o/77c. 
 
5.4.2  Photocyclisation of 77o the presence of G4 and duplex DNA 
Having demonstrated the photoswitching of ligands 77o/77c and 78o/78c in the absence of 
DNA, the effect of the presence of different DNA secondary structures on the photocyclisation 
of 77o (Figure 5.9) was examined. DNA was added to the samples of 77o and the kinetics of 
the cyclisation were compared. In separate UV/visible titration studies (Section 5.5.3) it was 
observed that at 10 μM ligand concentration a G4 concentration of 35 μM was sufficient to 
result in full ligand binding to G4; the same DNA and ligand concentrations were employed 
here. The cyclisation of 77o was too rapid under irradiation with 450 nm light for kinetic studies 
with the experimental setup available, so the samples in this case were irradiated under 
ambient light. Interestingly, the presence of both G-quadruplex structures examined (telo23-
K+ hybrid G4 and telo22-Na+ antiparallel G4) markedly accelerated the cyclisation of 77o 
relative to the kinetics observed in the absence of DNA. Indeed, the extracted rate constant in 
the presence of antiparallel telo22 G4-Na+ (kisom = 7.6 x 10-4 s-1) was over five-fold higher than 
that observed in the absence of DNA (kisom = 1.7 x 10-4 s-1). Meanwhile, in the presence of 
duplex DNA (ds26), a less that 2-fold increase in the kisom was observed, suggesting that the 
DNA-accelerated photocyclisation is specifically accelerated by binding to the four-stranded 
structures. These interesting results are worthy of further exploration though were not taken 
further in the present project due to time constraints. 
 





Figure 5.9. Effect of different DNA structures on the photocyclisation kinetics of 77o to 77c.  
Ligand concentration: 10 μM, DNA concentration: 35 μM in 100 mM sodium phosphate 
buffer. Samples were exposed to ambient light under identical conditions. (a-d) UV/visible 
spectra following irradiation for the times shown: (a) telo23-K+ hybrid G4, (b) telo22-Na+ 
antiparallel G4, (c) ds26 duplex DNA, (d) no DNA; (e) fitting of kinetic plots to first order rate 
equation to determine kisom under the reaction conditions. The error bars show the deviations 
of two independent experiments. 
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5.5  Biophysical assays 
With samples of the open and closed forms of ligands 77o/77c and 78o/78c in hand and 
confident that the ligands could be photoisomerised in conditions relevant to DNA folding, 
efforts turned to investigating the activities of the different compounds using the biophysical 
assays introduced in previous chapters. 
 
5.5.1  FRET thermal melting assays  
The ligands were initially screened for binding activity in the FRET thermal melting assay to 
provide insights into their ability to stabilise G4 DNA structures and consider the selectivity 
between G4 and duplex DNA. 
 
5.5.1.1 Assay considerations 
Two potential issues regarding the deployment of the FRET melting assay to study the DTE 
ligands were identified. The first was the possibility of unwanted photocyclisation of the two 
ligand forms under the assay conditions. However, at the excitation wavelength (λex = 492 nm) 
employed in the assay, this was not expected to be problematic, since neither 77o or 78o 
absorb at this wavelength (Figures 5.7a and 5.7b). Of more concern was the potential for 
thermal cycloreversion of the closed isomers. The stability of the closed from at elevated 
temperature was therefore examined by UV/visible spectroscopy (Figure 5.10). Quinolinium 
ligand 78o was shown to be stable at temperatures up to 90 °C with negligible cycloreversion 
observed at this temperature even at prolonged irradiation times (Figure 5.10b) Meanwhile, 
ligand 77c appeared stable at lower temperatures but measurable cycloreversion was 
detected as the temperature was increased in the manner of the FRET assay. Therefore, the 
FRET results for this compound should be interpreted with caution since some isomerisation 
back to the open form could be expected to occur on the timescale of the experiment. Further 
isothermal techniques (CD spectroscopy, UV/visible spectroscopy and NMR spectroscopy) 
that are not vulnerable to this complication were later employed to more rigorously examine 
binding differences between the open and closed forms of the ligands. 
 
5.5.1.2 Assay results 
Ligands 77o/77c and 78o/78c were screened against three G4 models: the telomeric F21T 
G4 model under potassium- and sodium- rich conditions, and the oncogene promoter model 
FmycT. The self-complementary duplex hairpin was included to assess the selectivity of the 
ligands between G4 and duplex DNA.  
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The results of the FRET assay are shown graphically in Figure 5.11 and representative raw 
data in Appendix A5 (Figures A5.1-A5.4). From the results, it can be seen that all ligands show 
selectivity for G4 DNA over the duplex model. Figures 5.11a-5.11c show measurable 
stabilisation of all G4 sequences is observed across the concentration range studied, whilst 
the stability of the duplex hairpin is comparatively unaffected even at high ligand 
concentrations (Figure 5.11d). For example, whilst ligands 77o/78c induce stabilisation of all 
three G4 sequences at 2 μM (e.g. ΔTm [F21T-K+] = 15 °C for 78c, Figure 5.11a), no 
stabilisation of the duplex DNA is observed at this concentration (Figure 5.11d). Indeed, even 
at 10 μM ligand concentration only slight (ΔTm [F10T] = 4 °C) thermal stabilisation is induced 
in duplex DNA by 78c (Figure 3.11d). This result suggests that DTE derivatives are better 
suited to binding G4 structures despite previous studies on the DNA binding of this scaffold 
being directed towards duplex DNA. 
 
 
Figure 5.10: Investigations of the thermal stability of ligands (a) 77c and (b) 78c by 
UV/visible spectroscopy in water. 






Figure 5.11: FRET thermal melting studies of ligands 77o/77c and 78o/78c. (a)-(d): thermal 
stabilisation values (ΔTm) induced in (a) F21T-K+ G4, (b) F21T-Na+ G4, (c) FmycT G4, (d) 
F10T duplex. (e)-(f) comparison of representative melting curves of F21T-K+ in the absence 
and presence of (e) 77o/77c and (f) 78o/78c 
 
Another evident feature of the results is that the quinolinium ligands 78o/78c induce 
significantly higher thermal stabilisation in the G4 sequences than the pyridinium analogues 
77o/77c. For example, the ΔTm values induced in the F21T K+ G4 by the quinolinium 78o/78c 
ligands (ΔTm = 8 - 10 °C at 1 μM ligand concentration) are approximately two- to three-fold 
higher than those recorded for the pyridinium ligands 77o/77c (ΔTm = 3 °C) under comparable 
conditions (Figure 5.11a). Even greater differences between the ligands are observed for the 
FmycT (Figure 5.11c) and F21T-Na+ (Figure 5.11d) G4 models. These results suggest that G-
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tetrad stacking interactions may be important in the binding of DTE ligands to G4 DNA 
structures since the more extended surface area of the quinoline appears to dramatically 
increase the ability of the ligand to stabilise the secondary structure. 
Of perhaps more importance to the desired application of the DTE derivatives as 
photoresponsive G4 binding molecules is the fact that a difference in activity between the open 
and closed forms can be observed. This is particularly evident for the F21T model, in which 
both closed isomers induce higher thermal stabilisation in the G4 sequence than the 
corresponding open forms. For example, at 1 μM and 2 μM ligand concentration, the ΔTm 
values are 3 – 4 °C higher for closed isomer 78c than the open form 78o. A similar effect is 
observed for the pyridinium ligands 77o/77c, where the stabilisation values are in general 2 - 
3  °C higher for the closed isomer. For both ligand pairs, the difference in activity can also be 
visualised by inspection of the raw melting curves which shows the greater thermal shift 
induced by the closed isomer at the same concentrations (Figures 5.11e and 5.11f). Though 
the differences in the ΔTm between the isomers are rather modest, they were significant 
enough to be reproducibly measured and indicate that the closed isomer is the more active 
ligand form. The difference in activity of the ligand isomers was also observed for 78o/78c 
against the FmycT sequence (Figure 5.11c) and the F21T-Na+ sequence at lower 
concentration (Figure 5.11b). The pyridinium 77o/77c isomers displayed similar activities 
against these G4 models, though the ΔTm values are perhaps too low for the differences in 
activity to be evident in the case of this ligand pair. 
The FRET results demonstrated DTE to be a viable scaffold for the design of new 
photochromic G4 ligands, demonstrating good ability to stabilise G4 with discrimination 
against duplex DNA. Furthermore, some difference in activity between the photochromic forms 
of both ligands was observed. Unfortunately, this activity difference was not sufficiently large 
to conclude these molecules could be deployed as photocontrolled G4 binders; possibly the 
change in ligand geometry upon photoisomerisation is insufficient to translate into large 
differences in activity. Nonetheless, in light of the possibility to photoisomerise the new DTE 
ligands without degradation in G4-relevant conditions, further studies into the binding modes 
of the photochromic ligand forms were therefore desired in order to obtain more direct 
evidence for the different ligand activities in light of these preliminary results. 
 
5.5.2  Binding studies by CD and NMR spectroscopy 
Though the FRET assays reveals some small differences in activity between the open and 
closed forms of ligands 77 and 78 the differences were not sufficiently large to draw strong 
conclusions, and more direct evidence of the differences in G4 binding between the respective 
isomers was desired. The potential of ligands 77o/77c and 78o/78c to influence the folding 
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dynamics of G4 structures was investigated by NMR and circular dichroism spectroscopy 
which together allow the systems to be explored in greater detail.  
 
5.5.2.1 Studies of N-methylquinolinium ligands 78o and 78c 
Attempts were initially made to investigate quinolinium ligands 78o/78c, since these 
derivatives appeared to the stronger G4 ligands based on the results of FRET assay. The 
telo22-Na+ sodium structure was initially employed, since this sequence folds into a single 
well-characterised G4 conformation, allowing facile assignment of many of the imino and 
aromatic resonances from simple 1D 1H spectra as discussed in previous chapters. 
The closed isomer 78c induces distortion of the CD spectrum baseline (Figure 5.12b) of the 
G4, which was attributed to aggregation of the ligand in this rigid planar form as also suggested 
by UV/visible studies (Figure 5.7b). A control titration of the ligand into buffer (with no DNA 
present) revealed the same distortion, indicating the effect is ligand-specific and not the result 
of induced CD upon binding to the chiral DNA (Appendix A5, Figure A.5.5). It is therefore 
difficult to draw inferences about the ligand binding, other than that the overall antiparallel G4 
signature appears to be preserved. Meanwhile, the CD baseline appears stable upon titration 
with ligand 78o and therefore the spectral differences can be reasonably attributed to ligand 
binding events (Figure 5.12a). In this case, the ligand induces hypochromicity in the positive 
band at 240 nm and the negative band at 260 nm. These effects suggest that the ligand 
induces a disruption of the folded topology, possibly arising from an intercalative binding 
mechanism. NMR experiments of telo22 titrated with ligand 78o reveal chemical shift 
perturbations of the resonances corresponding to the imino protons of the top (G4, G16, G21) 
and middle G-tetrad (G9, G15 and G3) suggesting that the ligand is able to intercalate the 
DNA structure between these two tetrads whilst resonances corresponding to the lower tetrad 
(G2, G10, G22) are not perturbed (Figure 5.12c).  As the titration progresses the G8 resonance 
disappears, possibly suggesting disruption of the top G-tetrad by the binding of ligand 78o, 
which may also explain the observed hypochromic effects in the CD signature. Meanwhile, 
the aromatic resonances of telo22 broaden slightly upon ligand binding but otherwise remain 
well-resolved and are largely comparable to the resonances observed in the absence of 
ligand. 
 




Figure 5.12: CD and NMR investigations of the binding of 78o/78c  to telo22-Na+ G4 (a)-
(b) CD spectra of telo22 in the absence (black trace) and presence (dark grey trace) of 7 
equiv. ligand (a) 78o and (b) 78c (DNA concentration 4.2 μM), intermediate titration points 
are shown as light grey traces; (c)-(d) overlaid imino and aromatic NMR spectra of telo22 
(black) and increasing concentrations (grey) of ligand (c) 78o  and (d) 78c up to 2 equiv. 
ligand (DNA concentration 185 μM). The cartoon representation in (c) identifies the 
resonances that disappear (red), are perturbed (purple) and not perturbed (green) by 
ligand 78o. 




Figure 5.13  CD and NMR investigations of the binding of 77o/77c  to telo22-Na+ G4 (a)-
(b) CD spectra of telo22 in the absence (black trace) and presence (dark grey trace) of 7 
equiv. ligand (a) 77o  and (b) 77c  (DNA concentration 4.2 μM), intermediate titration 
points are shown as light grey traces; (c)-(d) overlaid imino and aromatic NMR spectra of 
telo22 (black) and increasing concentrations (grey) of ligand (c) 77o and (d) 77c up to 2.5 
equiv. ligand (DNA concentration 185 μM). The cartoon representations in (c) and (d) 
identifies the resonances that are perturbed (purple) on addition of ligand. 
 
Chapter 5: Dithienylethene G4 ligands 
157 
 
In contrast to the titration with 78o, the closed isomer 78c does not cause any specific 
chemical shift perturbations of the telo22 imino resonances (Figure 5.12d) and all signals 
appear to broaden and reduce in intensity in a similar manner. Given that the CD studies 
indicate ligand aggregation even at comparatively low concentration, it is likely this effect 
complicates the behaviour of the ligand in the NMR studies resulting in the non-specific 
broadening observed. Therefore, the binding mode of this form of the ligand could 
unfortunately not be reliably compared with ligand 78o. 
 
5.5.2.2 Studies of N-methylpyridinium ligands 77o and 77c 
Neither form of ligand 77o/77c induced perturbations in the CD spectrum of telo22 DNA 
(Figures 5.13a and 5.13b). This was not surprising, since the association of ligand with the 
telomeric G4 in sodium-rich conditions was indicated to be rather weak in the FRET studies. 
Nonetheless, weaker binding can still be observed in the NMR studies, as the concentrations 
employed are higher. Ligand 77o does not significantly change the chemical shifts of the imino 
resonances (Figure 5.13c) but does induce specific perturbations of the aromatic resonances 
of bases A7 and T18 corresponding to the capping residues of the lateral loops above the top 
G-tetrad. That all residues of the lower G-tetrad are unperturbed suggests that ligand 77o 
binds exclusively to the top of the G4 with 1:1 stoichiometry. 
Meanwhile, the closed isomer 77c causes clear perturbations to the chemical shifts of imino 
resonances (Figure 5.13d): G8 is shifted upfield whilst several aromatic proton resonances 
corresponding to the top G-tetrad are also perturbed, particularly G8 and G20. Significant 
shifts can also be observed for imino protons G22 and G14 corresponding to the lower G-
tetrad, implying that ligand 77c binds with a 2:1 stoichiometry to the upper and lower faces of 
the G4. 
Pleasingly, the binding mode of the ligand could be reversibly switched several times by in 
situ photoisomerisation of the ligand. The sample was irradiated alternately with blue (450 nm) 
or red (635 nm) light and the switch in binding mode monitored by the chemical shift of the G8 
and G4 imino resonances. The switching process was shown to be fully reversible with no 
observable degradation of the nucleic acid (Figure 5.14). 
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Encouraged by these results, the effect of the 77o/77c couple on the telo23-K+ hybrid form of 
G4 DNA also investigated (Figure 5.15, stacked spectra in Appendix A5, Figure A5.6) since 
this sequence has greater physiological relevance owing to the higher concentration of 
potassium ions in cellular environments. As in the case of the antiparallel telo22-Na+ G4, the 
closed isomer 77c causes significant chemical shift perturbations (Figure 5.15a) of the imino 
signals of several guanine residues, indicative of stacking with the exposed G-tetrads. Again, 
since signals corresponding to both upper (G9/G21) and lower (G15/G23) tetrads are 
perturbed, a 2:1 ligand binding stoichiometry was inferred in this case. The intensity of the 
imino signals is maintained throughout the titration and the circular dichroism spectrum of the 
oligonucleotide is unaffected (Figure 5.15b) indicating that the binding of 77c takes place 
 
 
Figure 5.14: Reversible switching of binding mode of 77o/77c to telo22-Na+ G4. (a) NMR 
spectra of telo22 (DNA concentration 185 μM) and 1 equiv. ligand 77o before and after 
each subsequent irradiation dose; (b)-(c) monitoring the change in ligand binding mode 
via the observed chemical shift of the (b) G8 and (c) G4 imino resonances. 
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without disruption of the hybrid G4 fold. In sharp contrast, ligand 77o induces the pronounced 
attenuation of many of the G4 imino signals, particularly G9, G10, G21 and G22 (Figure 5.15a, 
stacked spectra in Appendix A5, Figure A5.6). Indeed, only a small number of distinctive imino 
environments can be seen in the spectrum of the telo23/77o complex, rather than the 12 
signals expected for a fully-folded G4 (if present as a single species). This suggests an 
intercalative binding mechanism for the open form of the ligand, requiring partial disruption of 
the G-tetrad network. Indeed, while the CD spectrum of telo23-K+ is unperturbed by the 
addition of ligand 77c, the addition of 77o results in attenuation of ellipticity from 240-280 nm, 
also suggesting the disruption of the native G-tetrad network by addition of ligand (Figure 
5.15c). 
In a similar way to telo22-Na+ these different effects of the 77o/77c couple could be reversibly 
toggled by photoirradiation (Figure 5.16). Pleasingly, alternate irradiation with blue and red 
visible light allowed the switching process to be achieved at least 7 times. The degree of the 
conversion was followed by the integral of the G9/G10 imino resonances and was shown to 
depend on the irradiation time (Figure 5.16b). The regeneration of the CD intensity upon 
photocyclisation of 77o to 77c with blue light was also demonstrated (Figure 5.16c).  
 






Figure 5.15. NMR and CD investigations of the binding of 77o/77c to hybrid telo23-K+ G4. 
(a) spectra of telo23 in absence of ligand and the presence of (middle) 2.5 equiv. 77c and 
(top) 2.5 equiv. 77o. DNA concentration = 185 μM; (b)-(c) CD spectra of telo23-K+ in the 
absence (black trace) and presence of 50 μM (dotted grey trace) and 100  μM (dashed grey 
trace) (b) 77c and (c) 77o (DNA concentration 4.2 μM). 
 





Figure 5.16:  Reversible switching of binding mode of 77o/77c to telo23-K+ G4. (a) stacked 
NMR spectra of the DNA/ligand complex after each successive irradiation dose; (b)  
monitoring the change in ligand binding mode by the normalised integral of the shaded 
region in (a); (c) recovery of CD spectral intensity upon irradiation of the telo23/77o complex 
with blue light. 
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5.5.3  UV/visible titration absorbance titrations 
Having demonstrated the ligand binding mode to G4 DNA could be controlled in situ for the 
ligand 77o/77c couple, and in light of the small difference in activities observed between the 
open and closed ligand forms observed in the FRET assays, attempts were made to quantify 
the binding affinities of the ligands to antiparallel and hybrid telomeric DNA sequences using 
UV/visible titration studies in a manner to previous chapters. 
 
5.5.3.1 Titrations with antiparallel (telo22-Na+) G4 
Considering first the N-methylpyridinium ligands 77o/77c, binding of both open and closed 
forms to telo22 G4 is evidenced by hypochromicity in the ligand absorbance upon binding to 
DNA (Figure 5.17 and Table 5.1). For ligand 77c this is accompanied by a bathochromic shift 
of approximately 9 nm, which may be attributed to the stacking with the upper and lower G-
tetrads as observed in the NMR studies. The isotherms were fit to the independent and 
equivalent sites binding model (Eqn. (3.1), introduced in Section 3.3.2) assuming the 
stoichiometry suggested by the NMR studies, and similar binding constants (~ 1.5 x 105 M-1)  
for both isomers were found. It is perhaps surprising that the different binding modes occur 
with the same apparent affinity given the different binding modes observed in the NMR titration 
studies, but this observation nonetheless appears to corroborate the results of the FRET study 
which indicates the two isomers induce a similar thermal stabilisation in the F21T-Na+ G4 
model (Figure 5.11b). 
Turning attention to ligands 78o/78c, the stronger binding of these derivatives to antiparallel 
telo22-Na+ is observed (Figure 5.18), in agreement with the FRET results which indicate these 
induce greater thermal stabilisation of G4 at lower concentrations. The DNA-induced 
hypochromicity is larger than for the corresponding pyridine analogues, greater bathochromic 
shifts are observed and the fitted Ka values, (8.7 ± 2.9) x 105 M-1 for ligand 78o, are higher 
(Table 5.1). Again, the open and closed ligand forms appear to display comparable affinity for 
G4, with ligand 78c displaying an apparent Ka of (5.4 ± 0.04) x 105 M-1. 
 
5.5.3.2 Titrations with hybrid (telo23-K+) G4 
In the case of the telo23-K+ G4 both ligands, stronger binding of all the ligands to the hybrid 
G4 was suggested by larger hypochromicities and bathochromic shifts in the spectra (Table 
5.2). Despite this, the association constants calculated were similar to those observed for the 
telo22-Na+ quadruplex and in both cases, with the exception of ligand  78c which displays a 
Ka approximately two-fold higher, (11.2 ± 0.4) x 105 M-1 for the hybrid telo23-K+ G4, than the 
antiparallel telo22-Na+ G4 model. Again, the binding constants of the respective open and 
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closed ligand forms are similar, which is surprising in light of the different effects observed in 







Table 5.1:  Summary of spectral changes observed for ligands 77o/77c and 78o/78c after 
addition of 3 equiv. antiparallel telo22-Na+ G4 DNA and fitted Ka values using the 





Apparent Ka  
/ 105 M-1 
Stoichiometry 
77o 17 0 1.6 ± 0.2 1 
77c 10 9 1.7 ± 0.8 2 
78o 26 11 8.7 ± 2.9 3 
78c 21 40 5.4 ± 0.04 3 
     
 
Table 5.2:  Summary of spectral changes observed for ligands 77o/77c and 78o/78c after 
addition of 3 equiv. telo23-K+ hybrid G4 DNA and fitted Ka values using the stoichiometry 





Apparent Ka  
/ 105 M-1 
Stoichiometry 
77o 35 5 1.5 ± 0.2 2 
77c 21 12 2.1 ± 1.3 2 
78o 35 15 8.1 ± 0.9 3 
78c 15 56 11.2 ± 0.4 3 
     





Figure 5.17:  UV/visible titration studies of ligands 77o and 77c with antiparallel telo22-Na+. 
(a),(c): titrations of 10 μM (a) 77o and (c) 77c with; (b),(d): extracted binding isotherms.  
 
Figure 5.18:  UV/visible titration studies of ligands 78o and 78c with antiparallel telo22-Na+. 
(a),(c): titrations of 10 μM (a) 78o and (c) 78c; (b),(d): extracted binding isotherms. 
 





Figure 5.19:  UV/visible titration studies of ligands 77o and 77c with hybrid telo23-K+. 
(a),(c): titrations of 10 μM (a) 77o and (c) 77c; (b),(d): extracted binding isotherms. 
 
Figure 5.20:  UV/visible titration studies of ligands 78o and 78c with hybrid telo23-K+. 
(a),(c): titrations of 10 μM (a) 78o and (c) 78c with G4 DNA; (b),(d): extracted binding 
isotherms. 
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Overall, the UV visible titration studies confirm all DTE interact with G4 DNA occurs as 
suggested by the FRET assay, based on the shapes of the obtained isotherms and the 
approximate Ka values extracted from the independent-and-equivalent sites treatment of the 
data. Unfortunately, the results do not show a large affinity difference between the open and 
closed ligand forms which might be required to exert appreciable effects on G4 structures in 
vivo. Whilst this is perhaps expected on the basis of the FRET assay, which suggests the 
difference in activity between the isomers is modest, it is surprising in light of the NMR 
experiments which indicate different ligand binding modes that would reasonably be expected 
to occur with different affinities. However, the model used to extract binding constants from 
the UV data relies on the assumption that the multiple ligand binding events are equivalent 
and occur statistically rather than co-operatively. This assumption is likely to be inaccurate, 
and the Ka values obtained should therefore be interpreted with caution. Further isothermal 
experiments to compare the relative binding affinity of the open and closed isomers, for G4 
such as competition dialysis studies, fluorescence indicator displacement assays or 
isothermal titration calorimetry should be employed to further interrogate the possible 
differences ability of the two ligand forms to recognise G4 structures, but unfortunately these 
could not be pursued in the timeframe of this project. 
  
Chapter 5: Dithienylethene G4 ligands 
167 
 
5.6  In vitro assays 
Despite the apparent similarly in affinity between ligand 77o and 77c suggested by the 
UV/visible studies, the differences in the interaction modes of these ligands with G4 suggests 
the different photoisomeric forms of these ligands may have potential to perturb G4 formation 
in different ways in biological systems. At this stage of the project, a detailed investigation of 
the biological activity of the compounds was not possible due to time constraints, but the 
toxicity of the two forms of ligand 77o/77c was measured in HeLa cells by Sadiyah Sheikh to 
provide an initial assessment of the potential of the 77o/77c ligand couple as a 
photopharmacological anticancer agent (Figure 5.21). Interestingly, alamarBlue cell viability 
assays carried out in HeLa cells exposed to the two ligand forms, 77o and 77c, over 72 hours 
showed a two-fold difference in cytotoxicity between the two ligands. The closed form (EC50 = 
10 μM) appearing more potent than the open form (EC50 = 22 μM). Whilst this preliminary 
result certainly does not provide a definitive link between the G4 binding properties of 77o and 
77c, it does suggest that the bioactivity of these derivatives warrants further investigation and 
potential photopharmacological agents. 
 
5.7  Chapter conclusions 
This work reported in this chapter aimed to employ the DTE photoswitch to address the key 
limitation of the previous stiff-stilbene system, seeking to achieve a G4 ligand for which activity 
can be controlled with light in a fully bi-directional manner. 
From the CD and NMR experiments, it can be concluded that the binding mode of DTE ligands 
can be reversibly manipulated in situ by controlling the structure of the ligand by 
 
 
Figure 5.21:  Dose-response curves for 77o and 77c against HeLa cells at 72 h exposure, 
measured by the alamarBlue cell viability assay. 
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photoisomerisation. This represents an advantage over the stiff-stilbene system reported in 
the previous chapters where the ligand photochemistry is irreversible. Whilst the change in 
binding mode observed for the antiparallel (telo22-Na+) G4 appears to take place without 
perturbing the underlying G4 structure, both CD and NMR suggest that the structure of the G-
tetrads is affected by the photoisomeric state of the 67o/67c couple. Whilst the difference in 
binding modes did not appear to correlate with a significant difference in binding affinities 
based on the results of the UV/visible titration experiments, the different photoisomers of 
77o/77c did exert differing toxicity to cancer cells, suggesting that photoresponsive G4 ligands 
may find application in photopharmacological anticancer strategies. Screening of more potent 
DTE ligands, such as quinolinium derivatives 78o/78c, against a wider panel of cell lines, 
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6  Conclusions and future work 
 
The overall goal of this thesis was the design of photoresponsive G-quadruplex ligands that 
allow G4 stability and structure to be photoregulated in biologically-relevant conditions, 
towards the development of G4-targeted photopharmacology or G4-based nanodevices. In 
pursuit of this goal, the potential of two photoresponsive scaffolds (stiff-stilbene and 
dithienylethene) to serve as the basis of G4-targeting ligands has been investigated. This has 
involved the design and synthesis of prototype ligands derived from each scaffold, 
investigation of their DNA-binding properties using a suite of biophysical methods, studies into 
the photochemistry of the compounds and preliminary assessments of their potential biological 
utility.  
Stiff-stilbene was first explored in attempt to build on previous work on azobenzene derivatives 
and deliver compounds that exert more powerful effects on G4 folding in physiologically-
relevant conditions. A prototype amine-decorated compound (E-41) demonstrated good 
stabilisation of quadruplex DNA structures whilst remaining ineffective at stabilising duplex 
DNA at the same concentrations. This selectivity was confirmed through competition 
experiments. Interestingly, the ligand appeared to bind preferentially to the hybrid telomeric 
G4 in preference to the antiparallel form in both the FRET and UV assays, though further 
screening of additional G4 structures should be undertaken verify this interesting selectivity. 
Critically, the Z-41 isomer was demonstrated to be ineffective at stabilising G4 DNA, providing 
an initial validation of the hypothesis that G4 ligand activity could ultimately be controlled by 
stiff-stilbene isomerisation. 
Unfortunately however, neither isomer perturbed the folded G4 structures in physiologically-
relevant buffers. Moreover, whilst the compounds displayed anticancer and antiparasitic 
activity in cellular assays, the activity did not correlate with their G4 binding properties and no 
selectivity between tumoral and non-tumoral cells was observed. This suggested that the G4 
affinity of these compounds was likely too low to result in G4-related mechanisms of 
therapeutic activity. Efforts to optimise the G4 binding properties by varying the substitution 
pattern, linker unit and amine moieties were ultimately unsuccessful and demonstrated only 
very limited effects on the activity of the compounds. 
This initial setback was overcome by an alternative ligand design strategy, in which the flexible 
amine-terminated chains were replaced with N-methylpyridinium moieties (Chapter 3). This 
led to significantly improved G4 binding properties. In particular, compound E-56 
demonstrated particularly high (ΔTm = 21 °C) stabilisation of G4 DNA structures at low ligand 
concentration, with good discrimination against duplex DNA in a competition assay. 
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Pleasingly, the difference in activity between the E and Z isomers was retained, with the 
isomer Z-56 being comparatively less effective at stabilising G4 DNA in a similar manner to 
the first-generation compounds.  
Unlike the amine-decorated compounds, the N-methylpyridinium compounds were found to 
exert significant effects on G4 folding equilibria. These effects were found to be most striking 
against the telo23-Na+ sequence in sodium buffer, with Z-56 stabilising an antiparallel 
structure, whilst the corresponding E-56 isomer induced the unfolding of the G4. Evidence of 
this effect was observed by CD spectroscopy, NMR spectroscopy and investigated further by 
molecular dynamics studies. Meanwhile, all ligands were found to maintain G4 structures in 
cell-like potassium-rich conditions, although different binding modes were observed by CD 
and NMR spectroscopy, with ligand E-56 appearing to target the G4 grooves rather than the 
G-tetrads.  
Interestingly, the bioactivity of the compounds appeared to correlate with G4 binding ability, 
though further work must be undertaken to obtain stronger evidence that the mechanism of 
action truly involves G4 targeting. In particular, the compounds should be screened against a 
much wider panel of cell lines than was possible in the current project, to ensure the selectivity 
for tumoral and non-tumoral cells at long exposure times is a general effect. Furthermore, the 
mechanism of action of the compounds should be elicited. For example, the telomerase repeat 
amplification protocol (TRAP) assay could be used to prove that the compounds inhibit 
telomerase through G4 binding. Meanwhile, gene expression assays should examine whether 
transcription of G4-containing sequences is selectively modulated by the compounds, and 
which specific genes are affected. Positive results in this area would then justify further 
optimisation of the ligand scaffold for pharmacological applications. 
Nonetheless, these present results reveal the lead compound to be 29-fold selective for a 
cancerous cell model over non-tumoral cells (EC50 HeLa = 62 nM), suggesting a promising 
therapeutic window for this molecule. The compounds also demonstrated potential as 
antiparasitic agents, with selectivity of up to 230-fold for T. brucei over non-tumoral human 
cells. Most importantly, towards the goal of photopharmacology, E-56 was found to be 85-fold 
more active than the Z-56 counterpart, suggesting the potential to exploit stiff-stilbene 
compounds as photoresponsive drugs. 
Towards this end, the photochemistry of the E/Z-56 pair was investigated (Chapter 4). Though 
Z-56 was found to photoisomerise to E-56 in DMSO, in aqueous conditions irradiation 
unfortunately led to photooxidation meaning that the reversible control of bioactivity could not 
be pursued further for this compound. Nonetheless, ligand E-56 could be deployed as a 
photoresponsive fuel to regulate the formation of G4 in sodium-rich conditions, based on the 
ligand-prompted unfolding of this structure which is subsequently reversed upon 
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photoirradiation. Whilst applications of this system can be envisaged, such as the 
phototriggered release of a G4 to sequester a protein target, the lack of full photoreversibility 
would likely limit the utility of such a system.  
Towards addressing this limitation, DTE derivatives were later investigated (Chapter 5). 
Though these molecules have previously only been studied as duplex DNA binders, it was 
found that N-methylpyridinium 77o/77c and N-methylquinolinium compounds 78o/78c induce 
selective stabilisation of G4 DNA in thermal melting assays, although they were not as 
powerful as the best stiff-stilbene compounds. The quinolinium derivatives were observed to 
be more effective, suggesting that the increased ligand surface area is beneficial for G4 
recognition in these compounds. Unfortunately, the difference in activity between the two 
photoisomers was not as marked as between the stilbene E/Z forms, but the closed ligands 
nonetheless induced approximately 3  °C higher thermal stabilisation in G4 than the open 
forms for the F21T-K+ and FmycT. 
Despite the similarities observed in the FRET assay, 77o/77c were found to display 
significantly different binding modes to G4 DNA. In the case of hybrid  telo23-K+ G4, the ligand 
appeared to switch from a stacking (77c) to intercalative (77o) binding mode causing some 
disruption of the G-tetrad network, evidenced by disappearance of imino resonances in the 
NMR spectrum and attenuation of ellipticity in the CD spectrum. Meanwhile the open isomer 
appeared to associate with the capping residues of the lateral loops of antiparallel telo22-Na+ 
whilst the closed isomer stacked with the terminal G-tetrads. 
Pleasingly, in contrast to the stiff-stilbene ligands, both 77o/77c and 78o/78c could be 
isomerised between open and closed forms repeatedly in DNA buffer, though this was found 
to be most efficient for the 77o analogue. Notably, the photocyclisation of this derivative was 
shown to be accelerated by G4 DNA, the first example of a G4-catalysed photoreaction. This 
interesting result should be explored further. In particular, it will be important to screen more 
DNA sequences to assess whether this effect is specific to G-quadruplexes. 
The photoresponsive control of ligand binding mode raises the possibility that these ligands 
may be used as supramolecular tools to modulate the behaviour of G4-based functional 
systems. In particular, it should be investigated whether the change in binding mode of the 
ligand may regulate the ability of G4 to bind to a second molecule, such as thrombin, and 
therefore used as a trigger for G4-mediated processes or networks. 
Finally, the toxicity of 77o/77c HeLa cells was examined, revealing a 2-fold difference in 
cytotoxicity between the isomers. Though the effective concentrations matched the 
approximate G4 affinity, and the slightly more active G4 stabilising isomer (77c) was the more 
effective cytotoxic agent, there is not yet sufficient evidence to confidently ascribe G4-targeting 
as the mode of action. Further studies, including screening of more potent DTE G4 ligands 
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such as quinolinium derivatives 78o/78c, as well as further analogues, must be undertaken to 
consider the generality of the approach. Nonetheless, this preliminary result suggests the 
utility of the photoresponsive ligand as a photopharmacological lead. 
In conclusion, two photoresponsive G4 ligand sets have been identified with together offer 
complementary means of photocontrol over G4/ligand assemblies. The ligands are sufficiently 
potent to exert effects in physiologically-relevant conditions and offer a means of control of G4 
ligand activity to complement the existing toolbox of G4-targeting molecules. It is hoped that 
this work demonstrates the potential of G4 targeting photoswitches in photopharmacology and 
nanotechnology, and that the reported research will generate further interest towards the 
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7  Experimental 
 
7.1  Ligand preparation 
For biophysical and cellular assays, stock ligand solutions were prepared at 10 mM 
concentration in DMSO-d6 and stored at -20 °C. Compounds were diluted in appropriate buffer 
immediately prior to use. 
 
7.2  Oligonucleotides 
All oligonucleotides used were purchased from Eurogentec (Belgium), purified by HPLC and 
delivered dry. Oligonucleotide concentrations were determined by UV-absorbance using a 
NanoDrop 2000 Spectrophotometer from Thermo Scientific through the relationship: 
 
concentration = A260 / ε260 
 
Where A260 is the absorbance of the sample at 260 nm at 1 cm path length and ε260 is the 
molar extinction coefficient at 260 nm. The sequences and respective extinction coefficients 






/ M-1 cm-1 
F21T 5’-FAM-GGGTTAGGGTTAGGGTTAGGG-TAMRA-3’ 268300 




F10T 5’-FAM-TATAGCTATA-HEG-TATAGCTATA-TAMRA-3’ 263600 
telo23 5’-TAGGGTTAGGGTTAGGGTTAGGG-3’ 236500 
telo22 5’-AGGGTTAGGGTTAGGGTTAGGG-3’ 228500 
Pu27 5’-TGGGGAGGGTGGGGAGGGTGGGGAAGG-3’ 279900 
ds26 5’-CAATCGGATCGAATTCGATCCGATTG-3’ 253200 
FAM = 6-carboxyfluorescein; 
TAMRA = 6-carboxy-tetramethylrhodamine; 
HEG = [(-CH2CH2O-)6] 
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Stock solutions of all sequences were prepared in HPLC-grade H2O and stored at -20 °C. 
Prior to use, solutions were thawed, diluted in appropriate buffer, and annealed by heating for 
2 minutes at 90 °C and then placing immediately into ice. 
 
7.3  Biophysical studies 
 
7.3.1  FRET thermal melting assays 
Fluorescence resonance energy transfer (FRET) melting assays were performed according to 
the procedure reported by De Cian and co-workers108 on a Roche LightCycler 480 or a 
Stratagene Mx3005P qPCR instrument. The assay was performed in 96-well plate format. The 
final volume of solution in each well was 25 µL and contained the appropriate oligonucleotide 
(200 nM) in 10 mM lithium cacodylate buffer (pH 7.2) plus the following salts depending on 
the sequence: 
DNA model FRET buffer additives 
F21T-K+ 10 mM KCl, 90 mM LiCl 
F21T-Na+ 100 mM NaCl 
FmycT 1 mM KCl, 99 mM LiCl 
Febr1T 10 mM KCl, 90 mM LiCl 
F10T 10 mM KCl, 90 mM LiCl 
 
Final ligand concentrations were either 1 µM, 2 µM, 5 µM or 10 µM and prepared from an 
intermediate stock of 50 µM in HPLC-grade H2O (0.5% DMSO). Each sample was tested in 
duplicate on the same plate, and each plate was repeated in at least duplicate. Samples were 
heated at 1 °C increments and allowed to equilibrate for one minute at each temperature 
before measuring FAM fluorescence (λex = 492 nm, λem 516 nm). Appropriate negative controls 
(DNA in the absence of ligand) were carried out for each sample set to allow calculation of the 
ΔTm. The melting temperatures were determined from the normalised curves where % 
fluorescence = 0.5.  
 
7.3.2  Circular dichroism titrations 
Circular dichroism titrations were recorded using a Jasco J-810 spectrometer fitted with a 
Peltier temperature controller. Measurements were taken at 20 °C in a quartz cuvette with a 
path length of 5 mm, at a 100 nm / min scanning speed at 1 nm intervals. The CD spectra 
were recorded between 800 and 200 nm, and baseline corrected for the buffer used. The 
oligonucleotide sequences used were: telo23, telo22 and Pu27. The oligonucleotides were at 
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a concentration of 4.2 µM in 1 mL buffer. The buffer used was either sodium (telo22) or 
potassium (telo23, Pu27) phosphate (100 mM, pH 7.4). The ligand was added by aliquot from 
a 1 mM stock solution in the appropriate buffer (10% DMSO). The reported spectrum for each 
sample represents the average of 3 scans. Data processing was carried out using Prism 7 
with a second-order smoothing polynomial applied to all spectra. Observed ellipticities (in 
mdeg) were converted to molar ellipticity [θ] = deg cm2 dmol-1. 
 
7.3.3  Circular dichroism kinetics 
CD kinetic studies of the conformational switch of telo23-Na+ with ligand E-56 were undertaken 
by monitoring the ellipticity at 273 nm with time following the addition of ligand. E-56 (10 equiv.) 
was added to the bottom of an empty cuvette (5 mm path length) in 4 µL DMSO. Following 
stabilisation of the background CD signal, telo23 (1 equiv., 1 mL of 4.22 µM solution in 100 
mM sodium phosphate buffer, pH 7.4) was injected rapidly to facilitate mixing and the ellipticity 
at 273 nm monitored for 2500 sec. Three independent repeats were conducted and the 
change in ellipticity at 273 nm plotted as a function of time. Fitting to a single exponential 
function (θ = a – b*exp(-t/τ)) was carried out using Prism 7 software to determine the 
characteristic folding time (τ). 
 
7.3.4  UV/visible spectroscopy 
UV spectra were recorded on a Thermo Scientific BIOMATE 3S UV/visible spectrophotometer 
at ambient temperature. Measurements were taken in a 3 mL quartz cuvette with a path length 
of 10 mm. The UV/visible spectra were recorded between 800 nm and 200 nm and baseline 
corrected for the buffer used. 
 
7.3.5  UV/visible titrations 
The concentration of ligand was fixed at 10 µM in a constant volume of 1.5 mL buffer. The 
buffer used was either sodium (telo22) or potassium (telo23) phosphate (100 mM, pH 7.4). 
During the titration, aliquots of sample were removed and replaced with aliquots of 
oligonucleotide to give the required titration points (from a 100 µM stock solution in appropriate 
buffer containing also 10 µM ligand to maintain constant ligand concentration throughout the 
titration). The oligonucleotide stock solution was annealed by heating to 90 °C for 2 minutes 
and then cooling on ice prior to the addition of ligand (to avoid annealing in the presence of 
ligand). Following addition of each DNA aliquot, the solution was mixed thoroughly, and the 
UV/visible spectrum was acquired immediately. Data were fit to the appropriate binding 
models (discussed in the relevant chapters) using non-linear regression in Prism 7 software 
to provide estimates of the association constants. 
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7.3.6  NMR spectroscopy of G-quadruplex ligand complexes 
1H NMR spectra of G-quadruplex sequences were recorded at 298 K using a 600 MHz Varian 
VNMRS spectrometer equipped with a triple resonance cryogenically cooled probe head. The 
oligonucleotide sequences used were telo23 and telo22. Samples of oligonucleotide were 
dissolved in 90% H2O/10% D2O containing either 25 mM sodium phosphate (pH = 7.0) and 
70 mM sodium chloride (for telo22) or 20 mM potassium phosphate (pH = 7.0) and 70 mM 
potassium chloride (for telo23). All experiments employed sculpted excitation water 
suppression. NOESY spectra were acquired with a 300 ms mixing time. The final NMR 
samples contained 600 µL of 185 µM oligonucleotide (for 1D experiments) or 300 µM 
oligonucleotide (for 2D NOESY experiments). Aliquots of ligand (10 mM in DMSO-d6) were 
added to yield the desired titration points, the sample was mixed thoroughly, and NMR spectra 
were recorded immediately. Data were processed using MestReNova software (version 
11.0.2). Resonances were assigned from data provided in the literature by Wang and Patel 
(telo22)27 and by Patel et al. (telo23).37  
 
7.4  Photoirradiation experiments 
 
7.4.1 Stiff-stilbene ligands (Chapter 4) 
The 800 nm fundamental output of a Ti:Sapphire ultrafast amplifier (Libra, Coherent) was used 
to generate 397 nm light via second harmonic generation. The measured beam spot size 
(diameter) at the sample region was 0.4 cm and the energy used to irradiate solutions was 30 
mW. Experiments involving ligand in the absence of telo23 were conducted using 1.5 mL 
solution in a 3 mL quartz cuvette with a path length of 10 mm equipped with a magnetic stirrer. 
The concentration of the ligand was 1 mM in DMSO-d6 or 10 µM in sodium phosphate buffer 
(100 mM, pH 7.4). The photoreaction was followed using NMR or UV/visible spectroscopy. 
Experiments involving telo23 were conducted using 1 mL solution in a 2 mL quartz cuvette 
with a path length of 5 mm. The concentration of DNA was 4.2 µM in sodium phosphate buffer 
(100 mm, pH 7.4). The effect of photoirradiation on G4 topology was monitored by circular 
dichroism spectroscopy. For experiments involving the repeated addition of E-56, 10 equiv. of 
ligand were added by aliquot (82 µL) of 600 µM E-56 solution in water. The system was 
allowed to equilibrate for 20 min at 20 °C following addition of ligand before the CD spectrum 
was recorded. Photoirradiation of NMR samples was conducted by transferring the sample to 
a 2 mL quartz cuvette with a path length of 5 mm equipped with a magnetic stirrer, to ensure 
even irradiation. Samples were then transferred back to the NMR tube for analysis. 
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7.4.2 Dithienylethene ligands (Chapter 5) 
For photoirradiation experiments conducted in DMSO-d6 in the absence of DNA, samples of 
ligand were prepared at 10 mM concentration and irradiated in an NMR tube or glass screw-
cap vial with a 36 W UV-A lamp (320−400 nm) of domestic use (PL-L, approximate length 
30cm, Philips). The isomerisation was followed by NMR spectroscopy. 
Experiments in buffer were followed by UV/visible spectroscopy at a concentration of 50 µM. 
Samples were irradiated using monochromatic light at 450 nm (for photocyclisation) and 635 
nm (for photocycloreversion). Samples (2 mL volume) were irradiated in a 3 mL quartz cuvette 
containing a magnetic stirrer using collimated laser diode modules (ThorLabs, CPS450 and 
CPS635, 4.5 mW, elliptical beam) and the UV/visible spectra recorded at appropriate time 
points. The degree of conversion was estimated by comparison to a reference spectrum of 
the photostationary state achieved in DMSO, the composition of which was determined by 
NMR (vide supra) and then diluted to 50 µM in appropriate buffer for measurement of the 
reference UV/visible spectra. For photoirradiation experiments conducted in the presence of 
oligonucleotides and followed by NMR spectroscopy, to ensure even irradiation of the sample 
the solution (600 µL) was transferred to a 2 mL quartz cuvette with a 5 mm path length 
equipped with a magnetic stirrer and irradiated at the appropriate wavelength for the time 
specified, then transferred back to the NMR tube for analysis. 
 
7.5  Computational studies 
 
7.5.1  Density functional theory calculations 
Undertaken by Marta Duchi 
 
The ground state structures of ligands E-56, Z-56 and E-57 were calculated using Gaussian 
09 at the B3LYP/6-31G level of theory. 
 
7.5.2  Molecular dynamics simulations 
Undertaken by Dr Susanta Haldar 
 
7.5.2.1 Standard (unbiased) molecular dynamics simulations 
Docking calculations were performed using AutoDock Vina with the DNA structure kept fixed 
in its original solution conformation throughout the docking procedures.225 The highest affinity 
binding pose was then submitted to long microsecond molecular dynamics simulations in order 
to predict the stability of the binding pose.  
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All the simulations were performed using the Gromacs-5.0 software package.226 The recently 
introduced parm-BSC1 force field was used for the DNA parameterisation. For the ligand, the 
General Amber Force Field was used to generate parameters.227,228 The charges were 
calculated using the restrained electrostatic potential (RESP) fitting procedure.229 The RESP 
fit was performed onto a grid of electrostatic potential points calculated at the HF/6-31G(d) 
level as recommended by the force-field designers and recent literature.228,229 
To start the simulations, each docked ligand/DNA complex was solvated in a cubic box with 
the dimension of 74 x 74 x 74 Å3 along with 12982 TIP3P explicit water molecules.230 An extra 
19 Na+ ions were added to neutralise the system.231 The complexes were minimised prior to 
the equilibration and production run as follows: the minimisation of the solute hydrogen atoms 
on the DNA and the ligand was followed by the minimisation of the counterions and the water 
molecules in the box. In the next step, the DNA backbone along with the all the heavy atoms 
on the ligand were kept frozen, and the solvent molecules with counterions were allowed to 
move during a 50 ps MD run, to relax the density of the whole system. In the next step the 
nucleobases were relaxed in several minimisation runs with decreasing force constants 
applied to the DNA backbone atoms, however, a few phosphate atoms were kept restrained 
with a force constant of 2.39 kcal.mol-1 Å-2. After the full relaxation, the system was slowly 
heated to the room temperature to 300K using V-rescale thermostat with a coupling constant 
of 0.5 ps employing an NVT (constant-temperature, constant-volume) ensemble.232 As the 
system reached the temperature of interest, the equilibration simulation was performed for 
10000 ps (10 ns) using an NPT ensemble with Berendsen thermostat and Berendsen barostat, 
and 0.5 ps was used again as the coupling constant for both temperature and pressure, 
respectively.233 Finally, the production run was set for 1000000000 ps (1μs) using Nose-
Hoover thermostat234 and Parrinello-Rahman barostat235 with the same coupling constant as 
previously taken in the equilibration simulation in the NPT ensemble. All the simulations were 
carried out under the periodic boundary conditions. The particle-mesh Ewald method was 
used to calculate the electrostatic interactions with in a cut-off of 10 Å.236 The same cut-off 
was used for Lennard-Jones interactions. All simulations were performed with a 1.0 fs time 
step. 
 
7.5.2.2 Well-tempered metadynamics 
The plumed 2.3 plugin was used to carry out the simulation with the Gromacs-5.0.7 code.237 
The bias potential was calculated according to the WTMetaD scheme as follows: 
 
𝑉(𝑠, 𝑡) = ∑ 𝜔𝜏  𝑒
 ( , ) ∆⁄
, , ,…
𝑒
∑ [( ( ) ) ]  




where the deposition rate, ω, and deposition stride, τG, of the Gaussian hills were set to 0.358 
kcal.mol-1·ps-1 and 1.0 ps, respectively. The bias factor (T + ΔT)/T was set to 15, and the final 
free energy surface (FES) was calculated as follows: 
𝐹(𝑠, 𝑡) = −
∆
∆
(𝑉(𝑠, 𝑡) − 𝐶(𝑇))     
where the V(s,t) is the bias potential added to the Collective Variables (CV) used and the T 
represents the simulation temperature. ∆T is the difference between the temperature of the 
CV and the simulation temperature. The bias potential is grown as the sum of the Gaussian 
hills deposited along the chosen CV space and finally the sampling of particular CV space can 
be controlled with the tuning of the ∆T parameter.  
 
7.6  Cellular and parasitic studies 
 
7.6.1  Cell and parasite culture 
Conducted with assistance from Dr Pablo Peñalver 
 
MRC-5 cells (human lung fibroblasts) were grown in monolayer (37°C, 5% CO2 and 100% 
humidity) in DMEM medium (1 g/L glucose), supplemented with 10% heat-inactivated Fetal 
Bovine Serum, 2 mM L-glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin. HeLa 
cells were maintained at 37 °C and 5 % CO2 in high glucose DMEM (4.5 g/L) supplemented 
with 10% hiFBS, 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine and non-
essential amino acids (1X). Cells were cultured according to ATCC recommendations and 
were used for the experiments while in the exponential growth phase. 
T. brucei (bloodstream forms, “single marker” S427 (S16)) were cultured at 37 °C, 5 % CO2 in 
HMI-9 medium supplemented with 10% heat-inactivated fetal bovine serum (hiFBS, 
Invitrogen). L. major promastigotes (MHOM/IL/80/Friedlin) were cultured at 28 °C, 5 % CO2 in 
modified RPMI-1640 medium (Invitrogen, Carlsbad, CA) with 10% hiFBS. Parasites were split 
every other day and maintained in their experimental growth phase (below 2 million parasites 
per mL). 
 
7.6.2  Cytotoxicity 
Conducted with assistance from Dr Pablo Peñalver 
 
Cytotoxicity was measured through the alamarBlue assay (ThermoFisher). 5x103 MRC-5 or 
HeLa cells were seeded in 96-wells plates (100 µL/well) in the presence of increasing 
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concentrations of ligands. After 72h / 7d incubation at 37 °C, 20 µL of alamarBlue solution 
(110 ng/ml) was added to each well and cells were reincubated for 1 hr at 37 °C and then 
analysed by fluorescence (λex = 550 nm, λem 590 nm) using an Infinite F200 plate reader 
(TECAN Austria, GmbH). The results are expressed as the concentration of compound that 
reduces cell growth by 50% versus untreated control cells (EC50) using Prism software to fit 
the data to a sigmoidal curve. Data are presented as the average of two independent 
measurements all conducted in duplicate conditions. 
 
7.6.3  Parasitic toxicity  
Conducted with assistance from Dr Pablo Peñalver 
1x103 BSF T. brucei were incubated in 96-wells plates alone or in the presence of increasing 
concentrations of compounds for 72 hrs (5% CO2, 37°C). After 72 h of incubation at 37 °C, 20 
µL of alamarBlue solution (110 ng/mL) was added to each well and cells were reincubated for 
4 hrs at 37 °C. Then, 50 µL of 3% SDS were added to each well. The plate was incubated at 
37 °C for an extra hour and then analysed by fluorescence using an Infinite F200 plate reader 
(TECAN Austria, GmbH) as above. Data are presented as the average of two independent 
measurements all conducted in duplicate conditions. 
4×106/mL L. major promastigotes (MHOM/IL/80/Friedlin) were incubated for 72 h at 28 °C in 
96-well plates (50 μL/well) in the presence of increasing concentration of compounds. 
Proliferation was determined using the MTT-based assay (Sigma-Aldrich). After the 72 h 
incubation, 10 µL of MTT (5 mg/mL) was added to each well and parasites were reincubated 
for 4 h at 28 °C. Then, 50 µL of 20% SDS was added to each well. The plate was then 
incubated at 37 °C for 4-16 h and analysed using an Infinite F200 plate reader (TECAN 
Austria, GmbH). The absorbance was measured at a wavelength of 540 nm. Data are 
presented as the average of two independent measurements all conducted in duplicate 
conditions. 
 
7.6.3  Microscopy 
 
Undertaken by Dr Pablo Peñalver 
HeLa cells (20,000) and T. brucei parasites (10,000,000) were incubated with 0.5 and 1 μM 
ligand E-57, respectively, in 0.5 mL of each respective medium (without FBS) for 30 and 120 
min at 37 °C and 100% humidity. Deep Red Mitotracker (400 nM) was also added to the 
incubation well for the last 30 minutes.  
Parasites were fixed with cold paraformaldehyde 4% for 30 min, washed twice in cold 
phosphate buffered saline (PBS), and processed by microscope observation. Cells were 
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washed 5 times with room temperature PBS and fixed with paraformaldehyde 2% for 20 
minutes. Two extra PBS washings and an ethanol immersion of the cover slide were also 
necessary prior to sample processing for microscopy. ProLong DAPI (3-4 μL) was used as 
mounting medium in both cases. 
Images were acquired using a widefield Olympus ix81 microscope. Excitation was performed 
with the 350-450, 492-518 and 572-623 nm filters for DAPI, ligand 3 and Deep Red 
Mitotracker, respectively. The emission of ligand E-57 was detected between 510 and 550 nm 
with a narrow filter, whereas a triple filter (437-474, 508-550 and 595-670 nm) was used to 
detect the fluorescence emission of both DAPI and Mitotracker. 
The images were deconvoluted using Huygens Professional image processing software from 
Scientific Volume Imaging. The merges of the images were made with Fiji software. 
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7.7  Synthetic procedures and compound characterisation 
 
General experimental 
Chemicals were purchased and used without further purification. Dry solvents were obtained 
by distillation using standard procedures, or by passage through a column of anhydrous 
alumina using equipment from Anhydrous Engineering (University of Bristol) based on the 
Grubbs’ design.238 Reactions requiring anhydrous conditions were performed under N2; 
glassware and needles were either flame dried immediately prior to use, or placed in an oven 
(150 °C) for at least 2 h and allowed to cool in a desiccator or under reduced pressure. Liquid 
reagents, solutions or solvents were added via syringe through rubber septa; solid reagents 
were added via Schlenk type adapters. Reactions were monitored by TLC on Kieselgel 60F254 
(Merck), with UV light (254 nm) detection and by staining with basic potassium permanganate 
solution. Flash column chromatography was performed according to the method reported Still 
and co-workers using silica gel [Merck, 230−400 mesh (40−63 µm)].239 Solvents for flash 
column chromatography (FCC) and thin layer chromatography (TLC) are listed in 
volume:volume percentages. Extracts were concentrated in vacuo using both a Heidolph 
HeiVAP Advantage rotary evaporator (bath temperatures up to 50 °C) at a pressure of 15 
mmHg (diaphragm pump) or 0.1 mmHg (oil pump), as appropriate, and a high vacuum line at 
room temperature. 
Preparative HPLC was performed on a Grace Discovery Sciences Reveleris Prep System with 
a Phenomenex Luna 5 μm C18(2) 100 Å AXIA packed (250 × 21.2 mm) column. For 
purification, the instrument was set to monitor the ELSD signal as well as 220 nm, 254 nm and 
280 nm on the UV detector. Flow rates were 14 mL / min. Water soluble compounds were 
freeze dried on a Lyotrap Plus (LTE Scientific LTD). 
1H NMR and 13C NMR spectra were measured at 25°C in the solvent specified with Varian or 
Bruker spectrometers operating at field strengths listed. Chemical shifts are quoted in parts 
per million with spectra referenced to the residual solvent peaks. Multiplicities are abbreviated 
as: br (broad), s (singlet), d (doublet), t (triplet), q (quartet), p (pentet), m (multiplet) and app. 
(apparent) or combinations thereof. Assignments of 1H NMR and 13C NMR signals were made 
where possible, using COSY, HSQC and HMBC experiments. Mass spectra were obtained by 
the University of Bristol mass spectrometry service by electrospray ionisation (ESI), electron 
ionisation (EI) or matrix assisted laser desorption ionisation (MALDI) modes. Infra-red spectra 
were recorded in the range 4000-400 cm-1 on a Perkin Elmer Spectrum either as neat films or 
solids compressed onto a diamond window.   
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General procedure A (for formation of anilines) 
The appropriate bis-bromide (1 equiv.), BrettPhos Pd G3 (5 - 10 mol%) and sodium tert-
butoxide (4 equiv.) were added to a 10 mL reaction tube containing a stirrer bar. The tube was 
sealed with a septum crimp cap and the contents dried under high vacuum for 30 min. The 
tube was then purged with nitrogen and evacuated and backfilled with nitrogen a further three 
times. 1,4-Dioxane (2 mL) was added followed by the appropriate amine (2.2 equiv.). The 
reaction mixture was then heated to 80 °C and stirred for 2 h, then cooled and concentrated 
in vacuo. The crude mixture was filtered through a plug of silica, eluting with 80:20:1 
DCM:MeOH:Et3N. The solvent was removed in vacuo and the residue suspended in H2O (4 
mL). Trifluoroacetic acid (200 µL) was added, the mixture swirled to dissolve the majority of 
the solid, and the resulting suspension filtered. The filtrate was purified by reverse phase 
HPLC eluting with a gradient of 5% MeCN in H2O (0.05% TFA) to 80% MeCN in H2O (0.05% 
TFA) over 30 minutes. Lyophilisation of the relevant fractions afforded the target compounds 
as hygroscopic solids. 
 
General procedure B (for formation of ureas) 
The appropriate bis-aniline (1 equiv.) was added to a 10 mL reaction tube containing a stirrer 
bar. The tube was sealed with a septum crimp cap and the contents dried under high vacuum 
for 30 minutes. The tube was then purged with nitrogen and evacuated and backfilled with 
nitrogen three times. Anhydrous dichloromethane (1 mL) was added, followed by a solution of 
triphosgene (0.66 equiv.) in anhydrous DCM (1 mL). The reaction was stirred at room 
temperature for 10 min, then triethylamine (3 equiv.) was added, followed by the appropriate 
amine. The reaction was stirred at room temperature for 1 h, then concentrated in vacuo and 
suspended in H2O (4 mL). Trifluoroacetic acid (200 μL) was added, the mixture swirled to 
dissolve the majority of the solid, and the resulting suspension filtered. The filtrate was purified 
by reverse phase HPLC eluting with a gradient of 5% MeCN in H2O (0.05% TFA) to 80% 
MeCN in H2O (0.05% TFA) over 30 minutes. Lyophilisation of the relevant fractions afforded 
the target compounds as hygroscopic solids. 
  








Zinc powder (5.90 g, 90.2 mmol) was suspended in anhydrous THF (75 mL). TiCl4 (4.9 mL, 
45 mmol) was added dropwise as the solution was stirred vigorously. The solution was heated 
to reflux and stirred for 2 h. The mixture was then cooled to r.t. and 6-bromo-1-indanone (4.76 
g, 22.6 mmol) was added to the suspension. The mixture was heated to reflux and stirred for 
16 h, then quenched with sat. aq. NH4Cl solution (50 mL) and extracted with CHCl3 (3 × 100 
mL). The combined organic extractions were washed with H2O (100 mL) and then 
concentrated in vacuo to approximately 30 mL, at which volume a precipitate formed. The 
precipitate was collected by filtration under reduced pressure and dried under vacuum to afford 
bromide E-43 as a yellow solid (2.44 g, 55%). The filtrate was concentrated in vacuo and the 
residue purified by flash silica chromatography, eluting with hexane, to afford bromide Z-43 as 
a white solid (1.00 g, 22%). 
E-43: 
1H NMR (500 MHz, DMSO-d6) δ 7.68 (2H, d, J = 1.8 Hz, 7-CH), 7.41 (2H, dd, J = 8.0, 1.8 Hz, 
5-CH), 7.33 (2H, d, J = 8.0 Hz, 4-CH), 3.13 – 3.08 (4H, m, 2-CH2 or 3-CH2), 3.07 – 3.02 (4H, 
m, 2-CH2 or 3-CH2). 
13C NMR Too insoluble for this experiment. 
νmax / cm-1 (compressed solid) 2925 (w), 2887 (w), 2850 (w), 1889 (w), 1589 (m), 1560 (m), 
1464 (m), 1433 (m), 1405 (m), 1205 (m), 1174 (m) 1078 (m), 1037 (m), 879 (s), 819 (s). 
EI-LRMS for C18H14Br2+ [M]+ calcd: 389.9, found: 390.2. 
Proton NMR was consistent with literature data.178  
Z-43: 
1H NMR (500 MHz, DMSO-d6) δ 8.01 (2H, d, J = 1.8 Hz, 7-CH), 7.39 (2H, dd, J = 8.0, 1.8 Hz, 
5-CH), 7.32 (2H, d, J = 8.0 Hz, 4-CH), 2.93 – 2.90 (4H, m, 2-CH2 or 3-CH2), 2.80 – 2.76 (4H, 
m, 2-CH2 or 3-CH2). 
13C NMR (126 MHz, DMSO-d6) δ 147.6 (9-C), 141.8 (8-C), 135.2 (1-C), 130.2 (7-CH), 127.6, 
125.0 (4-CH and 5-CH), 118.7 (6-C), 34.4 (2-CH or 3-CH), 29.6 (2-CH or 3-CH). 
νmax / cm-1 (compressed solid) 2029 (w), 2895 (w), 2871 (w), 2837 (w), 1635 (w), 1590 (m), 
1559 (m), 1459 (m), 1444 (m), 1425 (m), 1264 (m), 1166 (m), 1071 (m), 803 (s). 
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EI-LRMS for C18H14Br2+ [M]+ calcd: 389.9, found: 390.0. 







Zinc powder (3.94 g, 60.3 mmol) was suspended in anhydrous THF (30 mL). TiCl4 (3.3 mL, 
30 mmol) was added dropwise as the solution was stirred vigorously. The solution was heated 
to reflux and stirred for 2 h. The mixture was then cooled to r.t. and 5-bromo-1-indanone (3.17 
g, 15.0 mmol) was added to the suspension. The mixture was heated to reflux and stirred for 
30 h, then quenched with sat. aq. NH4Cl solution (50 mL) and extracted with CHCl3 (3 × 100 
mL). The combined organic extractions were washed with H2O (100 mL) and then 
concentrated in vacuo to approximately 50 mL, at which volume a precipitate formed. The 
precipitate was collected by filtration under reduced pressure and dried under vacuum to afford 
bromide E-45 as an off-white solid (2.01 g, 68%). The filtrate was concentrated in vacuo and 
the residue purified by flash silica chromatography, eluting with hexane, to afford bromide Z-
45 as a white solid (550 mg, 18%). 
E-45: 
1H NMR (500 MHz, DMSO-d6) δ 7.55 (2H, s, 4-CH), 7.51 (2H, d, J = 8.4 Hz, 7-CH), 7.44 (2H, 
d, J = 8.4 Hz, 6-CH), 3.08 (8H, app. s, 2-CH2 and 3-CH2). 
13C NMR (126 MHz, DMSO-d6) δ 149.7 (9-C), 141.6 (8-C), 134.8 (1-C), 129.4 (6-CH), 127.9 
(4-CH), 125.9 (7-CH), 120.3 (5-C), 31.3 (2-CH2 or 3-CH2), 30.3 (2-CH2 or 3-CH2). 
νmax / cm-1 (compressed solid) 2942 (w), 2922 (m), 2877 (w), 2845 (w), 2832 (w), 1853 (w), 
1743 (w), 1582 (m), 1561 (w), 1466 (s), 1450 (m), 1422 (m), 1408 (m), 1368 (w), 1346 (w), 
1321 (w), 1297 (m), 1280 (m), 1250 (m), 1223 (w), 1204 (m), 1711 (s), 1116 (w), 1070 (m), 
871 (s), 819 (m), 783 (s), 653 (m), 551 (s), 428 (s). 








1H NMR (500 MHz, DMSO-d6) δ 7.80 (2H, d, J = 8.4 Hz, 7-CH), 7.54 (2H, d, J = 2.0 Hz, 4-
CH), 7.34 (2H, dd, J = 8.4, 2.0 Hz, 6-CH), 2.99 – 2.92 (4H, m, 3-CH2), 2.85 – 2.66 (4H, m, 2-
CH2) 
13C NMR (126 MHz, DMSO-d6) δ 150.9 (9-C), 138.9 (8-C), 134.5 (1-C), 128.8 (6-CH), 128.3 
(4-CH), 124.3 (7-CH), 120.2 (5-C), 34.3 (2-CH2), 29.8 (3-CH2). 
νmax / cm-1 (compressed solid) 2938 (m), 2922 (w), 2899 (w), 2870 (m), 2834 (w), 1638 (w), 
1583 (w), 1564 (w), 1467 (s), 1460 (s), 1442 (m), 1426 (m), 1411 (s), 1325 (w), 1302 (w), 1194 
(w), 1170 (s), 1099 (m), 1063 (s), 1000 (m), 872 (s), 809 (s), 792 (s), 716 (m), 542 (m), 428 
(s). 
MALDI-LRMS for C18H14Br2+ [M]+ calcd: 387.9457, found: 387.9455. 
 




Bromide E-43 (398 mg, 1.03 mmol), palladium(II) acetate (28 mg, 0.11 mmol), DPPF (89 mg, 
0.16 mmol) and sodium tert-butoxide (230 mg, 2.40 mmol) were added to a 10 mL reaction 
tube containing a stirrer bar. The tube was sealed with a septum crimp cap and the contents 
dried under high vacuum for 30 min. The tube was then purged with nitrogen and evacuated 
and backfilled with nitrogen a further three times. Anhydrous toluene (8 mL) was added and 
the solution degassed by bubbling nitrogen for five minutes. Benzophenone imine (450 μL, 
2.7 mmol) was added and the reaction mixture was then heated to 90 °C and stirred for 18 h, 
then cooled to r.t. and partitioned between CHCl3 (20 mL) and H2O (10 mL). The aqueous 
layer was back-extracted with CHCl3 (2 × 20 mL) and the combined organic phases dried 
(MgSO4) filtered and concentrated in vacuo. The resultant oil was purified by flash silica 
chromatography, eluting with 1% Et3N in DCM, to afford the imine intermediate (E-46) as a 
yellow solid. This was immediately re-dissolved in THF (50 mL), 2M aq. HCl (25 mL) was 
added and the reaction stirred at r.t. for 2 h. The mixture was then basified (pH ~ 10) by 
addition of a sat. aq. NaHCO3 solution (110 mL), then extracted with EtOAc (3 × 50 mL). The 
combined organic extractions were dried (MgSO4) and concentrated in vacuo. The residue 
was triturated in Et2O (20 mL) and the resultant solid filtered and air-dried to afford the title 
compound as a light-brown solid (195 mg, 72%). 
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1H NMR (500 MHz, DMSO-d6) δ 6.97 (2H, d, J = 7.9 Hz, 4-CH), 6.88 (2H, d, J = 2.0 Hz, 7-
CH), 6.46 (2H, dd, J = 7.9, 2.0 Hz, 5-CH), 4.89 (4H, s, NH2), 3.03 – 2.98 (4H, m, 2-CH2 or 3-
CH2), 2.91 – 2.87 (4H, m, 2-CH2 or 3-CH2). 
13C NMR (126 MHz, DMSO-d6) δ 147.2 (9-C), 143.4 (8-C), 134.7 (1-C or 6-C), 134.1 (1-C or 
6-C), 124.8 (4-CH), 113.6 (5-CH), 109.8 (7-CH), 31.9 (2-CH2 or 3-CH2), 29.5 (2-CH2 or 3-CH2). 
νmax / cm-1 (compressed solid) 3406 (w), 3328 (w), 2847 (w), 1602 (m), 1578 (m), 1485 (s), 
1450 (m), 1324 (s), 1308 (m), 1294 (w), 1281 (m), 1218 (m), 1203 (m), 1164 (w), 1105 (w), 
1408 (w), 967 (w), 827 (s), 610 (s). 
ESI-LRMS for C18H19N2+ [M+H]+ calcd: 263.2, found: 263.2. 






Bromide E-45 (752 mg, 1.92 mmol), palladium(II) acetate (52 mg, 0.21 mmol), DPPF (169 mg, 
0.305 mmol) and sodium tert-butoxide (371 mg, 3.86 mmol) were added to a 50 mL reaction 
tube containing a stirrer bar. The tube was sealed with a septum crimp cap and the contents 
dried under high vacuum for 30 min. The tube was then purged with nitrogen and evacuated 
and backfilled with nitrogen a further three times. Anhydrous toluene (10 mL) was added and 
the solution degassed by bubbling nitrogen for five minutes. Benzophenone imine (0.81 mL, 
4.8 mmol) was added and the reaction mixture was then heated to 90 oC and stirred for 18 h, 
then cooled to r.t. and partitioned between DCM (50 mL) and H2O (50 mL). The aqueous layer 
was back-extracted with DCM (2 × 50 mL) and the combined organic phases dried (MgSO4) 
filtered and concentrated in vacuo. The residue was purified by flash silica chromatography, 
eluting with DCM to 10% MeOH in DCM (1% Et3N), to afford the imine intermediate (E-47) as 
an orange solid. This was immediately redissolved in THF (80 mL), 2 M aq. HCl (30 mL) was 
added and the reaction stirred at r.t. for 3 h. The mixture was then basified (pH ~ 8) by addition 
of a sat. aq. NaHCO3 solution (100 mL), then extracted with EtOAc (3 × 50 mL). The combined 
organic extractions were dried (MgSO4) and concentrated in vacuo. The residue was triturated 
in Et2O (20 mL) and the resultant solid filtered and air-dried to afford the title compound as a 
light-brown solid (287 mg, 57%). 
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1H NMR (500 MHz, DMSO-d6) δ 6.32 (2H, d, J = 8.3 Hz, 7-CH), 5.64 (2H, d, J = 2.2 Hz, 4-
CH), 5.59 (2H, dd, J = 8.3, 2.2 Hz, 6-CH), 4.23 (4H, s, NH2), 2.03 (8H, app. s, 2-CH2 and 3-
CH2) 
13C NMR (126 MHz, DMSO-d6) δ 147.4 (9-C or 5-C), 147.3 (9-C or 5-C), 131.8 (8-C), 129.9 
(1-C), 124.2 (7-CH), 112.6 (6-CH), 110.0 (4-CH), 31.2 (2-CH2), 30.4 (3-CH2) 
νmax / cm-1 (compressed solid) 3389 (m), 3192 (w), 2837 (w), 1602 (s), 1579 (w), 1488 (s), 
1455 (s), 1334 (m), 1302 (m), 1269 (w), 1259 (s), 1198 (m), 854 (m), 822 (m), 795 (m), 722 
(m), 733 (s), 707 (s), 698 (s), 575 (s). 





. 6 TFA 
 
Synthesised by R.L.S. Fisher, MSc student 
Prepared according to General Procedure A using bromide E-43 (50 mg, 0.13 mmol), 
BrettPhos Pd G3 (8.0 mg, 8.8 μmol), sodium tert-butoxide (50 mg, 0.51 mmol) and 2-(4-
methylpiperazin-1-yl)ethan-1-amine (37 μL, 0.26 mmol).  After lyophilisation following HPLC, 
the title compound was obtained as a brown solid (14 mg, 9%). 
1H NMR (500 MHz, D2O): δ 7.59 (2H, d, J = 2.0 Hz, 7-CH), 7.54 (2H, d, J = 8.1 Hz, 4-CH), 
7.27 (2H, dd, J = 8.1, 2.0 Hz, 5-CH), 3.67 (4H, t, J = 5.7 Hz, 10-CH2), 3.65 – 3.50 (4H, br, 13-
CH2), 3.34 – 3.26 (8H, br, 12-CH2 and 13-CH2), 3.19 (8H, app. s, 2-CH2 and 3-CH2), 2.94 (6H, 
s, 14-CH3), 2.92 (4H, t, J = 5.7 Hz, 11-CH2), 2.74 (4H, s, 12-CH2). 
13C NMR (126 MHz, D2O): δ 162.9 (q, J = 35.5 Hz, CF3CO), 147.9 (9-C), 143.9  (8-C), 136.2 
(1-C), 134.6 (6-C), 126.5 (4-CH), 119.8 (5-CH), 117.5 (7-CH), 116.3 (q, J = 291.8 Hz, CF3CO), 
52.7 (13-CH2), 51.6 (11-CH2), 49.2 (12-CH2), 46.6 (10-CH2), 42.7 (14-CH3), 31.6 (2-CH2), 30.1 
(3-CH2). 
νmax / cm-1 (compressed solid): 1670 (s), 1459 (m), 1411 (m), 1373 (w), 1317 (w), 1169 (s), 
1124 (s), 966 (s), 830 (s), 796 (s), 721 (s). 
ESI-HRMS: for C32H47N6+ [M+H]+ calcd: 515.3857, found: 515.3856. 
 




biindenylidene]-6,6'-diamine, (E)-41 = B 
 
. 6 TFA 
 
Prepared according to General Procedure A using bromide E-43 (49 mg, 0.13 mmol), 
BrettPhos Pd G3 (7.0 mg, 7.7 μmol), sodium tert-butoxide (49 mg, 0.51 mmol) and 3-(4-
methylpiperazin-1-yl)propan-1-amine (49 μL, 0.29 mmol).  After lyophilisation following HPLC, 
the title compound (as the trifluoroacetate salt) was obtained as a brown solid (73 mg, 47%). 
1H NMR (400 MHz, D2O) δ 7.67 (2H, d, J = 1.6 Hz, 7-CH), 7.56 (2H, d, J = 8.1 Hz, 4-CH), 7.33 
(2H, dd, J = 8.1, 1.6 Hz, 5-CH), 3.79 – 3.46 (16H, br, 13-CH2 and 14-CH2), 3.58 (4H, t, J = 7.7 
Hz, 10-CH2), 3.34 (4H, t, J = 8.0 Hz, 12-CH2), 3.20 (8H, app. s, 2-CH2 and 3-CH2), 3.02 (6H, 
s, 15-CH3), 2.30 – 2.20 (4H, m, 11-CH2). 
13C NMR (126 MHz, D2O) δ 162.9 (q, J = 35.5 Hz, CF3CO), 149.5 (9-C), 144.2 (8-C), 136.3 
(1-C), 133.2 (6-C), 126.7 (4-CH), 121.0 (5-CH), 118.0 (7-CH), 116.3 (q, J = 291.8 Hz, CF3CO), 
53.5 (12-CH2), 50.4 (14-CH2), 48.9 (13-CH2), 48.1 (10-CH2), 42.8 (15-CH3), 31.5 (2-CH2), 30.2 
(3-CH2), 20.6 (11-CH2). 
νmax / cm-1 1670 (s), 1460 (m) 1418 (m), 1176 (s), 1120 (s), 961 (m), 831 (s), 797 (s), 720 (s). 





. 6 TFA 
 
Prepared according to General Procedure A using bromide Z-43 (59 mg, 0.15 mmol), 
BrettPhos Pd G3 (6.0 mg, 6.6 μmol), sodium tert-butoxide (58 mg, 0.61 mmol) and 3-(4-
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methylpiperazin-1-yl)propan-1-amine (44 μL, 0.33 mmol).  After lyophilisation following HPLC, 
the title compound (as the trifluoroacetate salt) was obtained as a brown solid (35 mg, 19%). 
1H NMR (500 MHz, D2O) δ 7.95 (2H, s, 7-CH), 7.56 (2H, d, J = 8.0 Hz, 4-CH), 7.29 (2H, d, J 
= 8.0 Hz, 5-CH), 3.91 – 3.18 (16H, br, 13-CH2 and 14-CH2), 3.47 (4H, t, J = 7.9 Hz, 10-CH2), 
3.27 (4H, t, J = 8.1 Hz, 12-CH2), 3.07 – 3.01 (4H, m, 2-CH2 or 3-CH2), 3.00 (s, 6H, 15-CH3) 
2.93 – 2.87 (4H, m, 2-CH2 or 3-CH2), 2.14 – 2.04 (4H, m, 4H, 11-CH2).  
13C NMR (126 MHz, D2O) δ 162.9 (q, J = 35.4, CF3CO), 149.4 (9-C), 141.5 (8-C), 136.0 (1-C), 
133.8 (6-C), 127.2 (4-C), 120.5, (5-CH), 116.3 (q, J = 291.7 Hz, CF3CO), 115.6 (7-CH), 53.5 
(12-CH2), 50.8 (14-CH2), 48.9 (13-CH2), 47.2 (10-CH2), 42.7 (15-CH3), 34.6 (2-CH2 or 3-CH2), 
29.9 (2-CH2 or 3-CH2), 20.9 (11-CH2). 
νmax / cm-1 (compressed solid) 1669 (s), 1439 (m), 1179 (s), 1125 (s), 839 (s), 799 (s), 723 
(s). 





. 6 TFA 
 
Synthesised by R.L.S. Fisher, MSc student 
Prepared according to General Procedure A using bromide E-43 (50 mg, 0.13 mmol), 
BrettPhos Pd G3 (8.0 mg, 8.8 μmol), sodium tert-butoxide (50 mg, 0.51 mmol) and 4-(4-
methylpiperazin-1-yl)butan-1-amine (45 μL, 0.26 mmol).  After lyophilisation following HPLC, 
the title compound (as the trifluoroacetate salt) was obtained as a brown solid (51 mg, 31%). 
1H NMR (500 MHz, D2O): δ 7.66 (2H, d, J = 2.0 Hz, 7-CH), 7.55 (2H, d, J = 8.1 Hz, 4-CH), 
7.32 (2H, dd, J = 8.1, 2.0 Hz, 5-CH), 3.73 – 3.53 (16H, br, 14-CH2 and 15-CH2), 3.51 (4H, t, J 
= 7.3 Hz, 10-CH2), 3.25 (4H, t, J  = 8.2 Hz, 13-CH2), 3.20 (8H, app. s, 2-CH2 and 3-CH2), 3.00 
(6H, s, 16-CH3), 1.91 – 1.81 (8H, m, 11-CH2 and 12-CH2).  
13C NMR (126 MHz, D2O): δ 162.9 (q, J = 35.5 Hz, CF3CO), 149.3 (9-C), 144.1 (8-C), 136.3 
(1-C), 133.4 (6-C), 126.6 (4-CH), 121.1 (5-CH), 118.1 (7-CH), 116.3 (q, J = 291.8 Hz, CF3CO), 
56.0 (13-CH2), 50.8 (10-CH2), 50.4 (15-CH2), 48.7 (14-CH2), 42.8 (16-CH3), 31.5 (2-CH2), 30.2 
(3-CH2), 22.4 (11-CH2 or 12-CH2),  20.8 (11-CH2 or 12-CH2). 
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νmax / cm-1 (compressed solid): 1670 (s), 1594 (w), 1483 (m), 1451 (m), 1415 (s), 1192 (s), 
1176 (s), 1114, (s), 1019 (m), 958 (s), 831 (s), 796 (s), 719 (s). 





. 4 TFA 
 
Prepared according to General Procedure B using bis-aniline (E)-14 (30 mg, 0.12 mmol), 
triphosgene (22 mg, 74 μmol), triethylamine (45 μL, 0.33 mmol) and 3-(4-methylpiperazin-1-
yl)propan-1-amine (41 μL, 0.24 mol). After lyophilisation following HPLC, the title compound 
(as the trifluoroacetate salt) was obtained as a brown solid (51 mg, 43%). 
1H NMR (500 MHz, D2O) δ 7.62 (2H, d, J = 1.9 Hz, 7-CH), 7.33 (2H, d, J = 8.1 Hz, 4-CH), 7.09 
(2H, dd, J = 8.1, 1.9 Hz, 5-CH), 3.69 (16H, br, 14-CH2 and 15-CH2), 3.37 – 3.34 (4H, m, 13-
CH2), 3.33 (4H, t, J = 5.8 Hz, 11-CH2) 3.13 – 3.05 (8H, br, 2-CH2 and 3-CH2), 3.04 (6H, s, 16-
CH3), 2.05 – 1.98 (4H, m, 12-CH2). 
13C NMR (126 MHz, D2O) δ 163.0 (q, J = 35.4 Hz, CF3CO), 158.5 (10-CO), 143.4 (8-C), 143.0 
(9-C), 136.4 (6-C), 135.7 (1-C), 125.3 (4-CH), 120.7 (5-CH), 117.4 (7-CH), 116.3 (q, J = 291.7 
Hz, CF3CO), 54.5 (13-CH2), 50.2 (15-CH2), 48.7 (14-CH2), 42.8 (16-CH3), 36.4 (11-CH2), 31.6 
(2-CH2), 29.9 (3-CH2), 24.4 (12-CH2). 
νmax / cm-1 (compressed solid) 3023 (w), 2931 (w), 2887 (w), 2842 (w), 1668 (s), 1647 (s), 
1556 (m), 1483 (m), 1434 (m), 1416 (m), 1281 (m), 1241 (m), 1171 (s), 1119 (s), 1017 (m), 
961 (m), 829 (s), 797 (s), 720 (s).  










































. 4 TFA 
 
Prepared according to General Procedure B using bis-aniline E-49 (30 mg, 0.12 mmol), 
triphosgene (23 mg, 78 μmol), triethylamine (45 μL, 0.33 mmol) and 3-(4-methylpiperazin-1-
yl)propan-1-amine (40 μL, 0.24 mmol). After lyophilisation following HPLC, the title compound 
was obtained (as the trifluoroacetate salt) as a brown solid (40 mg, 30%). 
1H NMR (500 MHz, D2O) δ 7.54 (2H, d, J = 8.5 Hz, 7-CH), 7.29 (2H, d, J = 2.1 Hz, 4-CH), 7.16 
(2H, dd, J = 8.5, 2.1 Hz, 6-CH), 3.57 – 3.33 (16H, br, 14-CH2 and 15-CH2), 3.29 (4H, t, J = 6.6 
Hz, 11-CH2), 3.12 (4H, t, J = 7.8 Hz, 13-CH2), 3.05 (8H, br, 2-CH2 and 3-CH2), 2.92 (6H, s, 16-
CH3), 1.97 – 1.90 (4H, m, 12-CH2). 
13C NMR (126 MHz, D2O) δ 163.0 (q, J = 35.3 Hz, CF3CO), 158.0 (10-CO), 148.7 (9-C), 138.0 
(8-C), 137.2 (5-C), 133.8 (1-C), 124.7 (7-CH), 118.8 (6-CH), 116.9 (4-CH), 116.3 (q, J = 291.8 
Hz, CF3CO), 54.4 (13-CH2), 51.0 (15-CH2), 49.1 (14-CH2), 42.9 (16-CH3), 36.7 (11-CH2), 31.2 
(2-CH2), 30.4 (3-CH2), 24.8 (11-CH2). 
νmax / cm-1 (compressed solid) 3308 (w), 3019 (w), 2928 (w), 1668 (s), 1636 (s), 1586 (s), 
1565 (s), 1488 (m), 1428 (m), 1276 (m), 1238 (m), 1171 (s), 1123 (s), 1019 (m), 962 (m), 830 
(s), 796 (s), 720 (s).  










. 4 TFA 
 
Prepared according to General Procedure B using bis-aniline E-49 (30 mg, 0.11 mmol), 
triphosgene (23 mg, 78 μmol), triethylamine (45 μL, 0.33 mmol) and 4-(4-methylpiperazin-1-
yl)butan-1-amine (43 μL, 0.24 mmol). After lyophilisation following HPLC, the title compound 
was obtained (as the trifluoroacetate salt) as a brown solid (61 mg, 46%). 
1H NMR (500 MHz, D2O) δ 7.43 (2H, d, J = 8.6 Hz, 7-CH), 7.23 (2H, d, J = 2.1 Hz, 4-CH), 7.10 
(2H, dd, J = 8.6, 2.1 Hz, 6-CH), 3.42 – 3.25 (16H, br, 15-CH2 and 16-CH2), 3.19 (4H, t, J = 6.9 
Hz, 11-CH2), 3.04 – 2.99 (8H, m, 3-CH2 and 14-CH2), 2.92 (4H, br, 2-CH2), 2.83 (6H, s, 17-
CH3), 1.74 – 1.67 (4H, m, 12-CH2 or 13-CH2), 1.58 (4H, app. p, J = 7.2 Hz, 12-CH2 or 13-CH2). 
13C NMR (126 MHz, D2O) δ 163.0 (q, J = 35.5 Hz, CF3CO), 157.8 (10-CO), 148.5 (9-C), 137.8 
(8-C), 137.3 (5-C), 133.6 (1-C), 124.6 (7-CH), 118.4 (6-CH), 116.4 (4-CH), 116.3 (q, J = 291.7 
Hz, CF3CO), 56.4 (14-CH2), 51.1 (16-CH2), 49.4 (15-CH2), 43.0 (17-CH3), 38.9 (11-CH2), 31.1 
(2-CH2), 30.4 (3-CH2), 26.6 (12-CH2 or 13-CH2), 21.4 (12-CH2 or 13-CH2). 
νmax / cm-1 (compressed solid) 3321 (w), 3028 (w), 2933 (w), 2867 (w), 1670 (s), 1632 (s), 
1581 (s), 1562 (s), 1487 (m), 1426 (m), 1268 (m), 1229 (m), 1175 (s), 1119 (s), 859 (m), 830 
(s), 797 (s), 719 (s). 





. 4 TFA 
 
Prepared according to General Procedure A using bromide E-43 (51 mg, 0.13 mmol), 
BrettPhos Pd G3 (7.6 mg, 8.4 μmol), sodium tert-butoxide (49 mg, 0.51 mmol) and 3-
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morpholinopropan-1-amine (42 μL, 0.29 mmol).  After lyophilisation following HPLC, the title 
compound (as the trifluoroacetate salt) was obtained as an off-white solid (53 mg, 42%). 
1H NMR (500 MHz, D2O) δ 7.64 (2H, d, J = 1.9 Hz, 7-CH), 7.55 (2H, d, J = 8.1 Hz, 4-CH), 7.31 
(2H, dd, J = 8.1, 1.9 Hz, 5-CH), 4.19 – 4.07 (4H, br, 13-CH2 or 14-CH2), 3.90 – 3.78 (4H, br, 
13-CH2 or 14-CH2), 3.57 (4H, t, J = 7.8 Hz, 10-CH2), 3.57 – 3.47 (4H, br, 13-CH2 or 14-CH2), 
3.30 (4H, t, J = 8.4 Hz, 12-CH2), 3.24 – 3.18 (12H, br, 2-CH2, 3-CH2 and 13-CH2 or 14-CH2), 
2.27 – 2.20 (4H, m, 11-CH2). 
13C NMR (126 MHz, D2O) δ 162.9 (q, J = 35.7 Hz, CF3CO), 148.7 (9-C), 144.1 (8-C), 136.3 
(1-C), 134.1 (6-C), 126.7 (4-CH), 120.7 (5-CH), 117.5 (7-CH), 116.3 (q, J = 291.8 Hz, CF3CO), 
63.7 (14-CH2), 53.8 (12-CH2), 51.8 (13-CH2), 47.6 (10-CH2), 31.5 (2-CH2), 30.2 (3-CH2), 20.2 
(11-CH2). 
νmax / cm-1 (compressed solid) 3017 (w), 2928 (w), 2869 (w), 2736 (w), 2641 (w), 2455 (w), 
1664 (s),  1481 (m), 1461 (m), 1421 (m), 1195 (s), 1175 (s), 1117 (s), 831 (s), 797 (s), 720 (s). 





. 4 TFA 
 
Prepared according to General Procedure A using bromide E-43 (49 mg, 0.13 mmol), 
BrettPhos Pd G3 (6.4 mg, 7.1 μmol), sodium tert-butoxide (49 mg, 0.51 mmol) and 4-
morpholinobutan-1-amine (47 μL, 0.29 mmol).  After lyophilisation following HPLC, the title 
compound (as the trifluoroacetate salt) was obtained as an off-white solid (69 mg, 55%). 
1H NMR (500 MHz, D2O) δ 7.67 (2H, d, J = 2.1 Hz, 7-CH), 7.57 (2H, d, J = 8.1 Hz, 4-CH), 7.34 
(2H, dd, J = 8.1, 2.1 Hz, 5-CH), 4.14 (4H, d, J = 13.2 Hz, 14-CH2 or 15-CH2), 3.80 (4H, t, J = 
12.8 Hz, 14-CH2 or 15-CH2), 3.57 – 3.49 (8H, m, 10-CH2 and 14-CH2 or 15-CH2), 3.26 – 3.15 
(8H, m, 13-CH2 and 14-CH2 or 15-CH2), 3.22 (8H, app. s, 2-CH2 and 3-CH2), 1.90 – 1.80 (8H, 
m, 11-CH2 and 12-CH2). 
13C NMR (126 MHz, D2O) δ 162.9 (q, J = 35.5 Hz, CF3CO), 149.3 (9-C), 144.0 (8-C), 136.3 
(1-C), 133.4 (6-C), 126.7 (4-CH), 121.2 (5-CH), 118.1 (7-CH), 116.3 (q, J = 291.8 Hz, CF3CO), 
63.7 (15-CH2), 56.2 (13-CH2), 51.6 (14-CH2), 50.7 (10-CH2), 31.5 (2-CH2), 30.2 (3-CH2), 22.3 
(11-CH2 or 12-CH2), 20.3 (11-CH2 or 12-CH2). 
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νmax / cm-1 (compressed solid) 2928 (w), 2715 (w), 2638 (w), 2526 (w), 1671 (s), 1485 (m), 
1455 (m), 1415 (m), 1198 (s), 1161 (s), 1128 (s), 1110 (s), 973 (m), 831 (s), 797 (s), 720 (s). 





. 2 TFA 
 
Prepared according to General Procedure B using bis-aniline E-48 (29 mg, 0.11 mmol), 
triphosgene (22 mg, 74 μmol), triethylamine (45 μL, 0.33 mmol) and 2-morpholinoethan-1-
amine (32 μL, 0.24 mmol). After lyophilisation following HPLC, the title compound was 
obtained (as the trifluoroacetate salt) as a brown solid (34 mg, 39%). 
1H NMR (500 MHz, D2O) δ 7.51 (2H, d, J = 2.0 Hz, 7-CH), 7.23 (2H, d, J = 8.0 Hz, 4-CH), 7.00 
(2H, dd, J = 8.0, 2.0 Hz, 5-CH), 4.14 (4H, app. d, J = 13.4 Hz, 13-CH2 or 14-CH2), 3.83 (4H, 
app. t, J = 12.6 Hz, 13-CH2 or 14-CH2), 3.65 – 3.62 (4H, br, 13-CH2 or 14-CH2), 3.61 (4H, t, J 
= 6.0 Hz, 11-CH2), 3.35 (4H, t, J = 6.0 Hz, 12-CH2), 3.25 (4H, app. t, J = 11.7 Hz, 13-CH2 or 
14-CH2), 3.07 – 2.81 (8H, br, 2-CH2 and 3-CH2). 
13C NMR (126 MHz, D2O) δ 162.9 (q, J = 35.4 Hz, CF3CO), 158.2 (10-CO), 143.03 (8-C), 
143.02 (9-C), 136.2 (6-C), 135.6 (1-C), 125.0 (4-CH), 119.8 (5-CH), 116.3 (q, J = 291.8 Hz, 
CF3CO), 116.9 (7-CH), 63.8 (14-CH2), 57.5 (12-CH2), 52.0 (13-CH2), 34.3 (11-CH2), 31.5 (2-
CH2), 29.8 (3-CH2). 
νmax / cm-1 (compressed solid) 3274 (w), 3056 (w), 2931 (w), 2878 (w), 1667 (s), 1590 (m), 
1552 (m), 1484 (m), 1422 (m), 1199 (s), 1176(s), 1125 (s), 1049 (m), 1017 (m(, 832 (s), 799 
(s), 721 (s). 













. 2 TFA 
 
Prepared according to General Procedure B using bis-aniline E-48 (29 mg, 0.11 mmol), 
triphosgene (22 mg, 74 μmol), triethylamine (45 μL, 0.33 mmol) and 3-morpholinopropan-1-
amine (35 μL, 0.24 mmol). After lyophilisation following HPLC, the title compound was 
obtained as a brown solid (38 mg, 42%). 
1H NMR (500 MHz, D2O) δ 7.49 (2H, s, 7-CH), 7.21 (2H, d, J = 8.0, 4-CH), 6.97 (2H, d, J = 
8.0 Hz, 5-CH), 4.13 (4H, dd, J = 13.5, 3.5 Hz, 14-CH2 or 15-CH2), 3.81 (4H, ddd, J = 13.5, 
11.9, 2.1 Hz, 14-CH2 or 15-CH2), 3.43 (4H, d, J = 12.7 Hz, 14-CH2 or 15-CH2), 3.30 (4H, t, J = 
6.5 Hz, 11-CH2), 3.24 – 3.20 (4H, m, 13-CH2), 3.17 (4H, td, J = 12.7, 3.7 Hz,14-CH2 or 15-
CH2), 2.93 – 2.83 (8H, br, 2-CH2 and 3-CH2), 2.08 – 1.84 (4H, m, 12-CH2) 
13C NMR  (126 MHz, D2O): 162.9 (q, J = 35.6 Hz, CF3CO), 158.2 (10-C), 143.0 (8-C), 142.8 
(9-C), 136.4 (6-C), 135.5 (1-C), 125.1 (4-CH), 119.7 (5-CH), 116.7 (7-CH), 116.3 (q, J = 291.7 
Hz, CF3CO), 63.8 (15-CH2), 54.7 (13-CH2), 51.6 (14-CH2), 36.4 (11-CH2), 31.5 (2-CH2), 29.8 
(3-CH2), 24.0 (12-CH2). 
νmax / cm-1 (compressed solid) 3313 (w), 3009 (w), 2931 (w), 2866 (w), 2632 (w), 2492 (w), 
1664 (s), 1591 (m), 1546 (m), 1482 (m), 1420 (m), 1197 (s), 1124 (s), 907 (m), 875 (m), 831 
(s), 798 (s), 720 (s). 





. 2 TFA 
 
Prepared according to General Procedure B using bis-aniline E-48 (30 mg, 0.11 mmol), 
triphosgene (23 mg, 78 μmol), triethylamine (45 μL, 0.33 mmol) and 4-morpholinobutan-1-
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amine (39 μL, 0.24 mmol). After lyophilisation following HPLC, the title compound was 
obtained as a brown solid (33 mg, 35%). 
1H NMR (500 MHz, D2O) δ 7.39 (2H, d, J = 1.7 Hz, 7-CH), 7.04 (2H, d, J = 8.2 Hz, 4-CH), 6.92 
(2H, dd, J = 8.2, 1.7 Hz, 5-CH), 4.02 (4H, dd, J = 13.1, 3.4 Hz, 15-CH2 or 16-CH2), 3.74 (4H, 
ddd, J = 13.7, 11.9, 2.1 Hz, 15-CH2 or 16-CH2), 3.56 – 3.32 (4H, m, 15-CH2 or 16-CH2), 3.14 
(4H, t, J = 7.0 Hz, 11-CH2), 3.12 – 2.84 (8H, m, 15-CH2 or 16-CH2 and 14-CH2), 2.77 – 2.66 
(8H, br, 2-CH2 and 3-CH2), 1.86 – 1.59 (4H, m, 12-CH2 or 13-CH2), 1.48 (4H, app. p, J = 7.2 
Hz, 12-CH2 or 13-CH2). 
13C NMR (126 MHz, D2O) δ 162.8 (q, J = 35.5 Hz, CF3CO), 157.8 (10-CO), 143.1 (8-C), 142.2 
(9-C), 136.8 (6-C), 135.4 (1-C), 124.9 (4-CH), 119.3 (5-CH), 116.3 (q, J = 291.9 Hz, CF3CO), 
116.2 (7-CH), 63.7 (16-CH2), 56.7 (14-CH2), 51.4 (15-CH2), 38.8 (11-CH2), 31.4 (2-CH2), 29.8 
(3-CH2), 26.4 (12-CH2 or 13-CH2), 20.5 (12-CH2 or 13-CH2). 
νmax / cm-1 (compressed solid) 3310 (w), 3013 (w), 2928 (w), 2972 (w), 2644 (w), 2491 (w), 
1667 (s), 1634 (s), 1587 (s), 1554 (s), 1482 (m), 1422 (m), 1449 (m), 1196 (s), 1176 (s), 1126 
(s), 1053 (m), 1019 (m), 833 (s), 799 (s), 720 (s). 





. 6 TFA 
 
Prepared according to General Procedure A using bromide E-45 (51 mg, 0.13 mmol), 
BrettPhos Pd G3 (7.3 mg, 8.1 μmol), sodium tert-butoxide (53 mg, 0.55 mmol) and 2-(4-
methylpiperazin-1-yl)ethan-1-amine (44 μL, 0.29 mmol).  After lyophilisation following HPLC, 
the title compound (as the trifluoroacetate salt) was obtained as a brown solid (75 mg, 48%). 
1H NMR (400 MHz, D2O) δ 7.71 (2H, d, J = 8.5 Hz, 7-CH), 7.28 – 7.16 (2H, s, 4-CH), 7.10 (2H, 
d, J = 8.5 Hz, 6-CH), 3.78 – 3.21 (16H, br, 12-CH2 and 13-CH2), 3.65 (4H, t, J = 6.1 Hz, 10-
CH2), 3.16 (8H, app. s, 2-CH2 and 3-CH2), 3.12 (4H, t, J = 6.1 Hz, 11-CH2), 2.97 (6H, s, 14-
CH3). 
13C NMR (126 MHz, D2O) δ 162.9 (q, J = 36.0 Hz, CF3CO), 149.9 (9-C), 139.3 (8-C), 138.6 
(5-C), 134.3 (1-C), 125.5 (7-CH), 117.3 (6-CH), 116.3 (q, J = 291.6 Hz, CF3CO), 115.1 (4-CH), 
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52.8 (11-CH), 51.9 (13-CH2), 49.0 (12-CH2), 43.5 (10-CH2), 42.7 (14-CH3), 31.4 (2-CH2), 30.4 
(3-CH2). 
νmax / cm-1 (compressed solid) 3559 (w), 3013 (w), 2924 (w), 2846 (w), 1665 (s), 1608 (m), 
1461 (m), 1411 (m), 1168 (s), 1120 (s), 1021 (m), 966 (m), 830 (s), 795 (s), 720 (s). 





. 6 TFA 
 
Prepared according to General Procedure A using bromide E-45 (49 mg, 0.13 mmol), 
BrettPhos Pd G3 (7.2 mg, 7.9 μmol), sodium tert-butoxide (49 mg, 0.51 mmol) and 3-(4-
methylpiperazin-1-yl)propan-1-amine (49 μL, 0.29 mmol).  After lyophilisation following HPLC, 
the title compound (as the trifluoroacetate salt) was obtained as a brown solid (73 mg, 47%). 
1H NMR (400 MHz, D2O) δ 7.63 (2H, d, J = 8.5 Hz, 7-CH), 7.19 (2H, s, 4-CH), 7.09 (2H, br, 6-
CH), 3.60 – 3.32 (16H, m, 13-CH2 and 14-CH2), 3.36 (4H, t, J = 8.3 Hz, 10-CH2), 3.19 – 3.11 
(4H, br, 12-CH2), 3.04 (8H, app. s, 2-CH2 and 3-CH2), 2.87 (6H, s, 15-CH3), 2.09 – 1.98 (4H, 
m, 11-CH2). 
13C NMR (126 MHz, D2O) δ 162.9 (q, J = 35.5 Hz, CF3CO), 150.2 (9-C), 141.8 (8-C), 135.9 
(5-C), 135.3 (1-C), 125.8 (7-CH), 119.0 (6-CH), 117.2 (4-CH), 116.3 (q, J = 291.7 Hz, CF3CO), 
53.7 (12-CH2), 50.5 (14-CH2), 48.9 (13CH2), 46.6 (10-CH2), 42.7 (15-CH3), 31.4 (2-CH2), 30.4 
(3-CH2), 21.1 (11-CH2) 
νmax / cm-1 (compressed solid) 3024 (w), 2939 (w) 2846 (w), 1662 (s), 1489 (m), 1417 (m), 
1278 (m), 1174 (s), 1116 (s), 963 (s), 830 (s), 796 (s), 719 (s).  











. 6 TFA 
 
Prepared according to General Procedure A using bromide (E)-11 (51 mg, 0.13 mmol), 
BrettPhos Pd G3 (7.2 mg, 7.9 μmol), sodium tert-butoxide (58 mg, 0.60 mmol) and 4-(4-
methylpiperazin-1-yl)butan-1-amine (53 μL, 0.29 mmol).  After lyophilisation following HPLC, 
the title compound (as the trifluoroacetate salt) was obtained as a brown solid (79 mg, 48%). 
1H NMR (500 MHz, D2O) δ 7.81 (2H, d, J = 8.5 Hz, 7-CH), 7.41 (2H, s, 4-CH), 7.31 (2H, d, J 
= 8.5 Hz, 6-CH), 3.81 – 3.52 (16H, br, 14-CH2 and 15-CH2), 3.48 (4H, t, J = 7.5 Hz, 10-CH2), 
3.28 (4H, t, J = 7.8 Hz, 13-CH2), 3.24 – 3.18 (8H, m, 2-CH2 and 3-CH2), 3.02 (6H, s, 16-CH3), 
1.95 – 1.78 (8H, m, 11-CH2 and 12-CH2). 
13C NMR (126 MHz, D2O) δ 162.9 (q, J = 35.5 Hz, CF3CO), 150.2 (9-C), 142.8 (8-C), 135.6 
(5-C), 134.6 (1-C), 125.8 (7-CH), 119.9 (6-CH), 118.3 (4-CH), 116.3 (q, J = 291.8 Hz, CF3CO2), 
56.0 (12-CH2), 50.3 (15-CH2), 50.0 (10-CH2), 48.7 (14-CH2), 42.8 (16-CH3), 31.4 (2-CH2), 30.4 
(3-CH2), 22.5 (11-CH2 or 12-CH2), 20.8 (11-CH2 or 12-CH2). 
νmax / cm-1 (compressed solid) 3407 (w), 3015 (w), 2447 (m), 1667 (s), 1458 (m), 1415 (m), 
1171 (s), 1120 (s), 1018 (m), 962 (m), 830 (s), 796 (s), 720 (s). 




















Bromide E-43 (245 mg, 0.628 mmol) and 4-pyridinylboronic acid (232 mg, 1.88 mmol) were 
suspended in toluene (22.5 mL) and EtOH (2.5 mL) and 2M aq. Na2CO3 (5 mL) was added. 
The solution was degassed by bubbling nitrogen for 30 min. Pd(PPh3)4 (144 mg, 0.123 mmol) 
was added in one portion and the mixture degassed for a further 10 min. The reaction was 
heated to 100 °C and stirred for 16 h. The mixture was then cooled to r.t., diluted with DCM 
(150 mL) and washed with H2O (100 mL). The aqueous was back extracted with DCM (50 mL) 
and the combined organic extractions dried (MgSO4) and filtered. The filtrate was 
concentrated in vacuo and the residue purified by flash silica chromatography, eluting with 0 
– 5% MeOH in DCM, to afford a white solid. This was triturated in Et2O (30 mL) and the 
remaining insoluble solid filtered and air-dried to afford the title compound as an off-white 
powder (128 mg, 53%). 
1H NMR (500 MHz, CDCl3) δ 8.68 (4H, d, J = 6.2 Hz, 12-CH), 7.86 (2H, s, 7-CH), 7.56 (4H, d, 
J = 6.2 Hz, 11-CH), 7.50 (2H, d, J = 7.8 Hz, 5-CH), 7.46 (2H, d, J = 7.8 Hz, 4-CH), 3.34 – 3.29 
(4H, br, 2-CH2), 3.24 – 3.20 (4H, br, 3-CH2). 
13C NMR (126 MHz, CDCl3) δ 150.4 (12-CH), 149.1 (10-C), 148.5 (9-C), 144.2 (8-C), 136.9 
(6-C), 135.9 (1-C), 126.3 (5-CH), 125.8 (4-CH), 123.2 (7-CH), 121.9 (11-CH), 32.4 (2-CH2), 
31.1 (3-CH2).  
νmax / cm-1 (compressed solid) 3025 (w) 2942 (w), 2929 (w), 2911 (w), 2845 (w), 1593 (s), 
1542 (m), 1474 (s), 1453 (w) 1434 (w), 1422 (w), 1440 (m), 1270 (m), 1069 (m) 992 (m), 887 
(w), 839 (m), 812 (s), 800 (s), 729 (m), 607 (m), 535 (s).  
















Bromide Z-43 (501 mg, 1.28 mmol) and 4-pyridinylboronic acid (495 mg, 4.02 mmol) were 
dissolved in toluene (22.5 mL) and EtOH (2.5 mL) and 2M aq. Na2CO3 (5 mL) was added. The 
solution was degassed by bubbling a stream of nitrogen for 30 min. Pd(PPh3)4 (147 mg, 0.127 
mmol) was added in one portion and the mixture degassed for a further 10 min. The reaction 
was heated to 100 °C and stirred for 16 h. The mixture was then cooled to r.t., diluted with 
DCM (150 mL) and washed with H2O (100 mL). The aqueous was back extracted with DCM 
(50 mL) and the combined organic extractions dried (MgSO4) and filtered. The filtrate was 
concentrated in vacuo and the residue purified by flash silica chromatography, eluting with 0 
– 5% MeOH in DCM, to afford a white solid. This was triturated in Et2O (30 mL) and the 
remaining insoluble solid filtered and air-dried to afford the title compound as an off-white 
powder (257 mg, 52%). 
1H NMR (500 MHz, CDCl3) δ 8.45 (4H, dd, J = 4.5, 1.8 Hz, 12-CH), 8.39 (2H, app. s, 7-CH), 
7.44 (2H, dd, J = 7.8, 1.6 Hz, 5-CH), 7.41 (2H, d, J = 7.8 Hz, 4-CH), 7.29 (4H, dd, 4.5, 1.8 Hz, 
11-CH), 3.09 – 3.05 (4H, m, 3-CH2), 2.92 – 2.89 (4H, m, 2-CH2). 
13C NMR (126 MHz, CDCl3) δ 150.3 (12-CH), 149.6 (9-C), 148.7 (10-C), 141.5 (8-C), 136.0 
(6-C), 135.4 (1-C), 126.4 (5-CH), 126.2 (4-CH), 122.1 (7-CH), 121.6 (11-CH), 34.9 (2-CH), 
30.6 (3-CH). 
νmax / cm-1 (compressed solid) 3066 (w), 3027 (w), 2939 (w), 2905 (w), 2840 (w), 1596 (s), 
1543 (m), 1472 (m), 1446 (w), 1422 (w), 1406 (w), 1268 (w), 1220 (w), 992 (w), 809 (s), 730 
(m), 613 (w), 606 (w), 533 (w). 

















Pyridine E-58 (20 mg, 0.052 mmol), was dissolved in anhydrous DMF (2 mL) and methyl iodide 
(60 μL, 0.96 mmol) was added. The reaction was heated to 90 °C and stirred for 16 h. The 
mixture was then cooled to r.t. and concentrated in vacuo. The residue was washed with 
acetone (5 mL), filtered and the dark solid dried to afford the title compound (14 mg, 41%).  
1H NMR (500 MHz, DMSO-d6) δ 9.00 (4H, d, J = 6.9 Hz, 12-CH), 8.56 (4H, d, J = 6.9 Hz, 11-
CH), 8.11 (2H, d, J = 1.6 Hz, 7-CH), 7.95 (2H, dd, J = 7.9, 1.6 Hz, 5-CH), 7.66 (2H, d, J = 7.9 
Hz, 4-CH), 4.36 (6H, s, 13-CH3), 3.40 – 3.36 (4H, m, 2-CH2), 3.25 – 3.22 (4H, m, 3-CH2). 
13C NMR (126 MHz, DMSO-d6) δ 154.8 (10-C), 151.6 (9-C), 145.5 (12-CH), 143.8 (8-C), 135.7 
(1-C), 132.4 (6-CH2), 127.6 (5-CH), 126.4 (4-CH), 124.3 (11-CH), 123.6 (7-CH), 47.1 (13-
CH3), 31.4 (2-CH2), 30.7 (3-CH2). 
νmax / cm-1 (compressed solid) 3121 (w), 3088 (w), 3038 (w), 2930 (w), 2910 (w), 2844 (w), 
1636 (s), 1601 (s), 1558 (m), 1522 (m), 1472 (s), 1439 (m), 1414 (m), 1348 (w), 1312 (m) 1298 
(m), 1289 (m), 1272 (m), 1223 (w), 1198 (s), 856 (w), 820 (s), 800 (m), 723 (m), 607 (m), 587 
(m), 534 (m), 510 (s), 426 (s). 







Pyridine Z-58 (20 mg, 0.052 mmol), was dissolved in anhydrous DMF (2 mL) and methyl iodide 
(60 μL, 0.96 mmol) was added. The reaction was heated to 90 °C and stirred for 1 h. The 
mixture was then cooled to r.t. and concentrated in vacuo. The residue was washed with 
acetone (5 mL), filtered and the dark solid dried to afford the title compound (22 mg, 65%) 
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1H NMR (500 MHz, DMSO-d6) δ 8.82 (4H, d, J = 6.5 Hz, 12-CH), 8.64 (2H, d, J = 1.9 Hz, 7-
CH), 8.31 (4H, d, J = 6.5 Hz, 11-CH), 7.97 (2H, dd, J = 7.9, 1.9 Hz, 5-CH), 7.66 (2H, d, J = 7.9 
Hz, 4-CH), 4.28 (6H, s, 13-CH3), 3.13 – 3.08 (4H, m, 3-CH2), 2.95 – 2.92 (4H, m, 2-CH2). 
13C NMR (126 MHz, DMSO-d6) δ 154.3 (10-C), 153.0 (9-C), 145.4 (12-CH), 141.1 (8-C), 135.5 
(1-C), 131.4 (6-C), 127.8 (5-CH), 126.9 (4-CH), 123.5 (11-CH), 121.9 (7-CH), 47.0 (13-CH3), 
34.5 (2-CH2), 30.1 (3-CH2). 
νmax / cm-1 (compressed solid) 3015 (w), 2929 (w), 1639 (s), 1594 (m), 1558 (m), 1522 (m), 
1473 (m), 1443 (m), 1425 (m), 1321 (m), 1279 (m), 1203 (m), 1194 (m), 819 (S), 722 (w), 599 
(m), 508 (s), 425 (s). 






Bromide E-45 (250 mg, 0.641 mmol) and 4-pyridinylboronic acid (236 mg, 1.92 mmol) were 
dissolved in toluene (23 mL) and EtOH (2.5 mL) and 2M aq. Na2CO3 (5 mL) were added. The 
solution was degassed by bubbling nitrogen for 30 min. Pd(PPh3)4 (74 mg, 0.064 mmol) was 
added in one portion and the mixture degassed for a further 10 min. The reaction was heated 
to 100 °C and stirred for 16 h. The mixture was then cooled to r.t., diluted with DCM (150 mL) 
and washed with H2O (100 mL). The aqueous was back extracted with DCM (50 mL) and the 
combined organic extractions dried (MgSO4) and filtered. The filtrate was concentrated in 
vacuo and the residue purified by flash silica chromatography, eluting with 0 – 5% MeOH in 
DCM, to afford the title compound a yellow solid (190 mg, 76%). 
1H NMR (400 MHz, CDCl3) δ 8.66 (4H, d, J = 6.2 Hz, 12-CH), 7.72 (2H, d, J = 8.2 Hz, 7-CH), 
7.62 (2H, d, J = 1.7 Hz, 4-CH), 7.56 (2H, dd, J = 8.2, 1.7 Hz, 6-CH), 7.54 (4H, d, J = 6.2 Hz, 
11-CH), 3.24 (8H, app. s, 2-CH2 and 3-CH2). 
13C NMR (101 MHz, CDCl3) δ 150.4 (12-CH), 148.5 (9-C), 148.2 (10-C), 144.2 (8-C), 136.9 
(5-C), 136.2 (1-C), 125.6 (6-CH), 125.2 (7-CH), 123.6 (4-CH), 121.6 (11-CH), 32.2 (2-CH2), 
31.2 (3-CH2). 
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νmax / cm-1 (compressed solid) 3485 (w), 3027 (w), 2920 (w), 2844 (w), 1594 (s), 1539 (m), 
1476 (m), 1428 (w), 1407 (m), 1308 (w), 1298 (w), 1258 (w), 1221 (w), 997 (w), 888 (w), 809 
(s), 731 (m), 719 (m), 613 (w), 527 (w). 







Pyridine E-59 (50 mg, 0.13 mmol) was dissolved in anhydrous DMF (2 mL) and the solution 
heated to 90 °C. Methyl iodide (24 μL, 0.34 mmol) was added and the reaction stirred for 1 h. 
The mixture was then cooled to r.t. and concentrated in vacuo. The residue was suspended 
in 1:1 H2O/MeCN (5 mL) and the precipitate filtered and dried under vacuum to afford the title 
compound as a bright orange powder (47 mg, 55%).  
1H NMR (500 MHz, DMSO-d6) δ 8.99 (4H, d, J = 6.4 Hz, 12-CH), 8.54 (4H, d, J = 6.4 Hz, 11-
CH), 8.15 (2H, s, 4-CH), 8.05 (2H, d, J = 8.5 Hz, 6-CH), 7.87 (2H, d, J = 8.5 Hz, 7-CH), 4.32 
(6H, s, 15-CH3) 3.33 (4H, s, 2-CH2), 3.27 (4H, s, 3-CH2). 
13C NMR (126 MHz, DMSO-d6) δ 154.1 (10-C), 149.4 (9-C), 146.4 (8-C), 145.9 (12-CH), 137.9 
(1-C), 132.7 (5-C), 127.3 (6-CH), 125.9 (7-CH), 125.0 (4-CH), 124.1 (11-CH), 47.4 (13-CH3), 
32.1 (2-CH2), 30.9 (3-CH2). 
νmax / cm-1 (compressed solid) 3020 (w), 2921 (w), 2882 (w), 1637 (s), 1600 (s), 1574 (m), 
1556 (m), 1525 (s), 1485 (s), 1473 (m), 1448 (m), 1422 (m), 1352 (m), 1316 (m), 1306 (m), 
1285 (m), 1239 (m), 1191 (s), 1161 (m), 1122 (m), 1053 (m), 822 (m), 849 (m), 829 (s), 795 
(s), 714 (m), 666 (m), 508 (s). 













6-Bromo-1-indanone (249 mg, 1.18 mmol) and 4-pyridinylboronic acid (256 mg, 2.08 mmol) 
were dissolved in toluene (45 mL) and EtOH (5 mL) and 2M aq. Na2CO3 (10 mL) were added. 
The solution was degassed by bubbling nitrogen for 30 min. Pd(PPh3)4 (137 mg, 0.119 mmol) 
was added in one portion and the mixture degassed for a further 10 min. The reaction was 
heated to 100 °C and stirred for 17 h. The mixture was then cooled to r.t., diluted with DCM 
(50 mL) and washed with H2O (50 mL). The aqueous was back extracted with DCM (2 x 50 
mL) and the combined organic extractions dried (MgSO4) and filtered. The filtrate was 
concentrated in vacuo and the residue purified by flash silica chromatography, eluting with 0 
– 5% MeOH in DCM, to afford a white solid. This was triturated in Et2O (20 mL) and the 
remaining insoluble solid filtered and air-dried to afford the title compound as an off-white 
powder (70 mg, 28%). 
1H NMR (500 MHz, DMSO-d6) δ 8.66 (2H, dd, J = 4.6, 1.6 Hz, 12-CH), 8.12 (1H, dd, J = 8.0 
1.9 Hz, 5-CH), 8.01 (1H, d, J = 1.9 Hz, 7-CH), 7.79 (2H, dd, J = 4.6, 1.6 Hz, 11-CH), 7.75 (1H, 
d, J = 8.0 Hz, 4-CH), 3.19 – 3.16 (2H, m, 3-CH2), 2.73 – 2.70 (2H, m, 2-CH2). 
13C NMR (126 MHz, DMSO-d6) δ 206.0 (1-CO), 156.2 (9-C), 150.3 (12-CH), 146.1 (10-C), 
137.6 (8-C), 136.5 (6-C), 133.2 (5-CH), 127.9 (4-CH), 121.4 (11-CH), 120.9 (7-CH), 36.3 (2-
CH2), 25.4 (3-CH2). 
νmax / cm-1 (compressed solid) 3058 (w), 3032 (w), 2956 (w), 2924 (w), 2915 (w), 1700 (s), 
1615 (m), 1594 (s), 1548 (m), 1481 (m), 1437 (m), 1402 (m), 1302 (m), 1267 (m), 1237 (m), 
1178 (m), 1118 (m), 1071 (m), 1043 (m), 1028 (m), 991 (m), 907 (w), 818 (s), 803 (s), 647 
(m), 560 (s), 468 (s). 















2-Chloro-5-methylthiophene (3.14 g, 23.6 mmol) and glutaryl chloride (2.00 g, 11.8 mmol) 
were dissolved in DCM (150 mL) and anhydrous aluminium chloride (4.57 g, 34.3 mmol) was 
added. The solution was stirred for at r.t. for 18 h, then poured onto ice water (200 mL). The 
layers were separated and the aqueous back extracted with DCM (2 x 100 mL). The combined 
organic extractions were dried (MgSO4), filtered and concentrated in vacuo to afford the title 
compound as a pale brown solid (3.60 g, 92%).  
1H NMR (400 MHz, CDCl3) δ 7.18 (2H, s, 4-CH), 2.85 (4H, t, J = 7.0 Hz, 7-CH2), 2.66 (6H, s, 
9-CH3), 2.05 (2H, p, J = 7.0 Hz, 8-CH2). 
13C NMR (101 MHz, CDCl3) δ 195.0 (6-CO), 147.9 (ArC), 135.0 (ArC), 127.0 (4-CH), 125.4 
(ArC), 40.6 (7-CH2), 18.3 (8-CH2), 16.2 (9-CH3). 
νmax / cm-1 (compressed solid) 3093 (w), 2961 (w), 2923 (w), 2896 (w), 1673 (s), 1524 (m), 
1455 (s), 1409 (m), 1374 (m), 1243 (m), 1203 (s), 1156 (m), 1130 (m), 1006 (m), 970 (m), 822 
(m), 784 (m), 729 (m), 483 (s). 
ESI-LRMS for C15H14Cl2O2S2Na+ [M+Na]+ calcd: 382.9, found: 383.0. 






Zinc powder (1.09 g, 16.6 mmol) was suspended in anhydrous THF (150 mL). TiCl4 (1.5 mL, 
13 mmol) was added dropwise as the solution was stirred vigorously. The solution was heated 
to reflux and stirred for 1 h. The mixture was then cooled to 0 °C and thiophene 82 (2.00 g, 
5.54 mmol) was added to the suspension. The mixture was heated to reflux and stirred for 4 
h, then quenched with sat. aq. Na2CO3 (10 mL) causing the evolution of a white precipitate. 
The solution was filtered through Celite and washed with EtOAc (20 mL). The filtrate was dried 
Chapter 7: Experimental 
207 
 
(MgSO4), concentrated in vacuo and the residue purified by flash silica chromatography, 
eluting with hexane, to afford the title compound as a pale yellow solid (1.20 g, 66%). 
1H NMR (400 MHz, CDCl3) δ 6.58 (2H, s, 4-CH), 2.72 (4H, t, J = 7.5 Hz, 7-CH2), 2.02 (2H, p, 
J = 7.5 Hz, 8-CH2), 1.89 (6H, s, 9-CH3). 
13C NMR (101 MHz, CDCl3) δ 135.0 (ArC), 134.6 (5-C), 133.4 (ArC), 126.8 (4-CH), 125.3 
(ArC), 38.5 (7-CH2), 23.0 (8-CH2), 14.3 (9-CH3). 
νmax / cm-1 (compressed solid) 2950 (m), 2919 (m), 2844 (m), 1553 (w), 1538 (w), 1457 (s), 
1439 (s), 1378 (w), 1310 (w), 1291 (w), 1202 (m), 1159 (m), 1144 (m), 1055 (w), 1014 (m), 
922 (s), 964 (w), 827 (s), 748 (w), 667 (w), 651 (w), 482 (s). 






Thiophene 83 (245 mg, 0.744 mmol) was dissolved in anhydrous THF (5 mL) and the solution 
cooled to 0 °C. n-BuLi (2.5 M in hexanes, 655 μL, 1.64 mmol) was added dropwise, and the 
solution stirred for 30 min. tris-n-butylborate (455 μL, 2.23 mmol) was added and the resulting 
solution warmed to r.t. and stirred for 1 h to afford crude boronic ester 84. Separately, 
Pd(PPh3)4 (86 mg, 0.074 mmol) and 4-bromopyridine hydrochloride (318 mg, 1.63 mmol) were 
dissolved in 2.5 M aq. K2CO3 (5 mL) and the solution was degassed by evacuation under 
vacuum and backfilling with nitrogen three times. The boronic ester solution was then added 
to this mixture and the resulting solution heated to 70 °C and stirred for 18 h. The mixture was 
cooled, diluted with DCM (50 mL) and washed with water (50 mL). The aqueous was back 
extracted with DCM (2 x 50 mL) and the combined organic extractions dried (MgSO4) and 
filtered. The filtrate was concentrated in vacuo and the residue purified by flash silica 
chromatography, eluting with 2:1 hexane:EtOAc, to yield a pale violet solid. This was further 
purified by trituration in 1:1 Et2O:pentane to afford the title compound as a purple amorphous 
solid (81 mg, 26%).  
1H NMR (400 MHz, CDCl3) δ 8.53 (4H, d, J = 5.2 Hz, 12-CH), 7.34 (4H, d, J = 5.2 Hz, 11-CH), 
7.21 (2H, s, 4-CH), 2.85 (4H, t, J = 7.5 Hz, 7-CH2), 2.11 (2H, p, J = 7.5 Hz, 8-CH2), 2.02 (6H, 
s, 9-CH3). 
Chapter 7: Experimental 
208 
 
13C NMR (101 MHz, CDCl3) δ 150.4 (12-CH), 141.4 (10-C), 137.4 (ArC), 137.2 (ArC), 136.8 
(ArC), 135.0 (6-C), 126.4 (4-CH), 119.4 (11-CH), 38.6 (7-CH2), 23.1 (8-CH2), 14.8 (9-CH3). 
νmax / cm-1 (compressed solid) 3065 (w), 3028 (w), 2952 (w), 2920 (w), 2946 (w), 1596 (s), 
1540 (w), 1498 (m), 1461 (m), 1437 (m), 1411 (m), 1378 (w), 1310 (w), 1294 (w), 1220 (m), 
1171 (w), 1120 (w), 992 (m), 909 (w), 857 (w), 814 (s), 729 (m), 601 (m), 542 (m), 4723 (m). 
ESI-LRMS for C25H23N2S2+ [M+H]+ calcd: 415.1, found: 415.1. 






Synthesised by Dr Javier Ramos Soriano 
Thiophene 83 (150 mg, 0.46 mmol) was dissolved in anhydrous THF (3 mL) and the solution 
cooled to 0 °C. n-BuLi (2.5 M in hexanes, 402 μL, 1.01 mmol) was added dropwise, and the  
solution stirred for 30 min. tris-n-butylborate (370 μL, 1.37 mmol) was added and the resulting 
solution warmed to r.t. and stirred for 1 h to afford crude boronic ester 84. Separately, 
Pd(PPh3)4 (54 mg, 0.046 mmol) was suspended in dry THF (2.5 mL) and the resulting mixture 
was heated at 70 °C. After 30 min, aq. 2.5 M K2CO3 (3 mL), ethylene glycol (1 drop) and 7-
bromoquinoline (220 mg, 1.01 mmol) were added. The boronic ester solution was then added 
to this mixture and the resulting solution heated to 70 °C and stirred for 19 h. The mixture was 
cooled and water (10 mL) was added. The aqueous layer was extracted with Et2O (3 x 20 mL) 
and the combined organic extractions dried (MgSO4) and filtered. The filtrate was 
concentrated in vacuo and the residue purified by flash silica chromatography, eluting with 1:1 
hexane:EtOAc, to afforded the title compound as a purple amorphous solid (188 mg, 80%).  
1H NMR (400 MHz, CDCl3) δ 8.88 (2H, dd, J = 4.2, 1.7 Hz, 13-CH), 8.21 (2H, m, 11-CH), 8.09 
(2H, ddd, J = 8.2, 1.7, 0.8 Hz, 15-CH), 7.76 (2H, d, J = 8.3 Hz, 17-CH), 7.71 (2H, dd, J = 8.3, 
1.8 Hz, 18-CH), 7.33 (2H, dd, J = 8.2, 4.2 Hz, 14-CH), 7.26 (2H, under CDCl3, 4-CH), 2.89 
(4H, t, J = 7.5 Hz, 7-CH2), 2.14 (2H, p, J = 7.5 Hz, 8-CH2), 2.07 (6H, s, 9-CH3) 
13C NMR (101 MHz, CDCl3) δ 151.0 (13-CH), 148.6 (12-C), 139.0 (5-C), 137.1 (2-C), 136.0 
(3-C), 135.7 (15-CH), 135.5 (10-C), 134.8 (6-C), 128.2 (17-CH), 127.3 (16-C), 125.3 (4-C), 
124.6 (18-CH), 124.5 (11-CH), 120.7 (14-CH), 38.6 (7-CH2), 23.0 (8-CH2), 14.6 (9-CH3); ESI- 
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νmax / cm-1 (thin film) 3053 (w), 3011 (w), 2922 (m), 2852 (w), 1617 (s), 1596 (m), 1502 (m), 
1439 (m), 1392 (w), 1321 (w), 1176 (w), 1152 (w), 1123 (w), 1128 (w), 1092 (w), 940 (w), 887 
(m), 830 (s), 767 (m), 736 (w), 665 (w), 644 (w) 






Thiophene 83 (245 mg, 0.744 mmol) was dissolved in anhydrous THF (5 mL) and the solution 
cooled to 0 °C. n-BuLi (2.5 M in hexanes, 655 μL, 1.64 mmol) was added dropwise, and the 
solution stirred for 30 min. tris-n-butylborate (455 μL, 2.23 mmol) was added and the resulting 
solution warmed to r.t. and stirred for 1 h to afford crude boronic ester 84. Separately, 
Pd(PPh3)4 (86 mg, 0.074 mmol) and 5-bromoquinoline (341 mg, 1.63 mmol) were dissolved in 
2.5 M aq. K2CO3 (5 mL) and the solution was degassed by evacuation under vacuum and 
backfilling with nitrogen three times. The boronic ester solution was then added to this mixture 
and the resulting solution heated to 70 °C and stirred for 18 h. The mixture was cooled and 
diluted with DCM (50 mL) and washed with water (50 mL). The aqueous was back extracted 
with DCM (2 x 50 mL) and the combined organic extractions dried (MgSO4) and filtered. The 
filtrate was concentrated in vacuo and the residue purified by flash silica chromatography, 
eluting with 2:1 hexane:EtOAc, afford the title compound as a pale red oil (113 mg, 30%). 
1H NMR (400 MHz, CDCl3) δ 8.84 (2H, dd, J = 4.2, 1.7 Hz, 18-CH), 8.39 (2H, ddd, J = 8.7, 
1.7, 0.9 Hz, 16-CH), 8.07 (2H, dt, J = 8.5, 1.1 Hz, 13-CH), 7.68 (2H, dd, J = 8.5, 7.2 Hz, 12-
CH), 7.57 (2H, dd, J = 7.2, 1.1 Hz, 11-CH), 7.23 (2H, dd, J = 8.7, 4.2 Hz, 17-CH), 6.90 (2H, s, 
4-CH), 2.89 (4H, t, J = 7.5 Hz, 7-CH2), 2.26 (6H, s, 9-CH3), 2.12 (2H, p, J = 7.5 Hz, 8-CH2). 
13C NMR (101 MHz, CDCl3) δ 150.5 (18-CH), 148.7 (14-C), 136.6 (2-C), 136.0 (5-C), 135.8 
(3-C), 135.4 (6-C), 134.2 (16-CH), 132.9 (10-C), 129.4 (13-CH and 4-CH), 128.9 (12-CH), 
128.0 (11-CH), 126.8 (15-C), 121.4 (17-CH), 38.2 (7-CH2), 23.3 (8-CH2), 14.5 (9-CH3). 
νmax / cm-1 (thin film) 3060 (w), 3031 (w), 2949 (w), 2916 (w), 2845 (w), 1592 (m), 1570 (m), 
1499 (m), 1484 (m), 1437 (m), 1393 (m), 1309 (m), 1197 (w), 1161 (w), 1146 (w), 1120 (w), 
1092 (w), 930 (m), 908 (m), 854 (w), 828 (m), 802 (s), 730 (s), 694 (m), 667 (w), 644 (w), 585 
(m), 542 (m). 
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ESI-HRMS for C33H27N2S2+ [M+H]+ calcd: 515.1610, found: 515.1626. 
 
4,4'-(cyclopent-1-ene-1,2-diylbis(5-methylthiophene-4,2-diyl))bis(1-methylpyridin-1-





Pyridine 85 (40 mg, 0.096 mmol) was dissolved in DCM (1 mL). Methyl iodide (13 μL, 0.21 
mmol) was added and the solution stirred at r.t. for 3 h. The solvent was removed in vacuo, 
the residue washed with 1:1 hexane:EtOAc and the precipitate filtered and dried under 
vacuum to afford the title compound as a green powder (52 mg, 78%). 
1H NMR (500 MHz, D2O) δ 8.51 (4H, d, J = 6.7 Hz, 12-CH), 7.97 (4H, d, J = 6.7 Hz, 11-CH), 
7.84 (2H, s, 4-CH), 4.24 (6H, s, 13-CH3), 2.89 (4H, t, J = 7.5 Hz, 7-CH2), 2.14 (2H, p, J = 7.5 
Hz, 8-CH2), 2.06 (6H, s, 9-CH3). 
13C NMR (126 MHz, D2O) δ 148.7 (10-C), 144.9 (ArC), 144.4 (12-CH), 138.8 (ArC), 135.3 (3-
C), 132.9 (5-C), 132.5 (ArC), 121.5 (11-CH), 46.8 (13-CH3), 37.9 (7-CH2), 22.7 (8-CH2), 14.1 
(9-CH3). 
νmax / cm-1 (compressed solid) 3026 (w), 2946 (w), 2922 (w), 2841 (w), 1634, (s), 1595 (m), 
1533 (m), 1511 (s), 1471 (m), 1435 (m), 1416 (m), 1372 (w), 1342 (w), 1313 (w), 1293 (w), 
1260 (w), 1220 (m), 1190 (s), 1181 (s), 1150 (m), 1069 (w), 1047 (w), 1028 (w), 993 (w), 920 
(w), 893 (w), 830 (s), 756 (w), 720 (w), 541 (m), 471 (s). 
ESI-LRMS for C27H28N2S22+ [M]2+ calcd: 222.1, found: 222.1. 


















Synthesised by Dr Javier Ramos Soriano 
Quinoline 86 (100 mg, 0.19 mmol) was dissolved in in acetonitrile (5 mL) and methyl iodide 
(73 µL, 1.2 mmol) was added. The solution was stirred in a sealed vessel at 70 °C for 16 h. 
The solvent was removed in vacuo and the residue was washed with Et2O and CHCl3 to afford 
the title compound as a green powder (108 mg, 70%). 
1H NMR (400 MHz, DMSO-d6) δ 9.41 (2H, d, J = 5.8 Hz, 13-CH), 9.17 (2H, d, J = 8.2 Hz, 15-
CH), 8.47 – 8.41  (4H, m, 11-CH, 17-CH), 8.26 (2H, dd, J = 8.6, 1.6 Hz, 18-CH), 8.09 – 8.01 
(4H, m, 4-CH, 14-CH), 4.63 (6H, s, 19-CH3), 2.96 (4H, t, J = 7.5 Hz, 7-CH2), 2.14 (2H, p, J = 
7.5 Hz, 8-CH2), 2.00 (6H, s, 9-CH3). 
13C NMR (101 MHz, DMSO-d6) δ 150.2 (13-CH), 146.2 (15-CH), 139.8 (10-C), 139.2 (12-C), 
138.6 (2-C), 137.8 (3-C), 136.6 (5-C), 134.5 (6-C), 131.3 (17-CH), 129.5 (4-C), 128.2 (16-C), 
127.2 (18-CH), 121.2 (14-CH), 112.5 (11-CH), 45.3 (19-CH3), 38.3 (7-CH2), 22.3 (8-CH2), 14.4 
(9-CH3). 
νmax / cm-1 (compressed solid) 3054 (w), 3012 (w), 2944 (w), 1752, (m), 1626 (s), 1593 (m), 
1512 (s), 1441 (m), 1370 (m), 1215 (m), 838 (s) 


















Quinoline 87 (50 mg, 0.097 mmol) was dissolved in DCM (1 mL) and methyl iodide (18 μL, 
0.29 mmol) was added. The solution was stirred in a sealed vessel at 50 °C for 16 h. The 
solvent was removed in vacuo, the residue was washed with 1:1 hexane:EtOAc and the 
precipitate filtered and dried under vacuum to afford the title compound as an orange powder 
(64 mg, 83%). 
1H NMR (500 MHz, D2O) δ 9.13 (2H, d, J = 5.8 Hz, 18-CH), 9.11 (2H, d, J = 8.7 Hz, 16-CH), 
8.34 (2H, dt, J = 9.0, 1.0 Hz, 13-CH), 8.20 (2H, dd, J = 9.0, 7.4 Hz, 12-CH), 7.97 (2H, dd, J = 
7.4, 1.0 Hz, 11-CH), 7.83 (2H, dd, J = 8.7, 5.8 Hz, 17-CH), 7.10 (2H, s, 4-CH), 4.65 (6H, s, 19-
CH3), 2.88 (4H, t, J = 7.4 Hz, 7-CH2), 2.28 (6H, s, 9-CH3), 2.12 (2H, p, J = 7.4 Hz, 8-CH2). 
13C NMR (126 MHz, D2O) δ 149.0 (18-CH), 145.3 (16-CH), 139.5 (14-C), 138.5 (3-CH or 2-
CH), 137.1 (3-CH or 2-CH), 135.6 (6-C), 135.2 (10-C), 135.0 (12-CH), 133.4 (5-C), 131.5 (4-
CH), 130.8 (11-CH), 128.1 (15-C), 121.2 (17-CH), 117.5 (13-CH), 45.8 (19-CH3), 37.4 (7-CH2), 
22.9 (8-CH2), 13.4 (9-CH3). 
νmax / cm-1 (compressed solid) 3042 (w), 3000 (w), 2942 (w), 2916 (w), 2840 (w), 1614, m), 
1586 (s), 1531 (s), 1477 (w), 1463 (w), 1355 (m), 1330 (m), 1229 (m), 1156 (m), 1133 (w), 
1117 (w), 1085 (w), 1070 (w), 993 (w), 978 (w), 855 (w), 795 (s), 762 (m), 721 (w), 693 (w), 
657 (w), 574 (m). 
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A1  Derivation of 1:1 binding model 
 
Beginning with Eqn (2.5) introduced in Chapter 2:  
Firstly, it is noted that the free ligand concentration is simply the total ligand concentration 
minus the concentration of bound ligand: 
Eqn. (A1) is substituted into Eqn. (2.5) to give Eqn. (A2). 
At the start of the titration only ligand is present and therefore the concentration of complex 
([𝐷. 𝐿]) is zero. The absorbance, 𝐴[ ] , is simply: 
Subtracting Eqn. (A3) from Eqn. (A2) gives: 
Which is simplified to: 
 
𝐴[ ] = 𝜀 [𝐿] + 𝜀 . [𝐷. 𝐿] (2.5) 
 
 
[𝐿] = [𝐿] − [𝐷. 𝐿] (A1) 
 
 
𝐴[ ] = 𝜀 ([𝐿] − [𝐷. 𝐿]) +  𝜀 . [𝐷. 𝐿] (A2) 
 
 
𝐴[ ] = 𝜀 [𝐿]  (A3) 
 
 
𝐴[ ] − 𝐴[ ] = 𝜀 ([𝐿] − [𝐷. 𝐿]) +  𝜀 . [𝐷. 𝐿] −  𝜀 [𝐿]  (A4) 
 
 





Where 𝜀∆ .  is the difference in extinction coefficient between the bound complex and free 
ligand and the observed absorbance change is related directly to the concentration of the 
bound ligand. Eqn. (A5) is next expressed in terms of the association constant and known 
concentrations of the total DNA and ligand through the following argument: 
By noting again Eqn. (A1) and also that: 
The association constant, Eqn (2.3), can be expressed in terms of the concentration of bound 
complex and the known total concentrations of DNA and ligand: 
Eqn. (A7) is then trivially rearranged and factorised into standard quadratic form: 
For which the solution for [𝐷. 𝐿] is given by the quadratic formula: 
Finally, substitution of Eqn. (A9) into Eqn. (A5) directly relates the observed absorbance 
change to the known quantities [𝐷]  and [𝐿]  and the unknown quantities 𝜀∆ .  and the 
association constant 𝐾  to give Eqn. (2.6) as presented in Chapter 2: 
 
[𝐷] = [𝐷] − [𝐷. 𝐿] (A6) 
 
 
𝐾 =  
[𝐷. 𝐿]




[𝐷. 𝐿]  − [𝐷] + [𝐿] +
1
𝐾




[𝐷] +  [𝐿] +
1
𝐾
− [𝐷] +  [𝐿] +
1
𝐾






∆𝐴 = 𝜀∆ .  ∙  
[𝐷] +  [𝐿] +
1
𝐾
− [𝐷] + [𝐿] +
1
𝐾






























Figure A2.1: Decomposition of ligand L in D2O solution. Similar results were obtained for 












Figure A2.2: 1H NMR spectrum (D2O) and representative FRET curves for ligand A 
 









Figure A2.4: 1H NMR spectrum (D2O) and representative FRET curves for ligand D 
 









Figure A2.6: 1H NMR spectrum (D2O) and representative FRET curves for ligand F 
 










Figure A2.8: 1H NMR spectrum (D2O) and representative FRET curves for ligand H 
 








Figure A2.10: 1H NMR spectrum (D2O) and representative FRET curves for ligand J 
 







Figure A2.12: 1H and 13C NMR specta (D2O) and representative FRET curves for ligand 







Figure A2.13: 1H and 13C NMR specta (D2O) and representative FRET curves for ligand 







































































A3  Supplementary data for Chapter 3 
 
 
Figure A3.1: 1H and 13C NMR specta (DMSO-d6) and representative FRET curves for 







Figure A3.2: 1H and 13C NMR specta (DMSO-d6) and representative FRET curves for 





Figure A3.3: 1H and 13C NMR specta (DMSO-d6) and representative FRET curves for 










































Figure A4.1: UV/visible spectra of (top) Z-56 and (bottom) E-56 after specified time points 
in the dark in 100 mM sodium phosphate buffer, pH = 7.4 showing stability of the ligand in 










































Figure A5.5:  CD titration of ligand 78c into 100 mM sodium phosphate buffer (100 mM, 
pH = 7.4) showing distortion of baseline proposed to arise from ligand aggregation. Black 
trace) buffer only; dark grey trace 30 μM ligand 78c. Intermediate titration points are 













Figure A5.6: Stacked 1H NMR spectra (imino region) of telo23-K+ G4 with increasing 
equivalents of (top) 77c and (bottom) 77o. DNA concentration: 185 μM. 
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